P00001606T0076|0 9|Comparison
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|30 47|hyperbilirubinemia
P00008171T0000|13 19|aspects
P00008997A0472|139 143|slope
P00008997A0472|4 6|CSF
P00008997A0472|34 40|CSF PCO2
P00008997A0472|8 11|HCO3
P00008997A0472|44 47|data
P00008997A0472|98 105|controls
P00008997A0472|24 31|function
P00008997A0472|60 63|rats
P00010943A0733|0 9|Flurazepam
P00010943A0733|96 97|mg
P00010943A0733|81 88|practice
P00010943A0733|69 71|use
P00010943A0733|44 47|drug
P00010943A0733|100 104|night
P00010943A0733|62 65|dose
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|18 27|CO2 removal
P00013683A0210|68 78|ventilation
P00013683A0210|54 57|VCO2
P00013683A0210|40 52|CO2 production
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|204 211|decrease
P00015731A0090|181 188|increase
P00015731A0090|99 99|p
P00015731A0090|197 200|p CO2
P00015731A0090|11 24|administration
P00015731A0090|64 76|acetazolamide
P00015731A0090|44 62|anhydrase inhibitors
P00015731A0090|78 90|methazolamide
P00015731A0090|214 215|pH
P00015731A0090|142 145|rise
P00015731A0090|99 99|p
P00015731A0090|226 230|blood
P00015731A0090|28 32|mg/kg
P00015731A0090|109 117|sulthiame
P00022143T0000|42 47|rabbit
P00022143T0000|20 30|etoperidone
P00022143T0000|2 4|rat
P00022143T0000|13 17|study
P00023348A0601|10 15|polyps
P00024600A0522|14 26|dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|11 26|HMG dosage regimen
P00025557A0100|28 28|%
P00025557A0100|7 16|CO2 content
P00025557A0100|32 38|animals
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|59 64|cattle
P00027739T0000|34 42|diagnosis
P00027739T0000|45 56|liver disease
P00027967A0207|97 105|formation
P00027967A0207|2 9|contrast
P00027967A0207|56 60|onset
P00027967A0207|56 60|onset
P00027967A0207|20 31|HI antibodies
P00027967A0207|80 87|patients
P00027967A0207|63 69|illness
P00027967A0207|148 153|levels
P00027967A0207|161 164|days
P00027967A0207|22 31|antibodies
P00027967A0207|63 69|illness
P00029555A0861|31 42|quantitation
P00029555A0861|18 27|virus assay
P00029555A0861|49 55|methods
P00029555A0861|7 15|exception
P00029555A0861|102 134|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|18 28|association
P00030183T0000|33 38|HLA-B5
P00030183T0000|10 16|disease
P00030937A0119|0 3|SGPT
P00030937A0119|13 45|alkaline phosphatase concentrations
P00030937A0119|72 79|subjects
P00030937A0119|5 8|SGOT
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|33 40|activity
P00033873T0001|53 57|fluid
P00033873T0001|28 31|GGTP
P00034935A0545|0 7|Patients
P00034935A0545|96 96|%
P00034935A0545|51 59|incidence
P00034935A0545|23 29|disease
P00034935A0545|77 89|drug treatment
P00034935A0545|62 70|psychoses
P00034935A0545|12 20|Parkinson
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|89 91|FLA
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|9 19|stimulation
P00038408T0000|57 65|treatment
P00039271T0000|49 59|application
P00039271T0000|20 27|diazepam
P00039271T0000|12 17|action
P00039271T0000|65 67|rat
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|33 38|mucoas
P00048373A0377|78 87|epithelium
P00048373A0377|61 67|absence
P00050628A0202|71 81|proteinuria
P00050628A0202|40 44|serum
P00050628A0202|15 24|gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|48 54|patient
P00050628A0202|48 55|patients
P00052597T0000|0 6|Studies
P00052597T0000|28 33|impact
P00052597T0000|48 61|Professor Dan H.
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|37 43|sojourn
P00054900A0226|50 57|esterase
P00054900A0226|10 23|reaction stains
P00055040A0000|3 14|out-patients
P00055040A0000|243 254|cryoglobulin
P00055040A0000|116 125|fibrinogen
P00055040A0000|92 100|technique
P00055040A0000|104 113|deposition
P00055040A0000|192 195|skin
P00055040A0000|284 288|blood
P00055040A0000|70 87|immunofluorescence
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|138 156|degradation products
P00055040A0000|229 236|fraction
P00055040A0000|263 278|plasma fibrinogen
P00055040A0000|238 240|HPF
P00055040A0000|158 167|FR-antigen
P00056837A0000|97 105|carcinoma
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|74 84|operability
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|15 21|albumin
P00056901A0308|1 7|mixture
P00056901A0308|68 75|dilution
P00056901A0308|23 23|%
P00060529A0695|116 125|percentage
P00060529A0695|215 218|A.B.
P00060529A0695|75 85|0acteriuria
P00060529A0695|27 42|acquisition-rate
P00060529A0695|98 103|figure
P00060529A0695|172 175|year
P00060529A0695|145 162|practice population
P00060529A0695|95 95|%
P00060529A0695|128 132|women
P00060529A0695|12 23|control group
P00061478T0000|48 56|nutrition
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00063680T0000|19 31|galactosaemia
P00063680T0000|8 16|diagnosis
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|89 95|results
P00066874T0000|61 73|contamination
P00066874T0000|100 109|experiment
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|83 87|blood
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|16 24|diagnosis
P00072928T0000|27 42|haemochromatosis
P00073344A0367|41 51|lymphocytes
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|68 76|treatment
P00073344A0367|3 10|subjects
P00074758T0000|0 7|Patients
P00074758T0000|16 29|hypothyroidism
P00074758T0000|10 13|risk
P00083846T0000|0 6|Albumin
P00083846T0000|16 24|AMP levels
P00083846T0000|48 52|child
P00083846T0000|37 42|fluids
P00084275T0063|0 6|Preface
P00086313A0000|88 93|groups
P00086313A0000|99 103|basis
P00086313A0000|20 31|Legionnaires
P00086313A0000|33 47|disease bacteria
P00086313A0000|106 113|findings
P00086313A0000|143 157|antibody testing
P00086313A0000|11 17|strains
P00088391A0181|72 78|antigen
P00088391A0181|43 59|coumarin treatment
P00088391A0181|14 19|factor
P00088391A0181|22 29|activity
P00088391A0181|10 19|hand factor
P00089778A0000|298 313|cataract patients
P00089778A0000|3 15|concentration
P00089778A0000|58 68|plasminogen
P00089778A0000|174 178|serum
P00089778A0000|70 82|C3-complement
P00089778A0000|199 203|Fuchs
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|165 170|humour
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|187 194|patients
P00089778A0000|259 266|cataract
P00089778A0000|84 112|fibrinogen degradation products
P00089778A0000|216 224|dystrophy
P00089778A0000|114 116|FDP
P00089778A0000|187 194|patients
P00089778A0000|133 140|activity
P00092689A0352|12 19|patients
P00092689A0352|6 6|%
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|43 50|patients
P00094639A0313|27 32|volume
P00094639A0313|54 57|dose
P00094639A0313|67 68|mg
P00096241A0087|0 1|T4
P00096241A0087|130 134|weeks
P00096241A0087|116 122|infants
P00096241A0087|145 155|term infants
P00096241A0087|157 157|P
P00096241A0087|5 8|FT4I
P00096241A0087|77 82|values
P00096241A0087|136 138|EGA
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|25 31|courses
P00097989A0106|42 49|patients
P00097989A0106|23 36|treatment plans
P00097989A0106|13 20|analysis
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100540T0000|28 41|susceptibility
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|135 144|norcocaine
P00100791A0425|5 11|results
P00100791A0425|126 132|effects
P00100791A0425|24 40|cynomolgus monkeys
P00101300A0257|43 44|T3
P00101300A0257|29 35|cancers
P00101300A0257|2 6|cases
P00101300A0257|46 47|N0
P00101300A0257|76 80|years
P00101300A0257|76 80|years
P00101300A0257|49 50|N1
P00101300A0257|63 70|followup
P00101300A0257|37 38|T1
P00101300A0257|99 104|months
P00101300A0257|40 41|T2
P00105401A0635|204 206|FT4
P00105401A0635|52 72|thyroid hormone binding
P00105401A0635|3 8|effect
P00105401A0635|17 19|DPH
P00105401A0635|210 212|FT3
P00105401A0635|122 134|clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|183 201|premedication levels
P00105401A0635|170 180|maintenance
P00105401A0635|36 47|interference
P00105401A0635|75 77|TBG
P00105401A0635|11 13|CBZ
P00105903A0288|30 40|possibility
P00105903A0288|45 62|polyethylene glycol
P00105903A0288|67 69|PEG
P00105903A0288|10 17|research
P00111174A0351|93 99|stimuli
P00111174A0351|45 51|neurons
P00111174A0351|45 51|neurons
P00111174A0351|45 51|neurons
P00111174A0351|93 99|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|93 99|stimuli
P00111174A0351|45 51|neurons
P00111174A0351|26 35|properties
P00112627A0542|28 32|mg/kg
P00112627A0542|86 98|normeperidine
P00112627A0542|28 32|mg/kg
P00112627A0542|0 12|Pentobarbital
P00112627A0542|132 143|alphaprodine
P00112627A0542|28 32|mg/kg
P00112627A0542|79 83|doses
P00112627A0542|28 32|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|157 164|fentanyl
P00112627A0542|28 32|mg/kg
P00112627A0542|49 59|combination
P00113657A0628|0 5|Pb foil
P00113657A0628|39 49|improvement
P00113657A0628|11 15|gcm-2
P00114144A0189|220 231|enzyme defect
P00114144A0189|85 94|hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|130 133|Type
P00114144A0189|28 32|study
P00114144A0189|159 166|Andersen
P00114144A0189|56 69|result emphasis
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|151 157|disease
P00115974A0576|59 62|days
P00115974A0576|3 8|groups
P00115974A0576|35 38|maze
P00115974A0576|65 67|age
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|0 11|Erythromycin
P00117748T0000|68 78|skin lesions
P00117748T0000|38 63|Corynebacterium diphtheriae
P00118044A0000|115 125|EMG activity
P00118044A0000|59 63|peaks
P00118044A0000|14 26|displacements
P00118044A0000|75 81|terms M1
P00118044A0000|29 34|monkey
P00118044A0000|83 84|M2
P00118044A0000|37 41|wrist
P00118044A0000|66 73|activity
P00118044A0000|140 146|muscles
P00118044A0000|89 95|M3 peaks
P00118810T0001|9 15|disease
P00119339A0400|142 153|degeneration
P00119339A0400|170 179|oesophagus
P00119339A0400|94 99|strain
P00119339A0400|158 164|lesions
P00119339A0400|118 128|myocarditis
P00119339A0400|6 11|animal
P00119339A0400|75 87|T. cruzi stocks
P00122718A0500|13 20|MRF units
P00122718A0500|86 93|activity
P00122718A0500|25 32|behavior
P00122718A0500|3 10|majority
P00122718A0500|76 79|case
P00129659T0000|0 10|Variability
P00129659T0000|63 76|sex differences
P00129659T0000|17 20|Down
P00129659T0000|32 41|trisomy-21
P00129659T0000|23 30|syndrome
P00129659T0000|79 81|IQs
P00130573T0054|0 2|VII
P00131739T0001|48 57|Uzbekistan
P00131739T0001|18 24|indices
P00131739T0001|35 45|populations
P00133214T0064|4 11|concepts
P00133214T0064|40 43|USSR
P00133214T0064|27 34|function
P00136175A1137|44 50|density
P00136175A1137|75 82|exercise
P00136175A1137|75 82|exercise
P00136175A1137|140 150|enlargement
P00136175A1137|3 13|maintenance
P00136175A1137|1 1|h
P00136175A1137|67 72|amount
P00136175A1137|111 114|week
P00136175A1137|153 155|ECA
P00137671A0896|100 110|coagulation
P00137671A0896|5 16|observations
P00137671A0896|76 84|indicator
P00137671A0896|50 59|VIII-ratio
P00139624A0318|5 9|hours
P00139624A0318|95 98|rats
P00139624A0318|18 31|administration
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|95 98|rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|32 43|progesterone
P00139827A0000|92 98|estriol
P00139827A0000|147 152|plasma
P00139827A0000|127 131|total
P00139827A0000|172 177|course
P00139827A0000|68 70|DHA
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|193 200|delivery
P00139827A0000|137 138|ml
P00139827A0000|19 30|pregnenolone
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|103 110|cortisol
P00142718A0156|115 130|chest radiographs
P00142718A0156|40 46|changes
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|9 16|patients
P00146327A0147|100 106|trachea
P00146327A0147|13 18|tumors
P00146327A0147|3 10|majority
P00146327A0147|93 98|larynx
P00146327A0147|65 74|incidences
P00146327A0147|110 120|stem bronchi
P00146327A0147|37 44|cavities
P00149899T0001|0 9|Prediction
P00149899T0001|29 39|development
P00149899T0001|15 19|times
P00150066A0100|33 43|coagulation
P00150066A0100|11 20|fibrinogen
P00150066A0100|52 59|thrombin
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|73 85|transcription
P00154430A0906|3 19|Southern technique
P00154430A0906|107 114|fragment
P00154430A0906|92 93|kb
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00155973A0387|56 56|%
P00155973A0387|43 48|errors
P00155973A0387|213 229|minute ventilation
P00155973A0387|172 183|gas flow rates
P00155973A0387|116 141|carbon dioxide concentration
P00155973A0387|56 56|%
P00155973A0387|206 210|range
P00155973A0387|194 198|min-1
P00155973A0387|79 84|system
P00155973A0387|26 31|limits
P00155973A0387|153 155|vol
P00155973A0387|194 198|min-1
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00159600A0871|17 19|SHR
P00159600A0871|149 153|curve
P00159600A0871|56 65|compliance
P00159600A0871|125 129|shift
P00159600A0871|91 99|ventricle
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|3 9|carcass
P00163384A0000|80 86|Ontario
P00163384A0000|103 110|necropsy
P00163384A0000|24 26|owl
P00167544A0067|157 180|surface specimen technique
P00167544A0067|111 128|electron microscopy
P00167544A0067|8 11|ears
P00167544A0067|25 39|microdissection
P00167544A0067|64 70|regions
P00168176A0000|0 6|Patulin
P00168176A0000|83 97|silica gel column
P00168176A0000|49 55|acetate
P00168176A0000|44 55|ethyl acetate
P00168176A0000|136 141|eluant
P00168176A0000|22 39|apple butter samples
P00168176A0000|9 15|extract
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|29 33|fluid
P00168431T0000|36 39|term
P00172199A0270|101 115|cross striations
P00172199A0270|74 83|appearance
P00172199A0270|3 8|matrix
P00172199A0270|50 59|morphology
P00172199A0270|23 30|clusters
P00173860A0475|0 9|Riboflavin
P00173860A0475|179 183|acids
P00173860A0475|80 96|excretion patterns
P00173860A0475|115 123|magnitude
P00173860A0475|143 153|elimination
P00173860A0475|54 60|animals
P00173860A0475|129 140|disturbances
P00173860A0475|25 34|percentage
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 29|suture absorption
P00176742T0000|50 56|enzymes
P00176742T0000|36 39|role
P00183063A0300|112 119|patients
P00183063A0300|112 119|patients
P00183063A0300|3 11|incidence
P00183063A0300|53 59|cancers
P00183063A0300|35 38|cent
P00183063A0300|35 38|cent
P00183063A0300|63 70|patinets
P00183063A0300|35 38|cent
P00183063A0300|14 26|DNCB reactions
P00183063A0300|42 46|Stage
P00183063A0300|53 58|cancer
P00183063A0300|42 46|Stage
P00183063A0300|53 58|cancer
P00183063A0300|42 46|Stage
P00188387A0975|0 6|Studies
P00188387A0975|56 63|families
P00188387A0975|44 51|children
P00188387A0975|92 103|heart disease
P00188387A0975|9 20|lipoproteins
P00188387A0975|75 76|FH
P00193088A0196|18 25|subjects
P00193088A0196|31 31|g
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193587T0000|29 37|phenomena
P00193587T0000|0 12|EEG theta waves
P00193587T0000|49 56|analysis
P00193587T0000|40 45|review
P00196255A0000|0 14|REM dream content
P00196255A0000|176 186|bizarreness
P00196255A0000|30 32|ego
P00196255A0000|61 69|influence
P00196255A0000|27 36|categories
P00196255A0000|79 88|hemisphere
P00196255A0000|154 158|music
P00196255A0000|79 88|hemisphere
P00196255A0000|114 126|verbalization
P00196255A0000|167 174|salience
P00198510T0000|0 10|Innervation
P00198510T0000|44 60|Locusta migratoria
P00198510T0000|23 31|diaphragm
P00198510T0000|37 42|locust
P00199012T0000|31 46|thyroid carcinoma
P00199012T0000|7 18|ACTH syndrome
P00201881A0487|26 32|studies
P00201881A0487|63 68|PI ACTH
P00201881A0487|45 55|correlation
P00201881A0487|9 15|finding
P00201881A0487|72 82|MSH contents
P00205074A0000|55 61|rickets
P00205074A0000|7 22|hypophosphatemia
P00205074A0000|38 41|type
P00209664A0836|28 34|serum LH
P00209664A0836|10 20|correlation
P00209664A0836|66 73|age group
P00209664A0836|132 148|parallel phenomena
P00209664A0836|53 59|bone age
P00209664A0836|10 20|correlation
P00210220X0000|34 38|drugs
P00210220X0000|9 22|neurochemistry
P00211881A0602|126 128|PBB
P00211881A0602|0 6|Efforts
P00211881A0602|29 34|amount
P00211881A0602|118 123|action
P00211881A0602|52 64|kidney lesions
P00211881A0602|112 115|site
P00211881A0602|37 40|time
P00216939T0001|0 5|Effect
P00216939T0001|83 86|rats
P00216939T0001|45 70|acid dehydrogenase reactions
P00216939T0001|107 114|chloride
P00216939T0001|8 15|succimer
P00216939T0001|21 29|intensity
P00216939T0001|76 80|brain
P00219533T0001|15 26|correlations
P00219533T0001|0 11|Distribution
P00219533T0001|88 92|women
P00219533T0001|59 69|populations
P00219533T0001|29 42|serum uric-acid
P00219533T0001|77 79|men
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|3 11|incidence
P00219565A0172|65 68|cent
P00219565A0172|40 50|transfusion
P00219674A0000|0 13|Technetium-99m
P00219674A0000|146 155|infarction
P00219674A0000|89 96|patients
P00219674A0000|45 55|scintigrams
P00219674A0000|22 34|pyrophosphate
P00219674A0000|114 118|range
P00219674A0000|108 112|weeks
P00221136A0984|39 44|humans
P00221136A0984|8 17|phenomenon
P00221725A0523|43 52|peroxidase
P00221725A0523|15 22|activity
P00221725A0523|85 95|neutrophils
P00221725A0523|3 9|decline
P00221725A0523|15 22|activity
P00221725A0523|110 117|decrease
P00221725A0523|61 72|lipid content
P00221725A0523|25 41|cytochrome oxidase
P00222102A0227|134 141|response
P00222102A0227|0 8|Treatment
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|172 184|serum-calcium
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|146 151|regard
P00222102A0227|157 169|normalisation
P00222102A0227|12 19|patients
P00222827A0000|59 63|depth
P00222827A0000|0 6|Workers
P00222827A0000|86 95|mechanisms
P00222827A0000|33 44|diisocyanate
P00222827A0000|68 74|attempt
P00222827A0000|46 48|TDI
P00222827A0000|107 121|hyperreactivity
P00222827A0000|12 22|sensitivity
P00224013A0661|26 31|groups
P00224013A0661|117 120|fall
P00224013A0661|54 60|limb VO2
P00224013A0661|260 269|comparison
P00224013A0661|5 7|VO2
P00224013A0661|145 154|resistance
P00224013A0661|44 50|hypoxia
P00224013A0661|44 50|hypoxia
P00224013A0661|236 243|delivery
P00224013A0661|335 359|beta-Vasodilator receptors
P00224013A0661|392 405|vasodilatation
P00224013A0661|26 30|group
P00224013A0661|216 226|utilization
P00224013A0661|294 309|extraction ratios
P00224013A0661|95 104|beta-Block
P00224013A0661|54 57|limb
P00224013A0661|44 50|hypoxia
P00224013A0661|383 386|part
P00224013A0661|280 283|body
P00224013A0661|326 333|pressure
P00224013A0661|54 57|limb
P00225352T0000|21 31|alterations
P00225352T0000|53 61|vitamin D3
P00225352T0000|83 90|rat liver
P00225352T0000|50 51|3H
P00225352T0000|37 46|metabolism
P00227393T0000|0 9|Modulation
P00227393T0000|63 96|cytochrome P-450 monooxygenase system
P00227393T0000|48 60|aminophylline
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227610A1593|54 63|messengers
P00227610A1593|31 37|DBP mRNA
P00227610A1593|66 69|SV40
P00227610A1593|73 86|polyoma viruses
P00227610A1593|11 18|respects
P00231555T0001|0 5|Effect
P00231555T0001|46 61|combination drugs
P00231555T0001|74 77|ACTH
P00231555T0001|81 98|cortisol production
P00232354A0286|0 8|Serum ACTH
P00232354A0286|34 43|metyrapone
P00232354A0286|24 30|insulin
P00232456T0000|84 91|leukemia
P00232456T0000|0 6|Anatomy
P00232456T0000|39 41|MH2
P00232456T0000|95 103|carcinoma
P00232456T0000|18 29|gene products
P00232456T0000|120 124|class
P00232456T0000|105 112|evidence
P00232456T0000|32 35|MC29
P00232456T0000|139 143|genes
P00232456T0000|60 71|tumor viruses
P00232456T0000|12 14|RNA
P00234206T0000|0 7|Bertioga
P00234206T0000|75 82|Sao Paulo
P00234206T0000|84 89|Brazil
P00234206T0000|31 45|Bunyamwera group
P00234206T0000|23 29|Anhembi
P00234206T0000|9 18|Guama group
P00234206T0000|54 64|arboviruses
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|84 91|children
P00234264A0164|121 125|weeks
P00234264A0164|104 114|aminopyrine
P00234264A0164|53 57|times
P00234264A0164|77 81|limit
P00234626T0036|0 2|XXI
P00239014A0000|90 100|blood plasma
P00239014A0000|84 87|acid
P00239014A0000|26 31|method
P00239014A0000|79 82|CPIB
P00239014A0000|38 50|determination
P00239169T0000|60 64|study
P00239169T0000|0 23|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00240016T0033|0 1|V.
P00240518A0000|18 26|procedure
P00240518A0000|33 45|determination
P00240518A0000|78 82|serum
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00242427T0001|4 8|field
P00242427T0001|34 38|nurse
P00242427T0001|11 16|stress
P00254537T0000|32 39|programs
P00254537T0000|5 13|graduates
P00254537T0000|49 59|state boards
P00254537T0000|25 29|types
P00261981A0434|60 63|rats
P00261981A0434|18 34|serum somatomedin A
P00261981A0434|76 82|litters
P00264240A1843|112 120|T clusters
P00264240A1843|152 170|X. laevis oocyte 5S DNA
P00264240A1843|144 149|region
P00264240A1843|3 11|sequences
P00264240A1843|50 56|5S genes
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|85 92|residues
P00265964A0562|4 12|mechanism
P00265964A0562|34 46|grain boundary
P00267764A0651|40 56|treatment failures
P00267764A0651|4 9|report
P00267764A0651|30 36|reasons
P00267764A0651|91 100|management
P00267764A0651|73 82|philosophy
P00294502T0001|0 8|Diagnosis
P00294502T0001|31 37|Class II
P00294502T0001|39 46|division
P00294502T0001|12 28|treatment planning
P00300314A0132|16 25|infections
P00300314A0132|227 241|treatment cycles
P00300314A0132|116 124|drug death
P00300314A0132|96 110|hospitalization
P00300314A0132|194 197|days
P00300314A0132|54 74|degrees F. granulocytes
P00300314A0132|149 165|calcium leucovorin
P00300314A0132|203 214|methotrexate
P00300314A0132|173 177|mg/m2
P00300314A0132|27 31|fever
P00300314A0132|136 143|patients
P00300314A0132|89 90|mm
P00303189A0247|14 16|way
P00303189A0247|79 86|efficacy
P00303189A0247|45 58|serum chemistry
P00303189A0247|122 128|process
P00303189A0247|36 42|patient
P00303189A0247|24 28|drugs
P00304240A0369|43 50|presence
P00304240A0369|19 23|tests
P00304240A0369|66 72|disease
P00304310A0000|3 11|end-stage
P00304310A0000|113 116|time
P00304310A0000|76 88|stabilization
P00304310A0000|54 64|retinopathy
P00304310A0000|104 110|periods
P00304310A0000|91 96|vision
P00304310A0000|26 30|phase
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|73 78|groups
P00304806A0760|45 51|infants
P00304806A0760|136 138|mg%
P00304806A0760|5 9|basis
P00304806A0760|107 120|concentrations
P00313766A0666|83 89|control
P00313766A0666|2 9|patients
P00313766A0666|65 72|function
P00313766A0666|2 2|p
P00313766A0666|80 80|%
P00313766A0666|91 95|range
P00313766A0666|53 62|depression
P00313766A0666|80 80|%
P00316723A0558|0 6|Changes
P00316723A0558|31 38|behavior
P00316723A0558|9 18|body weight
P00321261A0104|191 195|women
P00321261A0104|139 144|phases
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|36 39|PGE2
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|10 17|response
P00321261A0104|159 163|cycle
P00321261A0104|105 110|routes
P00330364A0132|230 241|laboratories
P00330364A0132|1 5|total
P00330364A0132|173 177|cases
P00330364A0132|114 122|abscesses
P00330364A0132|64 71|cultures
P00330364A0132|88 92|batch
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|10 19|BCG strains
P00330364A0132|13 19|strains
P00330364A0132|13 19|strains
P00330364A0132|13 19|strains
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|13 19|strains
P00330364A0132|10 12|BCG
P00330364A0132|125 132|children
P00331128A0000|4 9|levels
P00331128A0000|38 45|patients
P00331128A0000|62 68|failure
P00331128A0000|12 26|serum calcitonin
P00331936T0000|0 8|Detection
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00331936T0000|26 35|antibodies
P00336354A0543|13 19|serum GH
P00336354A0543|3 10|response
P00336354A0543|74 85|hypoglycemia
P00336354A0543|22 37|arginine infusion
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|3 15|mortality rate
P00336547A0000|124 127|mice
P00336547A0000|266 272|CBA/LAC
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|36 43|features
P00336547A0000|124 127|mice
P00336547A0000|243 257|New Zealand Black
P00336547A0000|136 141|C3H/eB
P00336547A0000|213 224|mouse strains
P00336547A0000|136 148|C3H/eB origins
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|130 132|ICR
P00336547A0000|259 264|BALB/c
P00337102T0058|0 7|Williams
P00337102T0058|10 15|August
P00339289T0049|0 2|Use
P00339289T0049|29 37|chemistry
P00339289T0049|16 23|isotopes
P00339289T0049|40 47|proteins
P00340692T0033|1 8|Emeritus
P00340692T0033|10 37|John Henri Roosegaarde Bisschop
P00342623A0228|87 96|reactivity
P00342623A0228|49 60|type B antigen
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|9 16|vaccines
P00350465T0000|34 42|disorders
P00350465T0000|9 17|diagnosis
P00352569A0000|30 44|blood parameters
P00352569A0000|85 89|mg/kg
P00352569A0000|69 73|rates
P00352569A0000|7 18|oxygen supply
P00352569A0000|105 113|endotoxin
P00354315T0000|20 27|patients
P00354315T0000|32 51|ataxia telangiectasia
P00354315T0000|7 17|dysfunction
P00358945A0225|70 74|weeks
P00358945A0225|18 26|treatment
P00358945A0225|10 15|period
P00361059T0000|1 5|study
P00361059T0000|69 88|clobetasol propionate
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|57 65|% ointment
P00361059T0000|22 29|efficacy
P00361059T0000|57 65|% ointment
P00361340A0529|29 42|osteodystrophy
P00361340A0529|187 205|hyperparathyroidism
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|213 219|failure
P00361340A0529|92 100|condition
P00361340A0529|157 168|significance
P00361340A0529|9 17|phenomena
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|73 82|deficiency
P00369397A0280|5 7|FSH
P00369397A0280|134 141|controls
P00369397A0280|5 7|FSH
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|43 49|addicts
P00369397A0280|43 49|addicts
P00369397A0280|11 18|LH levels
P00369397A0280|88 95|LH values
P00369683T0000|0 9|Adriamycin
P00369683T0000|30 37|schedule
P00369683T0000|73 84|breast cancer
P00369683T0000|30 37|schedule
P00369683T0000|11 20|comparison
P00369683T0000|62 70|treatment
P00377466A0188|30 36|hormone
P00377466A0188|90 99|oestradiol
P00377466A0188|173 179|disease
P00377466A0188|123 134|testosterone
P00377466A0188|38 39|LH
P00377466A0188|9 16|controls
P00377466A0188|69 71|FSH
P00377466A0188|85 85|P
P00377466A0188|143 151|catabolic
P00377466A0188|105 116|progesterone
P00377466A0188|74 82|prolactin
P00377466A0188|136 136|T
P00377466A0188|42 67|follicle stimulating hormone
P00377466A0188|101 102|E2
P00377466A0188|155 166|healing phase
P00377466A0188|84 87|HPRL
P00378492A0475|0 11|Renin studies
P00378492A0475|200 213|artery stenosis
P00378492A0475|98 116|plasma renin activity
P00378492A0475|67 76|recipients
P00378492A0475|37 44|patients
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|87 95|elevation
P00378492A0475|51 62|control group
P00378735A0000|259 266|carriers
P00378735A0000|82 86|blood
P00378735A0000|171 174|days
P00378735A0000|56 56|g
P00378735A0000|68 72|fever
P00378735A0000|90 102|marrow culture
P00378735A0000|40 47|patients
P00378735A0000|114 124|amoxycillin
P00378735A0000|188 202|chloramphenicol
P00378735A0000|270 281|relapse rates
P00378735A0000|19 23|trial
P00378735A0000|250 256|respect
P00378735A0000|207 212|regard
P00378735A0000|226 244|temperature response
P00378735A0000|128 141|dosage schedule
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|119 138|rye-ergot derivatives
P00383169A0000|73 78|agents
P00383169A0000|46 61|dopamine receptor
P00383169A0000|97 107|derivatives
P00383169A0000|80 90|apomorphine
P00383169A0000|6 12|article
P00383169A0000|109 117|piribedil
P00383169A0000|198 207|properties
P00383169A0000|157 161|basis
P00383169A0000|25 31|actions
P00384744T0000|23 34|hypofunction
P00385457A0187|84 90|healing
P00385457A0187|70 78|influence
P00385457A0187|40 44|juice
P00385457A0187|20 25|pepsin
P00385457A0187|8 17|inhibition
P00385457A0187|101 105|ulcer
P00386251A0899|26 34|detection
P00386251A0899|83 102|sulphonamide residues
P00386251A0899|3 19|IDF standard method
P00386251A0899|49 52|milk
P00386251A0899|49 52|milk
P00386251A0899|26 34|detection
P00386251A0899|37 46|penicillin
P00390932T0001|8 15|antigens
P00393598A0198|47 49|ALS
P00393598A0198|3 8|course
P00393598A0198|11 24|endotoxin fever
P00397806T0039|4 16|Algerian cases
P00401521A0138|20 27|patients
P00401521A0138|11 17|percent
P00401521A0138|39 49|ticarcillin
P00401676A0414|71 82|radiotherapy
P00401676A0414|35 42|patients
P00401676A0414|18 24|staging
P00406585T0001|8 17|hematology
P00406585T0001|23 25|age
P00409927A0570|0 7|Neomycin
P00409927A0570|127 135|organisms
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00411465A0142|27 33|section
P00411465A0142|51 60|trabeculae
P00411465A0142|67 73|contact
P00411465A0142|42 45|cent
P00411465A0142|86 93|cavities
P00413854A0958|0 6|Changes
P00413854A0958|86 90|blood
P00413854A0958|9 18|tissue PCO2
P00414575T0000|10 19|evaluation
P00414575T0000|27 33|calculi
P00415543A0320|0 10|Recognition
P00415543A0320|133 143|lung disease
P00415543A0320|56 62|quality
P00415543A0320|33 43|radiographs
P00415543A0320|91 95|films
P00415543A0320|107 114|patients
P00415543A0320|91 95|films
P00415543A0320|13 21|emphysema
P00416758T0001|0 8|Isolation
P00416758T0001|44 53|adaptation
P00416758T0001|56 72|laboratory animals
P00416758T0001|31 35|Zaire
P00416758T0001|11 28|T. gambiense strains
P00417166T0000|15 21|profile
P00417166T0000|24 33|clonazepam
P00417166T0000|36 48|rhesus monkeys
P00417301T0001|30 40|brucellosis
P00417301T0001|43 48|humans
P00417301T0001|11 20|mechanisms
P00418341T0000|31 35|parts
P00418341T0000|10 19|adaptation
P00420460A0291|2 9|patients
P00420460A0291|81 86|change
P00420460A0291|150 150|P
P00420460A0291|93 105|blood pressure
P00420460A0291|48 77|log baseline plasma renin activity
P00420460A0291|34 46|drug treatment
P00420460A0291|16 16|r
P00420460A0291|111 112|SQ
P00423649A0259|56 60|claim
P00423649A0259|94 99|regard
P00423649A0259|5 14|techniques
P00423649A0259|78 87|innovation
P00423649A0259|33 38|people
P00423649A0259|46 50|years
P00425547A0000|2 9|patients
P00425547A0000|21 33|osteomyelitis
P00425547A0000|112 116|weeks
P00425547A0000|21 22|os
P00425547A0000|91 100|cephalexin
P00427715A0000|125 134|University
P00427715A0000|1 5|total
P00427715A0000|82 82|B
P00427715A0000|31 37|disease
P00427715A0000|55 63|diaphragm
P00427715A0000|65 70|Stages
P00427715A0000|137 143|Florida
P00427715A0000|99 114|radiation therapy
P00427715A0000|22 28|Hodgkin
P00427715A0000|10 17|patients
P00429151T0000|43 46|unit
P00429151T0000|0 3|Year
P00429151T0000|59 69|Glasgow area
P00429151T0000|24 35|practitioner
P00429893A0000|30 40|round window
P00429893A0000|99 100|mm
P00429893A0000|109 120|scala tympani
P00429893A0000|22 26|array
P00429893A0000|135 140|trauma
P00429893A0000|49 60|implantation
P00429893A0000|126 132|minimum
P00429893A0000|164 174|stimulation
P00429893A0000|79 84|system
P00429949A0000|108 116|prolactin
P00429949A0000|218 228|immunoassay
P00429949A0000|119 126|ampoules
P00429949A0000|17 39|World Health Organization
P00429949A0000|161 193|International Reference Preparation
P00429949A0000|44 58|Expert Committee
P00429949A0000|108 116|prolactin
P00429949A0000|61 85|Biological Standardization
P00429949A0000|195 197|IRP
P00429949A0000|90 100|preparation
P00430889T0001|15 22|fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|42 61|beta receptor blockers
P00431832T0001|24 28|blood
P00432615A0541|134 145|interference
P00432615A0541|151 164|Sephadex system
P00432615A0541|46 55|literature
P00432615A0541|57 77|heterophile antibodies
P00432615A0541|167 170|RIST
P00432615A0541|10 20|differences
P00432615A0541|91 103|gammaglobulin
P00435187T0000|14 25|flowers bloom
P00437749A0242|42 48|context
P00437749A0242|54 63|psychology
P00437749A0242|7 25|treatment modalities
P00437749A0242|104 107|pain
P00437749A0242|75 84|physiology
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|63 71|poisoning
P00439618T0001|23 36|diethylamino-2
P00439618T0001|74 82|childhood
P00439618T0001|54 61|ajmaline
P00439618T0001|39 51|hydroxypropyl
P00439716T0001|32 48|blood flow velocity
P00439716T0001|20 29|evaluation
P00439716T0001|67 73|fistula
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|28 30|SPG
P00445720A0263|73 74|LA
P00445720A0263|56 57|LV
P00445720A0263|46 54|ventricle
P00445720A0263|91 122|high-fidelity pressure transducers
P00445720A0263|66 71|atrium
P00445720A0263|11 26|pressure gradient
P00450367T0000|26 37|hysterectomy
P00450367T0000|103 107|stage
P00450367T0000|62 67|radium
P00450367T0000|120 128|carcinoma
P00450367T0000|26 37|hysterectomy
P00450367T0000|12 16|trail
P00450367T0000|62 67|radium
P00450367T0000|26 37|hysterectomy
P00450559A0269|13 19|patient
P00450559A0269|94 104|thermometer
P00450559A0269|80 87|accuracy
P00450559A0269|43 51|Clinitemp
P00450559A0269|5 9|basis
P00450559A0269|22 27|report
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 24|Raynaud
P00450760T0001|27 34|syndrome
P00451192A0248|0 3|Data
P00451192A0248|100 119|LV region-of-interest
P00451192A0248|81 85|curve
P00451192A0248|36 50|computer program
P00453780A0430|15 30|serum IgA response
P00453780A0430|119 122|lung
P00453780A0430|100 105|tissue
P00453780A0430|136 141|source
P00453780A0430|44 60|patient population
P00453780A0430|20 22|IgA
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|84 84|V
P00454780A0340|60 73|titanium alloys
P00454780A0340|81 82|Ta
P00454780A0340|118 126|corrosion
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|101 112|fatigue limit
P00456424A0000|88 96|heart rate
P00456424A0000|72 84|blood pressure
P00456424A0000|3 9|effects
P00456424A0000|119 125|rabbits
P00456424A0000|56 68|microgram kg-1
P00456424A0000|45 53|clonidine
P00456424A0000|36 41|i.c.i.
P00456424A0000|154 166|cisterna magna
P00456424A0000|141 148|catheter
P00456424A0000|26 34|injection
P00463973A0000|116 118|age
P00463973A0000|0 13|Platelet number
P00463973A0000|72 76|women
P00463973A0000|59 67|pregnancy
P00463973A0000|17 24|life span
P00463973A0000|120 122|SGA
P00463973A0000|48 56|trimester
P00463973A0000|124 130|infants
P00463973A0000|166 177|birth weights
P00463973A0000|124 130|infants
P00463973A0000|72 76|women
P00464387A1185|58 72|disease activity
P00464387A1185|6 17|measurements
P00464387A1185|25 32|serum IgE
P00464387A1185|51 55|index
P00464387A1185|75 78|ABPA
P00465223A0373|58 64|delta PU
P00465223A0373|93 96|mmHg
P00465223A0373|68 74|delta PM
P00465223A0373|90 91|SD
P00465223A0373|17 34|difference betweent
P00465223A0373|6 13|patients
P00465223A0373|50 55|values
P00465681A0000|72 81|blood serum
P00465681A0000|1 4|rise
P00465681A0000|45 52|increase
P00465681A0000|106 119|oxygen pressure
P00465681A0000|131 134|hour
P00465681A0000|89 92|mice
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|149 153|state
P00465681A0000|123 125|atm
P00465681A0000|123 125|atm
P00465681A0000|149 153|state
P00465681A0000|63 66|iron
P00465829T0000|0 5|Nernst
P00465829T0000|63 72|potentials
P00465829T0000|8 28|Planck analog equations
P00465829T0000|42 54|state membrane
P00473229T0000|0 6|Effects
P00473229T0000|43 59|trichloroethylene
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|9 25|methylene chloride
P00473229T0000|95 105|development
P00473229T0000|108 119|chick embryos
P00473229T0000|83 89|toluene
P00473229T0000|27 41|trichloroethane
P00473249T0000|0 5|Effect
P00473249T0000|58 77|electroencephalogram
P00473249T0000|24 37|administration
P00473249T0000|80 86|rabbits
P00473249T0000|40 52|streptolysin O
P00474064A0205|115 127|phenoperidine
P00474064A0205|6 14|situation
P00474064A0205|66 74|pethidine
P00474064A0205|89 99|piritramide
P00474064A0205|138 145|fentanyl
P00474064A0205|130 130|R
P00474064A0205|130 130|R
P00474064A0205|44 53|substances
P00474064A0205|18 36|convlusion threshold
P00474064A0205|77 87|mg.kg-1 I.V.
P00474064A0205|84 87|I.V.
P00474064A0205|148 157|sufentanil
P00474064A0205|103 110|morphine
P00476020T0000|43 48|growth
P00476020T0000|3 14|biochemistry
P00476020T0000|25 29|fluid
P00476572A0139|94 98|cases
P00476572A0139|24 29|lesion
P00476572A0139|94 98|cases
P00476572A0139|113 124|radiodensity
P00477794T0000|0 6|Effects
P00477794T0000|101 106|oralis
P00477794T0000|59 65|neurons
P00477794T0000|41 56|response patterns
P00477794T0000|81 97|nuclei principalis
P00477794T0000|26 35|tractotomy
P00478714T0000|0 7|Efficacy
P00478714T0000|33 55|alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|176 180|years
P00479222A0682|101 114|immersion times
P00479222A0682|152 159|degrees C
P00479222A0682|137 141|fluid
P00479222A0682|86 95|properties
P00479222A0682|143 146|PECF
P00479222A0682|35 45|environment
P00479222A0682|65 73|retention
P00479246T0000|28 40|osteomyelitis
P00481612A1121|58 66|ventricle
P00481612A1121|102 107|action
P00481612A1121|110 117|fentanyl
P00481612A1121|23 31|receptors
P00483716A0366|41 47|carotid
P00483716A0366|2 5|case
P00483716A0366|97 107|anastomosis
P00483716A0366|57 69|carotid artery
P00484177A0242|97 99|VT.
P00484177A0242|4 13|expression
P00484177A0242|50 59|expiration
P00484177A0242|90 94|range
P00484177A0242|26 43|laminar flow regimen
P00484177A0242|76 82|CT value
P00485615A0935|116 123|syndrome
P00485615A0935|141 150|occurrence
P00485615A0935|68 73|entity
P00485615A0935|221 227|surgery
P00485615A0935|158 169|pancreatitis
P00485615A0935|19 27|existence
P00485615A0935|5 8|data
P00485615A0935|51 56|crisis
P00485615A0935|89 98|importance
P00485615A0935|176 186|performance
P00485615A0935|126 130|order
P00488534A0308|2 9|addition
P00488534A0308|113 118|MR rats
P00488534A0308|66 82|defecation numbers
P00488534A0308|22 48|Treatment X Strain interaction
P00488534A0308|113 118|MR rats
P00490336A0181|43 47|m/sec
P00490336A0181|5 22|conduction velocity
P00490336A0181|49 54|group C
P00493818A0422|3 10|failures
P00493818A0422|95 98|days
P00493818A0422|120 128|insertion
P00493818A0422|109 114|months
P00493818A0422|34 51|patient intolerance
P00493818A0422|68 70|fit
P00494659A0391|15 25|metabolites
P00494659A0391|33 47|3-carboxyphenyl
P00494659A0391|85 95|glucuronide
P00494659A0391|98 107|toloxatone
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00495097A0663|101 106|tissue
P00495097A0663|63 76|fiber synthesis
P00495097A0663|5 19|characteristics
P00495097A0663|83 88|matrix
P00495097A0663|42 49|activity
P00497494A0112|32 36|PACO2
P00497494A0112|3 13|ventilation
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|60 71|sperm studies
P00499588T0000|28 39|semen profile
P00499588T0000|49 55|insulin
P00499588T0000|41 47|glucose
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|139 146|findings
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|103 115|transaminases
P00503336A0285|162 170|diagnosis
P00503336A0285|73 78|levels
P00503336A0285|61 65|fever
P00503336A0285|45 51|attacks
P00503336A0285|121 125|serum
P00503336A0285|34 37|CIEC
P00506559A0000|32 39|furfural
P00506559A0000|12 29|inhalation toxicity
P00506559A0000|64 71|hamsters
P00506649T0000|0 6|Changes
P00506649T0000|58 63|stress
P00506649T0000|19 40|serum protein components
P00509703A0581|5 15|differences
P00509703A0581|54 62|textbooks
P00510341T0036|1 5|study
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|58 58|L
P00512215A0000|60 64|f2-f1
P00512215A0000|60 61|f2
P00512215A0000|136 137|L1
P00512215A0000|63 64|f1
P00512215A0000|136 137|L1
P00512215A0000|10 14|study
P00512215A0000|113 117|f2/f1
P00512215A0000|139 140|L2
P00512215A0000|38 56|difference tone level
P00512215A0000|63 64|f1
P00512215A0000|139 140|L2
P00512215A0000|81 90|parameters
P00512215A0000|104 108|input
P00512215A0000|26 35|dependence
P00513284A0000|146 160|pediatrics field
P00513284A0000|199 200|mg
P00513284A0000|38 41|DOTC
P00513284A0000|168 174|results
P00513284A0000|13 23|preparation
P00513284A0000|38 41|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|76 87|tetracycline
P00513284A0000|246 250|mg/kg
P00513284A0000|136 140|study
P00513284A0000|220 221|ml
P00513284A0000|112 123|drip infusion
P00513284A0000|224 238|glucose solution
P00513284A0000|128 133|series
P00513284A0000|54 59|Pfizer
P00513284A0000|26 36|doxycycline
P00513284A1255|14 17|days
P00513284A1255|67 75|functions
P00513284A1255|54 58|liver
P00513284A1255|79 83|blood
P00513284A1255|23 34|DOTC infusion
P00513284A1255|36 50|laboratory tests
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|114 131|glomerulonephritis
P00516545T0001|85 92|function
P00516545T0001|50 70|peroxidation processes
P00516545T0001|10 24|characteristics
P00516545T0001|95 102|children
P00517890A0468|71 76|levels
P00517890A0468|29 32|mode
P00517890A0468|117 121|onset
P00517890A0468|35 46|transmission
P00517890A0468|79 102|hepatitis A virus excretion
P00517890A0468|10 14|route
P00517890A0468|124 131|jaundice
P00517890A0468|50 59|hepatitis A
P00519173A0126|29 36|evidence
P00519173A0126|5 12|patients
P00519173A0126|39 50|oesophagitis
P00521732T0000|18 25|oestrone
P00521732T0000|47 54|oestriol
P00521732T0000|57 67|pregnancies
P00521732T0000|81 107|steroid sulphatase deficiency
P00521732T0000|7 15|excretion
P00521732T0000|27 43|oestradiol-17 beta
P00524451A0136|190 192|rat
P00524451A0136|72 82|amphetamine
P00524451A0136|179 184|organs
P00524451A0136|154 167|catecholamines
P00524451A0136|22 38|locomotor activity
P00524451A0136|129 132|time
P00524451A0136|108 120|hexobarbitone
P00524451A0136|63 67|death
P00524451A0136|41 44|mice
P00524451A0136|143 151|depletion
P00524451A0136|90 97|toxicity
P00528144T0000|27 32|uptake
P00528144T0000|44 53|tumor cells
P00528144T0000|5 8|role
P00528144T0000|35 41|gallium
P00528144T0000|11 21|transferrin
P00534613A0000|0 10|Irradiation
P00534613A0000|59 65|ability
P00534613A0000|68 76|aggregate
P00534613A0000|18 31|blood platelets
P00534613A0000|95 102|collagen
P00534613A0000|82 90|challenge
P00534613A0000|36 39|UV-A
P00535520A0239|74 88|cholangiography
P00535520A0239|24 29|method
P00535520A0239|11 20|exceptions
P00540707A0255|58 70|complications
P00540707A0255|257 269|vena cephalica
P00540707A0255|91 94|rate
P00540707A0255|108 122|tip displacement
P00540707A0255|165 171|Authors
P00540707A0255|190 195|method
P00540707A0255|44 50|account
P00540707A0255|99 103|cases
P00540707A0255|215 229|PMK implantation
P00540707A0255|198 200|use
P00540707A0255|24 30|results
P00540707A0255|126 139|pouch haematoma
P00540707A0255|204 211|approach
P00541752A1032|128 129|SD
P00541752A1032|68 73|adults
P00541752A1032|7 20|determinations
P00541752A1032|131 135|ng/ml
P00541752A1032|121 124|mean
P00541752A1032|47 52|plasma
P00541752A1032|87 92|values
P00541752A1032|76 82|October
P00541752A1032|38 44|samples
P00550399A0615|15 20|causes
P00550399A0615|23 27|death
P00550399A0615|50 55|groups
P00553858A0000|15 23|operation
P00553858A0000|15 23|operation
P00553858A0000|45 49|world
P00553858A0000|134 142|technique
P00553858A0000|195 204|principles
P00553858A0000|91 100|literature
P00553858A0000|8 12|Grice
P00553858A0000|111 122|publications
P00553858A0000|162 166|terms
P00553858A0000|63 69|account
P00555492A1034|42 50|blood flow
P00555492A1034|85 94|cimetidine
P00555492A1034|5 11|changes
P00555492A1034|47 50|flow
P00555492A1034|74 82|injection
P00555492A1034|74 82|injection
P00555492A1034|152 164|blood pressure
P00555495T0000|0 4|Study
P00555495T0000|25 33|ovulation
P00555495T0000|88 100|re-appearance
P00555495T0000|137 144|delivery
P00555495T0000|7 22|re-establishment
P00555495T0000|117 124|abortion
P00555495T0000|25 33|ovulation
P00555495T0000|65 73|treatment
P00555495T0000|39 49|termination
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00555583T0000|33 35|man
P00555583T0000|38 43|review
P00557559A0170|151 159|organisms
P00557559A0170|5 13|compounds
P00557559A0170|21 25|alpha
P00557559A0170|53 78|N-methylnitrone 1,4-dioxide
P00557559A0170|98 102|agent
P00564032A0724|14 20|content
P00564032A0724|0 6|Changes
P00564032A0724|54 63|mechanisms
P00564032A0724|70 77|pressure
P00564032A0724|92 95|duct
P00564032A0724|101 105|gland
P00564943A0444|0 5|Calves
P00564943A0444|71 78|SBO-milk
P00564943A0444|58 63|calves
P00564943A0444|11 11|T
P00564943A0444|9 16|MCT-milk
P00564943A0444|38 53|blood cholesterol
P00565136T0000|60 65|SO2Cl2
P00565136T0000|18 21|mice
P00565136T0000|55 58|CH2O
P00565136T0000|70 72|Br2
P00565136T0000|31 40|inhalation
P00565136T0000|7 15|mortality
P00565136T0000|48 52|doses
P00565314A0293|0 9|Guinea pigs
P00565314A0293|8 8|g
P00569989A0239|105 110|dPn/dt
P00569989A0239|60 63|time
P00569989A0239|28 47|flow pneumocardiogram
P00569989A0239|75 102|acceleration pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|154 169|pneumotachograph
P00569989A0239|132 136|apnea
P00574222T0000|31 41|development
P00574222T0000|16 27|implications
P00574222T0000|7 14|kindling
P00574222T0000|51 60|prostheses
P00574956A0304|115 125|equilibrium
P00574956A0304|17 26|stereotypy
P00574956A0304|66 73|dopamine
P00574956A0304|47 50|case
P00574956A0304|78 81|tone
P00574956A0304|253 265|manifestation
P00574956A0304|226 236|development
P00574956A0304|163 169|systems
P00575231A0422|0 3|None
P00575231A0422|9 23|cystometrograms
P00575231A0422|41 60|detrusor contractions
P00577440A0298|40 43|dose
P00577440A0298|5 12|duodenum
P00577440A0298|19 22|part
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00578648T0048|34 47|administration
P00578648T0048|10 16|effects
P00580106T0000|0 8|Treatment
P00580106T0000|18 24|disease
P00580106T0000|11 16|Graves
P00580151A0706|183 189|effects
P00580151A0706|117 127|convenience
P00580151A0706|83 92|se-T levels
P00580151A0706|164 167|cost
P00580151A0706|133 139|patient
P00580151A0706|108 112|range
P00580151A0706|61 72|testosterone
P00580151A0706|200 204|doses
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|142 154|inflammations
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|116 122|lesions
P00583004A0445|160 163|skin
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583522T0001|30 37|problems
P00583522T0001|52 63|inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|34 41|diseases
P00587791T0054|9 16|patients
P00589073A0000|173 183|infertility
P00589073A0000|129 133|group
P00589073A0000|15 43|plasma prolactin concentrations
P00589073A0000|86 90|phase
P00589073A0000|47 53|samples
P00589073A0000|111 115|women
P00589073A0000|164 170|history
P00589073A0000|138 145|patients
P00589073A0000|103 109|control
P00590594T0000|7 25|allotransplantation
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|8 15|reaction
P00592887T0000|40 51|lymphography
P00593119T0001|0 8|Screening
P00593119T0001|42 44|IgE
P00593119T0001|27 39|determination
P00593119T0001|65 72|spectrum
P00593119T0001|11 24|asthma patients
P00593119T0001|90 102|IgE antibodies
P00593119T0001|50 62|comprehension
P00594466T0001|14 21|seizures
P00594466T0001|99 109|stimulation
P00594466T0001|3 11|induction
P00594466T0001|45 56|allylglycine
P00594466T0001|66 76|combination
P00594466T0001|25 34|Papio papio
P00594617A0192|89 91|FDP
P00594617A0192|177 184|monomers
P00594617A0192|110 120|nephropathy
P00594617A0192|275 277|ESR
P00594617A0192|193 216|ethanol-gelification test
P00594617A0192|250 256|disease
P00594617A0192|18 28|correlation
P00594617A0192|47 54|presence
P00594617A0192|99 107|incidence
P00594617A0192|69 87|degradation products
P00594617A0192|186 190|Godal
P00594617A0192|47 54|presence
P00594617A0192|258 262|fever
P00594617A0192|233 237|signs
P00594617A0192|129 141|insufficiency
P00597715A0256|14 16|men
P00597715A0256|0 8|One-third
P00597715A0256|97 106|experience
P00597715A0256|152 160|prognosis
P00597715A0256|79 90|FSH elevation
P00597715A0256|118 121|work
P00597715A0256|21 31|azoospermia
P00597715A0256|39 50|sperm density
P00597715A0256|124 129|others
P00598012A0174|28 32|stage
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|52 59|menarche
P00598012A0174|63 66|boys
P00598012A0174|76 81|change
P00598012A0174|7 21|prolactin levels
P00599601A0260|132 141|physiology
P00599601A0260|64 75|pinealectomy
P00599601A0260|108 110|rat
P00599601A0260|104 114|alterations
P00599601A0260|37 46|procedures
P00600943T0001|13 31|lymphomononucleosis
P00600943T0001|1 5|cases
P00601401A0181|57 62|oxygen
P00601401A0181|96 119|delta log Po2/delta pH ratio
P00601401A0181|70 79|Bohr effect
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|46 53|affinity
P00602622A0362|116 123|activity
P00602622A0362|19 19|p
P00602622A0362|82 90|reduction
P00602622A0362|44 48|Roter
P00602622A0362|36 42|Vikalin
P00602622A0362|9 20|ulcer therapy
P00602622A0362|25 32|atropine
P00602702A0309|84 91|function
P00602702A0309|22 29|diarrhea
P00602702A0309|55 59|serum
P00602702A0309|5 11|patient
P00602702A0309|33 52|estriol concentration
P00602702A0309|33 52|estriol concentration
P00602702A0309|22 29|diarrhea
P00603783A0647|0 10|Serum levels
P00603783A0647|68 85|observers IgA levels
P00603783A0647|13 15|IgG
P00603783A0647|53 60|findings
P00603783A0647|19 21|IgM
P00606849T0000|56 62|rabbits
P00606849T0000|20 31|heart disease
P00606849T0000|41 53|thromboxane A2
P00614915T0001|0 9|Vitrectomy
P00614915T0001|18 29|traumatology
P00616575A0000|86 99|decimeter waves
P00616575A0000|117 129|investigation
P00616575A0000|54 59|action
P00616575A0000|106 107|DW
P00616575A0000|79 83|field
P00616575A0000|34 48|brain structures
P00616575A0000|10 20|sensitivity
P00616575A0000|138 149|unit activity
P00616575A0000|101 103|EMF
P00617815A0215|12 25|L-R differences
P00618078A0367|1 8|decrease
P00618078A0367|14 29|lysozyme activity
P00618078A0367|54 64|improvement
P00618078A0367|79 88|meningitis
P00619305A0759|70 79|dimensions
P00619305A0759|18 23|groups
P00619305A0759|47 55|dimension
P00619782A0058|73 92|ultraviolet radiation
P00619782A0058|26 30|backs
P00619782A0058|4 7|tans
P00619782A0058|55 62|exposure
P00619782A0058|94 97|UV-A
P00619782A0058|33 42|volunteers
P00619948A0000|89 90|mg
P00619948A0000|57 62|tablet
P00619948A0000|173 185|blood pressure
P00619948A0000|4 10|effects
P00619948A0000|235 244|detachment
P00619948A0000|89 90|mg
P00619948A0000|163 171|heart rate
P00619948A0000|219 225|anxiety
P00619948A0000|19 26|subjects
P00619948A0000|281 288|diazepam
P00619948A0000|89 90|mg
P00619948A0000|227 233|tension
P00619948A0000|74 85|fluphenazine
P00619948A0000|314 324|propranolol
P00619948A0000|200 205|scales
P00619948A0000|145 147|CNV
P00619948A0000|135 143|variation
P00619948A0000|89 90|mg
P00619948A0000|40 43|dose
P00619948A0000|248 257|depression
P00619948A0000|94 106|nortriptyline
P00619948A0000|209 217|alertness
P00619948A0000|89 90|mg
P00619948A0000|150 161|reaction time
P00619948A0000|46 52|Motival
P00619948A0000|305 311|placebo
P00621626T0000|0 12|Stress effects
P00621626T0000|42 49|subjects
P00621626T0000|15 36|affiliation preferences
P00621626T0000|82 96|behavior pattern
P00621626T0000|63 66|type
P00622556A0111|16 23|collagen
P00622556A0111|30 35|tissue
P00622556A0111|64 69|tendon
P00623361A0221|28 39|contribution
P00623361A0221|0 6|Smoking
P00623361A0221|51 61|dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|20 26|lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627039T0000|13 22|bagassosis
P00627129A0944|174 191|beta-adrenoceptors
P00627129A0944|115 120|effect
P00627129A0944|30 35|others
P00627129A0944|45 52|subjects
P00627129A0944|5 13|responses
P00627129A0944|123 131|labetalol
P00627129A0944|65 74|conditions
P00627129A0944|155 162|blockade
P00627202T0000|0 8|Diuretics
P00627202T0000|49 51|use
P00627202T0000|23 34|pharmacology
P00628990A0000|33 37|units
P00628990A0000|157 160|loop
P00628990A0000|5 12|patients
P00628990A0000|93 104|ureterostomy
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|63 76|reconstruction
P00630713T0000|0 9|Evaluation
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|43 64|Internal-External Locus
P00633909A0000|18 25|patients
P00633909A0000|18 25|patients
P00633909A0000|98 106|treatment
P00633909A0000|171 177|control
P00633909A0000|67 78|Control Scale
P00633909A0000|35 40|Rotter
P00633909A0000|27 32|scores
P00635143T0001|0 5|Action
P00635143T0001|33 46|Cyprinus carpio
P00635143T0001|23 30|metaphos
P00635143T0001|8 19|strontium-90
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|65 80|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|24 32|diagnosis
P00637637T0000|57 68|hypertension
P00637637T0000|11 17|factors
P00637637T0000|27 45|plasma renin activity
P00639410T0000|43 61|lipid clearing agents
P00639410T0000|0 8|Cortisone
P00639410T0000|16 26|bone changes
P00639410T0000|33 40|response
P00640584A0250|46 54|stability
P00640584A0250|17 25|principle
P00641395A0441|150 165|extraction method
P00641395A0441|4 15|blood samples
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|18 25|patients
P00641395A0441|126 131|levels
P00641395A0441|80 82|ZPP
P00641395A0441|67 77|measurement
P00641395A0441|89 99|fluorimeter
P00644314T0000|29 35|effects
P00644314T0000|46 60|anticoagulation
P00644314T0000|7 22|hypersensitivity
P00644314T0000|25 27|man
P00644539A0783|39 44|saline
P00644539A0783|66 66|%
P00644539A0783|53 56|FEV1
P00644539A0783|31 32|ml
P00644539A0783|115 123|reactions
P00644539A0783|18 27|inhalation
P00644539A0783|129 141|test solutions
P00644539A0783|106 112|subject
P00644539A0783|66 66|%
P00646023T0058|51 62|transmission
P00646023T0058|21 34|virus excretion
P00646023T0058|12 18|studies
P00646193T0000|0 6|Potency
P00646193T0000|20 23|dogs
P00646193T0000|9 17|enflurane
P00646193T0000|39 47|halothane
P00646193T0000|51 60|isoflurane
P00646193T0000|25 34|comparison
P00656008T0000|0 9|Prevention
P00656008T0000|41 59|superoxide dismutase
P00656008T0000|17 32|paraquat toxicity
P00656008T0000|35 38|rats
P00657551T0000|0 10|Measurement
P00657551T0000|34 36|man
P00657551T0000|55 60|tracer
P00657551T0000|48 51|26Mg
P00657551T0000|13 31|magnesium absorption
P00659962T0000|16 34|riboflavin excretion
P00659962T0000|53 65|acid ingestion
P00663166A0000|181 201|Eisenmenger physiology
P00663166A0000|150 171|patent ductus arteriosus
P00663166A0000|138 145|patients
P00663166A0000|128 135|shunting
P00663166A0000|83 94|particulates
P00663166A0000|37 47|body imaging
P00663166A0000|12 22|angiography
P00663166A0000|173 175|PDA
P00664320T0000|32 38|pathway
P00664320T0000|7 15|detectors
P00665053A0276|67 80|group affection
P00665053A0276|34 37|type
P00665053A0276|45 47|K13
P00665053A0276|49 50|H1
P00665053A0276|39 43|06a6b
P00665214A0374|3 8|method
P00665214A0374|45 54|physiology
P00665214A0374|65 69|cycle
P00665336A0908|43 57|EEG-information
P00665336A0908|9 12|time
P00668122A0414|0 7|Analysis
P00668122A0414|46 54|hepatitis
P00668122A0414|81 95|mean iron content
P00668122A0414|34 41|patients
P00668122A0414|67 75|variation
P00668122A0414|10 29|liver biopsy specimens
P00668122A0414|101 122|liver ferritin molecules
P00669800A0579|42 50|infection
P00669800A0579|55 59|males
P00669800A0579|6 9|mice
P00676416A0320|42 54|liver biopsies
P00676416A0320|22 26|years
P00676790T0000|0 16|Angiotensin effect
P00676790T0000|27 32|kidney
P00681550A0000|0 6|Procion
P00681550A0000|59 64|fibers
P00681550A0000|146 149|site
P00681550A0000|51 64|auditory fibers
P00681550A0000|67 74|goldfish
P00681550A0000|176 181|macula
P00681550A0000|113 124|response type
P00681550A0000|91 102|relationship
P00681550A0000|152 162|termination
P00681571T0028|23 31|epidermis
P00681571T0028|10 17|findings
P00681571T0028|54 74|eccrine sweat duct units
P00682762T0001|0 17|Silicosis mortality
P00685922A0451|71 73|IHB
P00685922A0451|66 69|tree
P00685922A0451|26 35|strictures
P00686836A0000|0 6|Pentane
P00686836A0000|71 87|gas chromatography
P00686836A0000|116 120|weeks
P00686836A0000|192 193|kg
P00686836A0000|33 49|lipid peroxidation
P00686836A0000|122 128|vitamin
P00686836A0000|105 108|rats
P00686836A0000|140 143|diet
P00686836A0000|90 102|breath samples
P00686836A0000|10 15|ethane
P00686836A0000|172 188|IU vitamin E acetate
P00693987T0001|0 13|Thromboplastic
P00693987T0001|29 36|activity
P00693987T0001|87 93|history
P00693987T0001|42 46|blood
P00693987T0001|122 125|year
P00693987T0001|80 82|men
P00693987T0001|68 77|intralipid
P00693987T0001|106 115|infarction
P00693987T0001|128 131|life
P00693987T0001|52 65|administration
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|3 9|authors
P00696680A0000|120 125|cervix
P00696680A0000|50 54|cases
P00696680A0000|107 117|endometrium
P00696680A0000|36 43|findings
P00696680A0000|62 66|women
P00696858A0000|116 130|porcine pancreas
P00696858A0000|69 77|secretion
P00696858A0000|3 8|effect
P00696858A0000|22 36|porcine secretin
P00696858A0000|39 47|endocrine
P00701144T0000|30 38|lens power
P00701144T0000|56 65|emmetropia
P00701144T0000|79 86|implants
P00701144T0000|67 73|results
P00701144T0000|9 16|analysis
P00701462A0722|0 14|Urine antibodies
P00701462A0722|47 51|cases
P00702773A0327|0 9|Althoug RBF
P00702773A0327|7 9|RBF
P00702773A0327|34 40|therapy
P00702773A0327|76 81|change
P00702773A0327|88 90|GFR
P00702773A0327|101 106|output
P00703350A0418|0 4|99mTc
P00703350A0418|0 11|99mTc phytate
P00703350A0418|42 48|sulfide
P00703350A0418|13 24|198Au colloid
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|3 10|patients
P00703932A0000|99 103|modes
P00703932A0000|69 73|shunt
P00703932A0000|35 45|association
P00703932A0000|106 112|therapy
P00704675A0199|129 135|trachea
P00704675A0199|40 40|d
P00704675A0199|31 37|bronchi
P00704675A0199|3 6|mass
P00704675A0199|3 6|mass
P00704675A0199|90 99|inhalation
P00704675A0199|46 56|bifurcation
P00704675A0199|9 11|UO2
P00710217T0001|18 25|hip joint
P00710217T0001|8 12|cysts
P00710372A0302|25 32|function
P00710372A0302|125 132|features
P00710372A0302|22 32|dysfunction
P00710372A0302|82 93|GH deficiency
P00712117A0521|39 42|base
P00712117A0521|95 101|variant
P00712117A0521|16 25|influenza A
P00712117A0521|6 13|outbreak
P00712117A0521|122 130|prototpye
P00712117A0521|107 118|A/Victoria/3
P00712117A0521|88 92|virus
P00712117A0521|71 79|A/Texas/1
P00712117A0521|49 56|February
P00713525A0268|69 80|presentation
P00713525A0268|108 111|data
P00713525A0268|21 35|disfluency rates
P00713525A0268|7 15|decreases
P00713525A0268|137 141|model
P00713525A0268|91 103|stimulus words
P00713525A0268|38 47|stutterers
P00715180T0074|0 5|Effect
P00715180T0074|41 50|inhalation
P00715180T0074|15 18|dose
P00715180T0074|25 27|rat
P00715180T0074|21 31|alterations
P00715180T0074|8 11|time
P00715180T0074|53 79|plutonium-239 dioxide aerosol
P00715753A0241|10 14|CK-MB
P00715753A0241|85 91|muscles
P00715753A0241|2 22|biopsies CK-MB fraction
P00715753A0241|53 69|total-CPK activity
P00715753A0241|48 48|%
P00715753A0241|104 112|% fraction
P00715753A0241|40 42|CPK
P00716366T0001|0 4|Value
P00716366T0001|88 95|jaundice
P00716366T0001|7 19|determination
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|106 119|liver cirrhosis
P00716366T0001|66 74|diagnosis
P00722298A0619|159 163|males
P00722298A0619|172 177|famale
P00722298A0619|101 105|field
P00722298A0619|55 59|women
P00722298A0619|93 98|groups
P00722298A0619|8 15|analysis
P00722298A0619|93 98|groups
P00722298A0619|136 138|rho
P00722298A0619|63 73|differences
P00722298A0619|157 163|females
P00722298A0619|18 25|variance
P00722298A0619|49 51|men
P00722298A0619|123 134|significance
P00722298A0619|101 115|field dependence
P00722652A0118|115 119|cecum
P00722652A0118|48 55|diameter
P00722652A0118|68 77|micrometer
P00722652A0118|11 33|2nd-generation schizonts
P00722652A0118|103 109|surface
P00725257A0452|40 42|DHE
P00725257A0452|32 32|E
P00725257A0452|52 53|M.
P00725257A0452|13 21|pD2 values
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725336T0000|35 42|Hong Kong
P00725336T0000|61 67|poultry
P00725534A0888|29 37|challenge
P00725534A0888|173 179|atrophy
P00725534A0888|53 60|antigens
P00725534A0888|95 104|epithelium
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|121 129|tolerance
P00725534A0888|195 199|villi
P00725534A0888|205 212|patients
P00725534A0888|40 47|M. leprae
P00725534A0888|139 151|IgA deficiency
P00725534A0888|228 234|leprosy
P00725752T0001|0 8|Treatment
P00725752T0001|102 109|apressin
P00725752T0001|28 38|combination
P00725752T0001|54 74|beta receptor blockader
P00725752T0001|76 82|obsidan
P00725752T0001|11 22|hypertension
P00725752T0001|90 100|vasodilator
P00726581T0122|0 5|Orthop
P00728718T0000|0 13|Thyroid disease
P00728718T0000|17 25|pregnancy
P00729003A1182|0 7|Residues
P00729003A1182|32 39|splicing
P00729003A1182|19 29|transcripts
P00733067A0188|28 31|loop
P00733067A0188|290 297|stitches
P00733067A0188|149 159|anastomosis
P00733067A0188|34 39|number
P00733067A0188|91 97|section
P00733067A0188|110 114|stump
P00733067A0188|10 15|reflux
P00733067A0188|269 274|mucosa
P00733067A0188|246 263|spiral introflexion
P00733067A0188|132 143|construction
P00733067A0188|149 159|anastomosis
P00733067A0188|182 189|creation
P00733067A0188|207 217|valve system
P00733067A0188|332 336|lumen
P00733067A0188|51 55|steps
P00736376A0371|27 35|mortality
P00736376A0371|43 50|ischemia
P00736376A0371|6 10|stage
P00736376A0371|75 81|urgency
P00736376A0371|101 105|skill
P00736376A0371|87 95|operation
P00737422A0832|0 8|Pathogens
P00737422A0832|45 51|bacilli
P00737422A0832|144 151|patients
P00737422A0832|76 81|member
P00737422A0832|96 102|numbers
P00737422A0832|96 102|numbers
P00737422A0832|84 88|staff
P00740409A0000|45 62|cerebellar deposits
P00740409A0000|74 78|Tonge
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00741476A0000|45 50|mg p.d.
P00741476A0000|89 93|birth
P00741476A0000|11 15|woman
P00741476A0000|74 81|abortion
P00741476A0000|62 65|days
P00741476A0000|24 41|Ergotamine Tartrate
P00743335T0001|0 12|Reaction times
P00743335T0001|51 59|diabetics
P00743335T0001|42 48|stimuli
P00745775A0170|133 134|M.
P00745775A0170|12 19|patients
P00745775A0170|88 100|complications
P00745775A0170|121 129|Urografin
P00745775A0170|45 57|arteriography
P00745775A0170|110 118|injection
P00747722A0486|42 50|injection
P00747722A0486|98 107|parameters
P00747722A0486|27 34|reaction
P00747722A0486|3 6|data
P00747722A0486|120 122|sec
P00747722A0486|89 92|drop
P00747722A0486|52 56|Phase
P00747722A0486|40 50|B1 injection
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|42 50|abortions
P00748978T0000|20 34|prostaglandin E2
P00753237A0000|468 478|prophylaxis
P00753237A0000|118 120|fig
P00753237A0000|64 67|arcs
P00753237A0000|64 67|arcs
P00753237A0000|108 116|outsentry
P00753237A0000|77 86|body weight
P00753237A0000|295 301|process
P00753237A0000|219 219|C
P00753237A0000|162 164|PPU
P00753237A0000|130 130|B
P00753237A0000|133 139|Plantar
P00753237A0000|22 31|phenomenon
P00753237A0000|225 231|patient
P00753237A0000|77 86|body weight
P00753237A0000|48 51|ends
P00753237A0000|118 120|fig
P00753237A0000|177 187|combination
P00753237A0000|436 451|blood circulation
P00753237A0000|371 381|compression
P00753237A0000|265 271|effects
P00753237A0000|325 339|PNEUMATIC INSOLE
P00753237A0000|90 93|PAIN
P00753237A0000|322 322|D
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|38 42|level
P00753237A0000|162 164|PPU
P00753237A0000|415 423|attrition
P00753237A0000|151 160|ulceration
P00753237A0000|48 51|ends
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|102 105|role
P00753237A0000|254 263|traumatism
P00753237A0000|461 464|cure
P00755245A0000|70 79|chloralose
P00755245A0000|0 5|Effect
P00755245A0000|41 53|vasomotor loci
P00755245A0000|122 126|sites
P00755245A0000|8 16|indoramin
P00755245A0000|92 95|cats
P00755245A0000|24 28|doses
P00755671A0485|14 20|heparin
P00755671A0485|101 109|hematomas
P00755671A0485|66 76|development
P00755671A0485|40 59|recalcification times
P00755869A0216|0 21|Contingency contracting
P00755869A0216|149 156|exercise
P00755869A0216|135 144|weight loss
P00755869A0216|44 61|parents/caregivers
P00755869A0216|29 35|clients
P00755869A0216|98 112|self-monitoring
P00755869A0216|128 133|intake
P00755869A0216|78 89|consequences
P00756511T0036|0 8|Dietetics
P00756511T0036|32 39|diabetes
P00756511T0036|11 19|childhood
P00757244A0000|3 9|results
P00757244A0000|48 56|membranes
P00757244A0000|62 70|placentas
P00757244A0000|25 29|study
P00759049A0185|45 53|ferrozine
P00759049A0185|60 87|bathophenanthroline chromogen
P00759049A0185|18 30|microcuvettes
P00759049A0185|3 13|micromethod
P00759049A0185|93 96|ICSH
P00759400T0000|0 16|Platelet serotonin
P00759400T0000|47 52|plasma
P00759400T0000|18 21|5-HT
P00759400T0000|65 72|patients
P00759400T0000|39 44|factor
P00759400T0000|18 21|5-HT
P00762763A0253|44 49|births
P00762763A0253|21 24|SIDS
P00762763A0253|10 18|incidence
P00764737X0000|3 15|vigilance task
P00764737X0000|46 53|deficits
P00764737X0000|22 32|measurement
P00767155T0001|16 21|revolt
P00767155T0001|3 10|December
P00767155T0001|47 55|personnel
P00767155T0001|24 29|Moscow
P00767161A0837|77 81|hours
P00767161A0837|55 59|pg/ml
P00767161A0837|103 105|day
P00767161A0837|77 81|hours
P00767161A0837|103 105|day
P00767161A0837|87 100|administration
P00767161A0837|11 19|increases
P00767161A0837|26 45|serum E2 concentration
P00768220X0000|3 11|motor unit
P00771729X0000|17 22|system
P00771729X0000|29 38|variations
P00771729X0000|41 49|responses
P00771729X0000|52 59|hormones
P00775582T0000|22 30|sumithion
P00775582T0000|10 19|properties
P00779272T0001|44 48|virus
P00779272T0001|61 73|mononucleosis
P00779272T0001|20 29|antibodies
P00779272T0001|11 17|studies
P00780639X0000|16 22|antigen
P00780639X0000|49 58|evaluation
P00780639X0000|24 26|CEA
P00780639X0000|28 37|procedures
P00792847A0000|74 78|agent
P00792847A0000|44 46|ALG
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|81 86|humans
P00799988A0554|96 102|placebo
P00799988A0554|5 9|basis
P00799988A0554|19 36|assessment patients
P00799988A0554|74 83|imipramine
P00799988A0554|61 70|preference
P00799988A0554|115 121|therapy
P00803867A0315|0 7|Patients
P00803867A0315|147 152|months
P00803867A0315|64 69|cancer
P00803867A0315|64 69|cancer
P00803867A0315|105 112|patients
P00803867A0315|129 135|disease
P00803867A0315|40 45|groups
P00806295A0193|98 105|subjects
P00806295A0193|0 9|Absorption
P00806295A0193|47 56|absorption
P00806295A0193|33 36|cent
P00806295A0193|33 36|cent
P00807356T0001|30 37|activity
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|0 7|Advances
P00808266T0000|44 59|radiation therapy
P00808266T0000|13 22|management
P00808266T0000|36 41|cancer
P00808898A0000|71 77|failure
P00808898A0000|32 38|patient
P00808898A0000|23 26|data
P00808898A0000|79 82|IPRF
P00811852T0001|61 68|patients
P00811852T0001|32 40|encounter
P00811852T0001|22 28|nursing
P00811852T0001|8 19|satisfaction
P00812183T0000|10 23|transfer factor
P00818380A0239|30 42|antibody tests
P00818380A0239|80 90|gold therapy
P00818380A0239|69 77|reactions
P00818380A0239|10 15|factor
P00818380A0239|128 138|populations
P00819176T0001|102 121|Pontella mediterranea
P00819176T0001|3 8|effect
P00819176T0001|123 142|Labidocera wollastoni
P00819176T0001|71 79|crustacea
P00819176T0001|35 50|swimming activity
P00819176T0001|81 100|Anomalocera patersoni
P00819176T0001|22 29|pressure
P00821833A0000|120 125|Panama
P00821833A0000|4 9|report
P00821833A0000|96 105|field study
P00821833A0000|64 79|Alouatta palliata
P00821833A0000|20 27|analysis
P00821833A0000|38 47|repertoire
P00821833A0000|50 62|howler monkeys
P00822611A0467|58 64|persons
P00822611A0467|77 89|binephrectomy
P00822611A0467|18 25|patients
P00822611A0467|10 15|number
P00823087A0608|28 35|patients
P00823087A0608|0 7|Deflunia
P00825571T0031|0 2|III
P00827364A0000|61 68|material
P00827364A0000|32 48|freeze-fracturing
P00827364A0000|71 75|ultra
P00827364A0000|4 13|instrument
P00827364A0000|80 85|vacuum
P00830568A0000|106 113|patients
P00830568A0000|235 246|pyloroplasty
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|248 250|V&P
P00830568A0000|61 68|test meal
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|39 51|emptying rates
P00830568A0000|160 165|STG-BI
P00830568A0000|191 197|STG-BII
P00830568A0000|96 102|persons
P00830568A0000|20 28|secretion
P00830568A0000|70 72|LTM
P00830568A0000|224 231|vagotomy
P00830568A0000|106 113|patients
P00830568A0000|126 136|gastrectomy
P00832096T0000|8 24|calcium metabolism
P00832096T0000|41 51|sarcoidosis
P00833472A0907|16 22|patient
P00833472A0907|149 152|drug
P00833472A0907|35 44|gallstones
P00833472A0907|109 119|cholesterol
P00833472A0907|67 76|colestipol
P00833472A0907|54 64|institution
P00833472A0907|90 104|gallbladder bile
P00833472A0907|78 87|saturation
P00836637A0000|134 144|EMR children
P00836637A0000|172 184|reinforcement
P00836637A0000|111 131|arithmetic performance
P00836637A0000|91 100|reinforcer
P00836637A0000|196 205|preference
P00836637A0000|91 100|reinforcer
P00836637A0000|11 20|experiment
P00836637A0000|65 79|music-listening
P00837262A0000|134 139|rabbit
P00837262A0000|3 16|responsiveness
P00837262A0000|46 55|colliculus
P00837262A0000|57 58|SC
P00837262A0000|32 33|VC
P00837262A0000|94 105|conditioning
P00837262A0000|113 115|OFF
P00837262A0000|25 30|cortex
P00837262A0000|107 108|ON
P00837262A0000|117 127|stimulation
P00837811A0675|56 83|fluid gamma globulin elevations
P00837811A0675|1 9|diagnosis
P00837811A0675|121 127|testing
P00837811A0675|44 48|signs
P00837811A0675|88 100|abnormalities
P00837811A0675|12 13|MS
P00838152A0863|14 32|mean temperature rise
P00838152A0863|134 147|qualifications
P00838152A0863|76 84|selection
P00838152A0863|109 121|disappearance
P00838152A0863|47 54|degrees C
P00838152A0863|175 186|predominance
P00838152A0863|47 54|degrees C
P00838152A0863|160 165|groups
P00838152A0863|134 147|qualifications
P00838152A0863|153 165|triplet groups
P00839378A0649|84 90|disease
P00839378A0649|39 46|increase
P00839378A0649|54 69|airway resistance
P00839378A0649|21 28|RDS group
P00839378A0649|11 15|Viso V
P00839378A0649|98 104|therapy
P00842406A0771|57 78|visuomotor coordination
P00842406A0771|44 47|task
P00842406A0771|16 20|tests
P00842406A0771|83 97|recognition task
P00842406A0771|16 19|test
P00842522T0000|76 84|emphysema
P00842522T0000|33 42|management
P00842522T0000|18 27|intubation
P00843232A0100|59 67|character
P00843232A0100|3 12|background
P00843232A0100|47 52|factor
P00843232A0100|81 90|epithelium
P00843232A0100|70 75|lesion
P00843670T0000|3 7|sense
P00843670T0000|10 13|self
P00846559A0000|172 179|capacity
P00846559A0000|141 146|France
P00846559A0000|96 116|F. sporotrichioides var
P00846559A0000|15 26|Fusarium poae
P00846559A0000|118 127|tricinctum
P00846559A0000|132 137|U.S.A.
P00846559A0000|6 12|strains
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|30 47|F. sporotrichioides
P00846559A0000|81 87|species
P00846559A0000|6 12|strains
P00846559A0000|187 194|T-2 toxin
P00847967T0000|17 20|uses
P00847967T0000|35 44|tomography
P00847967T0000|55 62|medicine
P00851041A0000|40 46|anomaly
P00851041A0000|31 37|Ebstein
P00851041A0000|19 26|patients
P00851041A0000|10 14|study
P00851286A0375|0 5|Deaths
P00851286A0375|15 19|hours
P00851286A0375|68 72|signs
P00851286A0375|15 19|hours
P00851286A0375|141 145|death
P00851286A0375|75 82|distress
P00851286A0375|62 64|ppm
P00851286A0375|25 44|copper concentrations
P00857024A0888|0 9|Recurrence
P00857024A0888|42 46|cases
P00857024A0888|107 112|median
P00857024A0888|76 90|properdin levels
P00857024A0888|12 24|bladder tumors
P00863184T0043|60 63|load
P00863184T0043|0 9|Adaptation
P00863184T0043|69 71|rat
P00863184T0043|24 39|transport maximum
P00863773T0000|0 6|Dangers
P00863773T0000|14 31|live-virus vaccines
P00863773T0000|9 11|use
P00866577A0579|61 66|agents
P00866577A0579|0 8|Treatment
P00866577A0579|122 128|patient
P00866577A0579|135 138|term
P00866577A0579|156 162|therapy
P00866577A0579|21 41|plasminogen activators
P00866577A0579|96 103|function
P00866577A0579|13 19|heparin
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868301A0043|29 32|peak
P00868301A0043|117 125|condition
P00868301A0043|2 21|diethyl ether solution
P00868301A0043|83 95|retention time
P00868301A0043|102 108|minutes
P00868903A0000|0 7|Amikacin
P00868903A0000|67 74|patients
P00868903A0000|20 28|treatment
P00868903A0000|53 62|infections
P00870859A0121|71 83|recirculation
P00870859A0121|3 6|data
P00870859A0121|107 112|factor
P00870859A0121|48 54|account
P00870859A0121|60 68|direction
P00871237A0601|6 13|activity
P00871237A0601|21 27|patient
P00871237A0601|37 42|angina
P00872442T0000|0 9|Estimation
P00872442T0000|44 66|LKB reaction rate analyser
P00872442T0000|30 35|plasma
P00872442T0000|23 27|serum
P00872442T0000|12 20|L-alanine
P00872922A0204|3 7|acids
P00872922A0204|50 55|esters
P00872922A0204|82 89|activity
P00872922A0204|22 31|hydrolysis
P00874942T0000|49 54|report
P00874942T0000|25 35|prematurity
P00874942T0000|12 21|amnionitis
P00875778T0000|0 9|Evaluation
P00875778T0000|18 38|Gravigard IUCD inserter
P00876722T0000|30 36|abscess
P00876722T0000|47 52|septum
P00876722T0000|9 18|meningitis
P00877857A0763|0 11|Serum amylase
P00877857A0763|58 65|serum FFA
P00877857A0763|72 80|mEq/liter
P00877857A0763|40 47|CU/100 ml
P00879329A0176|29 34|weight
P00879329A0176|101 104|mmHg
P00879329A0176|88 90|Pci
P00879329A0176|148 150|IIp
P00879329A0176|5 22|control preparation
P00879329A0176|114 120|colloid
P00879329A0176|79 86|pressure
P00879329A0176|141 146|plasma
P00879329A0176|79 86|pressure
P00879829A0564|0 6|Infants
P00879829A0564|26 30|hours
P00879829A0564|103 109|symptom
P00879829A0564|122 127|apnoea
P00879829A0564|61 73|birth asphyxia
P00879829A0564|36 38|IVH
P00881630A0000|187 190|rats
P00881630A0000|28 38|snake venoms
P00881630A0000|16 22|effects
P00881630A0000|169 184|cremaster vessels
P00881630A0000|81 86|Factor
P00881630A0000|49 60|A. piscivorus
P00881630A0000|106 114|compounds
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|162 165|lung
P00881630A0000|40 45|N. naja
P00881630A0000|40 45|N. naja
P00881630A0000|33 37|venom
P00885562A0281|15 24|components
P00885562A0281|27 41|cartilage matrix
P00885562A0281|46 54|depletion
P00885562A0281|5 8|GAGs
P00885562A0281|135 141|culture
P00885562A0281|121 132|GAG synthesis
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|94 99|method
P00890028A0507|140 155|Kolmogoroff scale
P00890028A0507|98 99|mm
P00890028A0507|3 14|length scales
P00890028A0507|98 99|mm
P00890028A0507|98 99|mm
P00890028A0507|77 86|macroscale
P00890028A0507|20 29|turbulence
P00890028A0507|104 119|Taylor microscale
P00890028A0507|51 64|Reynolds number
P00891370A0000|15 26|arteriograms
P00891370A0000|83 91|injection
P00891370A0000|32 36|limbs
P00891370A0000|94 108|contrast-medium
P00891370A0000|115 121|arm vein
P00891370A0000|141 148|patients
P00891370A0000|52 66|xeroradiography
P00892353A0686|68 76|degrees C.
P00892353A0686|2 12|hypotension
P00892353A0686|54 58|fever
P00892353A0686|35 41|toxemia
P00892353A0686|23 30|patients
P00898500A0246|143 161|IgE antibody activity
P00898500A0246|114 117|RAST
P00898500A0246|56 57|HD
P00898500A0246|15 24|secretions
P00898500A0246|3 6|sera
P00898500A0246|30 37|patients
P00898500A0246|60 64|mites
P00898500A0246|69 72|test
P00898500A0246|60 72|mites skin test
P00903772A0359|0 7|Wherever
P00903772A0359|20 42|conditioning stimulation
P00903772A0359|49 61|modifications
P00903772A0359|92 94|leg
P00903772A0359|78 86|ischaemia
P00903772A0359|11 14|site
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|186 190|doses
P00909114A0000|196 203|compound
P00909114A0000|19 21|DAN
P00909114A0000|166 167|sc
P00909114A0000|151 158|hamsters
P00909114A0000|104 112|incidence
P00909114A0000|35 46|nitrosamines
P00909114A0000|126 136|tract tumors
P00909114A0000|88 91|rats
P00909114A0000|77 85|neoplasms
P00910823A0196|86 95|blood flows
P00910823A0196|4 7|term
P00910823A0196|67 73|uterine
P00910823A0196|64 65|pH
P00910823A0196|53 62|blood gases
P00910823A0196|26 35|conditions
P00911590T0000|35 49|bocurarine block
P00911590T0000|83 90|children
P00911590T0000|23 32|antagonism
P00911590T0000|54 80|atropine-neostigmine mixture
P00911590T0000|12 20|responses
P00913623A0242|88 100|pyrophosphate
P00913623A0242|102 105|pass
P00913623A0242|134 149|passive diffusion
P00913623A0242|3 11|mechanism
P00913623A0242|69 72|EHDP
P00913623A0242|43 55|diphosphonate
P00913623A0242|126 129|bone
P00913623A0242|113 123|capillaries
P00913623A0242|24 32|molecules
P00915090A0536|58 61|rads
P00915090A0536|20 28|injection
P00915090A0536|67 72|testis
P00915090A0536|34 36|mCi
P00915090A0536|107 107|%
P00915090A0536|77 82|number
P00915090A0536|11 14|days
P00915090A0536|39 44|Tc-99m
P00915090A0536|110 116|control
P00915090A0536|85 93|sperm hads
P00916099A0000|0 16|Self-emasculation
P00916099A0000|22 30|end result
P00916099A0000|92 100|treatment
P00916099A0000|53 60|disorder
P00917572T0001|0 10|Possibility
P00917572T0001|47 60|hypothyroidism
P00917572T0001|36 44|detection
P00917572T0001|27 32|method
P00917721A0484|4 11|analysis
P00917721A0484|31 38|evidence
P00917721A0484|93 104|dream content
P00917721A0484|52 70|presleep suggestions
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|134 141|patients
P00918556A0000|3 12|prevalence
P00918556A0000|97 122|radio-immunoassay technique
P00918556A0000|153 165|liver diseases
P00918556A0000|49 56|anti-HBs
P00918556A0000|126 131|series
P00918556A0000|40 44|HBsAg
P00918965A0728|171 174|PAO2
P00918965A0728|46 52|failure
P00918965A0728|72 82|ventilation
P00918965A0728|18 25|patients
P00918965A0728|125 132|parallel
P00918965A0728|90 101|componenents
P00918965A0728|116 120|shunt
P00920381T0000|43 51|injection
P00920381T0000|16 23|glycogen
P00920381T0000|97 100|rats
P00921032T0000|43 48|Beagle
P00921032T0000|22 31|mibolerone
P00921032T0000|10 19|evaluation
P00921911A0159|0 5|Levels
P00921911A0159|85 94|dilatation
P00921911A0159|67 72|labour
P00921911A0159|18 21|PGFM
P00921911A0159|106 107|cm
P00921911A0159|122 126|onset
P00921911A0159|67 72|labour
P00921911A0159|12 14|PGF
P00926272A0000|13 17|cause
P00926272A0000|49 52|cord
P00926272A0000|95 100|reflux
P00926272A0000|60 66|patient
P00926272A0000|25 37|deterioration
P00926604A0504|131 136|effect
P00926604A0504|0 10|Propranolol
P00926604A0504|150 154|doses
P00926604A0504|98 108|development
P00926604A0504|199 208|myocardium
P00926604A0504|82 86|heart
P00926604A0504|68 76|apparatus
P00926604A0504|35 38|dose
P00926604A0504|157 169|strophanthin K
P00926604A0504|12 18|Inderal
P00926751A0000|71 79|irritancy
P00926751A0000|6 12|studies
P00926751A0000|89 97|materials
P00926751A0000|59 68|evaluation
P00926751A0000|49 53|organ
P00926751A0000|25 33|rat larynx
P00927633T0001|74 85|Rattus rattus
P00927633T0001|57 64|Reissner
P00927633T0001|46 54|formation
P00927633T0001|67 71|fiber
P00927633T0001|8 15|electron
P00927633T0001|27 40|investigations
P00928529T0001|0 14|Feeding behavior
P00928529T0001|110 116|bundles
P00928529T0001|67 74|hamsters
P00928529T0001|26 35|body weight
P00928529T0001|39 56|hibernation rhythms
P00929418T0001|0 3|Role
P00929418T0001|20 27|diseases
P00929418T0001|9 36|infectious-disease specialist
P00929418T0001|63 71|incidence
P00930947A0629|42 47|effect
P00930947A0629|42 47|effect
P00930947A0629|129 133|drugs
P00930947A0629|50 59|probenecid
P00930947A0629|78 80|PZA
P00930947A0629|67 75|secretion
P00930947A0629|13 16|drug
P00930947A0629|42 47|effect
P00930947A0629|13 28|drug interactions
P00931089T0001|22 34|operating room
P00931089T0001|11 16|arrest
P00932738A0116|25 26|BP
P00932738A0116|32 35|mmHg
P00932738A0116|91 96|levels
P00932738A0116|37 53|C02 responsiveness
P00932738A0116|11 23|blood pressure
P00932738A0116|25 26|BP
P00932817A0499|87 95|MTF values
P00932817A0499|44 46|MEC
P00932817A0499|0 9|Iodine-123
P00932817A0499|50 67|pinhole collimators
P00932817A0499|124 128|99mTc
P00932817A0499|76 79|turn
P00933251T0000|19 24|plaque
P00933251T0000|7 16|meningioma
P00933251T0000|49 56|ear tumor
P00935526A0000|144 145|ng
P00935526A0000|3 14|difficulties
P00935526A0000|85 88|lack
P00935526A0000|159 168|resolution
P00935526A0000|180 186|columns
P00935526A0000|91 101|sensitivity
P00935526A0000|54 67|chromatography
P00935526A0000|24 37|prostaglandins
P00935526A0000|39 40|PG
P00938594A0149|13 26|steroid therapy
P00938594A0149|159 167|arthritis
P00938594A0149|2 10|cessation
P00938594A0149|30 36|patient
P00938594A0149|169 170|RA
P00938594A0149|106 108|HOA
P00938594A0149|61 74|manifestations
P00938594A0149|89 104|osteoarthropathy
P00938594A0149|129 146|laboratory features
P00941050T0000|3 8|effect
P00941050T0000|17 38|procainamide absorption
P00941050T0000|11 14|food
P00947327A0000|295 307|sulfanilamide
P00947327A0000|59 64|region
P00947327A0000|365 374|pyrimidine
P00947327A0000|416 424|Supristol
P00947327A0000|238 242|tests
P00947327A0000|410 414|Nevin
P00947327A0000|110 117|activity
P00947327A0000|12 17|survey
P00947327A0000|189 199|antibiotics
P00947327A0000|403 404|CN
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|229 235|results
P00947327A0000|23 31|situation
P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
P00947327A0000|75 81|Bavaria
P00947327A0000|238 242|tests
P00947327A0000|142 153|trimethoprim
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|392 396|ratio
P00947327A0000|138 140|SMZ
P00947327A0000|266 267|N1
P00947327A0000|455 461|TMP/SMZ
P00947327A0000|219 224|agents
P00947327A0000|159 169|combination
P00947327A0000|310 320|sulfamoxole
P00947327A0000|142 153|trimethoprim
P00947327A0000|44 53|resistance
P00947327A0000|159 169|combination
P00947327A0000|155 157|TMP
P00947834X0000|0 6|RESULTS
P00947834X0000|29 36|tendency
P00947834X0000|13 21|IgE levels
P00951909X0001|57 65|diagnosis
P00951909X0001|116 123|patients
P00951909X0001|46 52|opinion
P00951909X0001|135 156|Billroth-II gastrectomy
P00951909X0001|12 23|loop syndrome
P00951909X0001|38 43|author
P00951909X0001|12 23|loop syndrome
P00952734T0000|0 5|Letter
P00952734T0000|41 45|cause
P00952734T0000|66 76|elastolysis
P00952734T0000|80 88|cutis laxa
P00952734T0000|23 28|damage
P00952734T0000|90 93|PECL
P00954819A1041|128 139|AChE activity
P00954819A1041|59 66|function
P00954819A1041|88 92|Soman
P00954819A1041|72 83|intoxication
P00954819A1041|31 38|recovery
P00954819A1041|5 8|data
P00954819A1041|120 125|return
P00954819A1041|95 99|Sarin
P00956364A0138|0 12|Batch cultures
P00956364A0138|15 30|S. mutans serotype
P00956364A0138|46 51|growth
P00956364A0138|54 60|MSB agar
P00956554A0414|14 18|serum
P00956554A0414|71 80|reactivity
P00956554A0414|45 64|solid-phase allergens
P00956554A0414|5 11|samples
P00956554A0414|95 107|IgE antibodies
P00958550T0001|0 5|Crisis
P00958550T0001|22 30|community
P00958550T0001|38 44|Britain
P00959656A0250|39 50|antithrombin
P00959656A0250|15 18|term
P00959656A0250|31 36|levels
P00959656A0250|8 12|women
P00961711T0000|0 16|Hematology problem
P00961711T0000|28 31|band
P00961711T0000|34 36|seg
P00961711T0000|22 26|month
P00962222A0633|58 64|changes
P00962222A0633|67 92|erythrocyte characteristics
P00962222A0633|22 31|variations
P00962222A0633|34 45|heme turnover
P00962222A0633|102 118|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|42 59|gelatine derivative
P00962277T0000|30 35|bypass
P00962277T0000|63 69|priming
P00964758T0001|31 42|parotid gland
P00964758T0001|14 25|plasmacytoma
P00967223T0059|0 1|I.
P00968181A0264|73 76|days
P00968181A0264|57 65|challenge
P00968181A0264|31 38|immunity
P00968181A0264|90 98|infection
P00968181A0264|12 17|calves
P00970320A0000|3 13|performance
P00970320A0000|33 60|chemical cartridge respirators
P00970320A0000|103 115|copper smelter
P00970320A0000|64 66|SO2
P00970320A0000|90 99|conditions
P00970488A0105|144 149|effect
P00970488A0105|170 180|development
P00970488A0105|200 207|symptoms
P00970488A0105|152 163|neuroleptics
P00970488A0105|22 29|increase
P00970488A0105|67 72|degree
P00970488A0105|75 92|DA receptor blocking
P00970488A0105|39 48|DA turnover
P00970488A0105|52 60|indicator
P00970839A0118|0 11|Rainbow trout
P00970839A0118|70 76|feeding
P00970839A0118|105 109|weeks
P00970839A0118|91 97|pellets
P00970839A0118|39 47|trout farm
P00970839A0118|62 66|water
P00974901A0080|0 10|Stimulation
P00974901A0080|86 91|effect
P00974901A0080|105 118|susceptibility
P00974901A0080|39 62|Bordetella pertussis cells
P00974901A0080|13 30|macrophage function
P00975314T0001|56 64|karyotype
P00975314T0001|82 95|gonadoblastoma
P00975314T0001|7 17|amenorrhoea
P00975314T0001|68 69|xy
P00975540T0000|14 20|methods
P00975540T0000|75 95|high-accuracy analyses
P00975540T0000|31 39|chemistry
P00975540T0000|54 72|mass fragmentography
P00975540T0000|41 51|application
P00980255T0000|44 51|coupling
P00980255T0000|0 10|Application
P00980255T0000|75 83|blood flow
P00980255T0000|16 38|2-deoxy-D-glucose method
P00980255T0000|62 71|metabolism
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|154 158|study
P00984209A0614|115 125|V&P patients
P00984209A0614|38 42|group
P00984209A0614|52 87|background serum gastrin concentrations
P00984209A0614|130 140|V&A patients
P00985110T0001|43 49|putamen
P00985110T0001|31 37|portion
P00985110T0001|94 96|cat
P00985110T0001|82 88|regions
P00985110T0001|8 18|projections
P00985110T0001|105 110|cortex
P00985276A0000|0 8|Preflight
P00985276A0000|116 119|part
P00985276A0000|149 158|adaptation
P00985276A0000|71 80|astronauts
P00985276A0000|22 52|postflight exercise response tests
P00985276A0000|170 183|weightlessness
P00985276A0000|124 133|evaluation
P00985276A0000|10 17|inflight
P00985276A0000|92 97|Skylab
P00985276A0000|92 104|Skylab mission
P00985279A0493|15 38|hemoglobin concentrations
P00985279A0493|0 3|Mean
P00985279A0493|66 73|decrease
P00985279A0493|15 15|h
P00985279A0493|81 86|groups
P00985279A0493|91 98|CO2 group
P00986800A0325|114 119|body Cu
P00986800A0325|26 31|organs
P00986800A0325|3 10|Cu values
P00986800A0325|55 69|saturation level
P00986800A0325|153 155|day
P00986800A0325|158 165|delivery
P00986800A0325|5 10|values
P00986800A0325|91 99|exception
P00986800A0325|130 133|dams
P00986800A0325|73 83|mug Cu/g diet
P00986925A0002|28 33|amount
P00986925A0002|86 89|47Ca
P00986925A0002|3 8|effect
P00986925A0002|70 77|glucagon
P00986925A0002|55 66|pentagastrin
P00986925A0002|111 118|subjects
P00986925A0002|80 108|plasma 47Ca radioactivity curves
P00986925A0002|36 42|calcium
P00986925A0002|11 20|calcitonin
P00987649T0001|0 4|State
P00987649T0001|16 24|disorders
P00987649T0001|66 76|hypokinesia
P00987649T0001|47 53|rhythms
P00987649T0001|10 13|body
P00988572A0000|133 138|oxygen
P00988572A0000|0 12|Oxygen tension
P00988572A0000|97 103|chamber
P00988572A0000|23 27|lymph
P00988572A0000|121 147|catheter-tip oxygen electrode
P00988572A0000|36 39|PLO2
P00988572A0000|168 171|data
P00988572A0000|46 59|rabbit hind limb
P00988572A0000|23 34|lymph vessels
P00988572A0000|177 182|source
P00989973A0000|3 10|response
P00989973A0000|55 63|injection
P00989973A0000|16 36|plasma fibrinogen level
P00989973A0000|134 140|rabbits
P00989973A0000|134 140|rabbits
P00989973A0000|55 63|injection
P00989973A0000|196 203|busulfan
P00989973A0000|106 114|endotoxin
P00989973A0000|66 75|turpentine
P00992316A0178|49 58|activities
P00992316A0178|21 34|pressure curves
P00992316A0178|100 107|criteria
P00992316A0178|127 135|gravidity
P00993176A0066|35 44|hemoglobin
P00993176A0066|132 132|%
P00993176A0066|5 13|myoglobin
P00993176A0066|50 61|heme pigments
P00993176A0066|134 136|NH4
P00993176A0066|19 25|extract
P00993176A0066|79 85|portion
P00993176A0066|35 44|hemoglobin
P00993176A0066|138 149|2SO4 solution
P00996272A0397|101 112|instructions
P00996272A0397|16 22|sources
P00996272A0397|25 29|error
P00996272A0397|39 49|variability
P00996272A0397|62 74|investigation
P00996364X0000|0 0|E
P00999494A0000|58 62|doses
P00999494A0000|3 10|patients
P00999494A0000|18 26|diagnosis
P00999494A0000|91 106|agent propranolol
P00999494A0000|34 38|mania
P01000378T0000|0 5|Effect
P01000378T0000|16 29|plasma glucagon
P01000378T0000|56 60|sheep
P01000378T0000|33 53|insulin concentrations
P01000378T0000|8 13|trauma
P01003819A0498|38 47|refraction
P01003819A0498|14 24|nomogram one
P01003819A0498|53 62|axis length
P01003819A0498|66 81|corneal curvature
P01003819A0498|7 10|help
P01004298A0744|58 58|%
P01004298A0744|4 13|up-grading
P01004298A0744|34 44|CA component
P01004298A0744|103 107|level
P01004298A0744|24 28|score
P01004298A0744|85 90|scores
P01004298A0744|73 80|students
P01009451A0728|28 34|OCS rats
P01009451A0728|23 24|UB
P01009451A0728|89 100|nocturnality
P01009451A0728|75 83|reduction
P01009451A0728|10 17|controls
P01009451A0728|103 110|drinking
P01009739T0001|0 5|Effect
P01009739T0001|30 40|circulation
P01009739T0001|42 47|effect
P01009739T0001|50 52|ECG
P01009739T0001|8 19|indomethacin
P01009841T0001|29 40|trunk muscles
P01009841T0001|4 14|innervation
P01009841T0001|43 55|lamprey larvae
P01009841T0001|21 26|fibers
P01010638A0161|3 6|feed
P01010638A0161|34 34|%
P01012640T0001|73 78|Sipple
P01012640T0001|36 43|patients
P01012640T0001|7 21|characteristics
P01012640T0001|81 88|syndrome
P01012640T0001|24 33|eye changes
P01012640T0001|48 63|pheochromocytoma
P01012904A0333|122 127|sample
P01012904A0333|59 69|populations
P01012904A0333|82 91|Stroop test
P01012904A0333|141 146|format
P01012904A0333|13 30|interference effect
P01019207A0232|99 103|range
P01019207A0232|113 125|mug ruscogenin
P01019207A0232|73 83|betaI% value
P01019207A0232|30 39|conditions
P01019207A0232|47 56|dependence
P01019207A0232|87 89|lgC
P01021091T0000|98 108|vasopressin
P01021091T0000|3 11|influence
P01021091T0000|45 56|blood vessels
P01021091T0000|35 42|response
P01021091T0000|110 120|Octapressin
P01021091T0000|24 29|nerves
P01021091T0000|62 70|rabbit ear
P01027644T0001|10 13|test
P01030985T0090|0 1|I.
P01035457A0623|45 54|importance
P01035457A0623|5 10|tumour
P01035457A0623|20 34|nipple discharge
P01035457A0623|73 81|treatment
P01035457A0623|61 69|diagnosis
P01036714A0072|0 6|Studies
P01036714A0072|102 109|increase
P01036714A0072|159 164|levels
P01036714A0072|83 92|chrysotile
P01036714A0072|123 136|cell population
P01036714A0072|67 73|animals
P01036714A0072|36 42|changes
P01036714A0072|115 118|lung
P01044338A0240|43 51|estimates
P01044338A0240|57 63|heating
P01044338A0240|22 39|temperature changes
P01044338A0240|8 19|measurements
P01047417T0000|8 32|National Health Dis-service
P01047895T0001|13 23|patient care
P01047895T0001|2 10|criticism
P01047895T0001|57 61|value
P01047895T0001|13 23|patient care
P01047895T0001|2 10|criticism
P01047895T0001|63 70|Patients
P01048020T0000|0 7|Critique
P01048020T0000|45 59|Credit/No Credit
P01048020T0000|31 41|Test Anxiety
P01048020T0000|22 28|Effects
P01048020T0000|113 129|Course Information
P01048020T0000|62 78|A-F Grade Condition
P01048968A0152|72 82|penicillin G
P01048968A0152|28 35|majority
P01048968A0152|84 95|erythromycin
P01048968A0152|44 56|staphylococci
P01048968A0152|5 11|studies
P01048968A0152|108 121|beta-lactamase
P01050144A0297|114 123|83A complex
P01050144A0297|66 76|antibiotics
P01050144A0297|16 23|decrease
P01050144A0297|29 34|number
P01050144A0297|37 43|strains
P01050144A0297|37 43|strains
P01050400T0000|0 10|Improvement
P01050400T0000|83 89|infants
P01050400T0000|67 70|ward
P01050400T0000|45 48|time
P01050400T0000|51 59|discharge
P01050400T0000|13 30|nursing instruction
P01057137A0192|2 11|difference
P01057137A0192|69 74|groups
P01057137A0192|25 37|acceptability
P01064124A0560|42 47|lesion
P01064124A0560|64 72|specimens
P01064124A0560|7 7|d
P01064124A0560|9 18|subsurface
P01067493A0119|28 32|women
P01067493A0119|16 22|pattern
P01067493A0119|78 84|methods
P01067493A0119|51 57|percent
P01071715A0903|16 24|technique
P01071715A0903|36 58|blood pressure recordings
P01075075T0038|0 1|I.
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|109 125|ALG administration
P01078982A0227|96 104|treatment
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|92 94|ALG
P01078982A0227|142 147|dosage
P01078982A0227|52 67|cyclophosphamide
P01080374A0709|86 89|form
P01080374A0709|0 7|Evidence
P01080374A0709|98 104|disease
P01080374A0709|69 74|entity
P01080374A0709|92 96|Coats
P01080374A0709|23 27|Leber
P01080374A0709|38 54|aneurysm retinitis
P01081904A0198|42 49|patients
P01081904A0198|59 79|pull-out arteriography
P01081904A0198|110 117|symptoms
P01081904A0198|22 29|catheter
P01082726A0248|44 49|DC-ERG
P01082726A0248|3 11|influence
P01082726A0248|31 38|response
P01082726A0248|21 25|pupil
P01082833A0000|149 158|guinea pigs
P01082833A0000|208 216|pleuritis
P01082833A0000|160 175|carrageenin edema
P01082833A0000|238 248|peritonitis
P01082833A0000|34 38|agent
P01082833A0000|139 146|erythema
P01082833A0000|83 94|indomethacin
P01082833A0000|114 121|response
P01082833A0000|96 97|IM
P01082833A0000|251 254|rats
P01082833A0000|66 75|inhibition
P01082833A0000|40 45|Y-8004
P01083321X0000|115 126|productivity
P01083321X0000|158 162|years
P01083321X0000|2 7|stands
P01083321X0000|2 7|stands
P01083321X0000|17 25|dominance
P01083321X0000|96 100|rates
P01083321X0000|43 45|age
P01083321X0000|47 58|subalpine fir
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|27 44|childhood cirrhosis
P01083784T0000|59 66|patients
P01083784T0000|0 23|Lymphocyte subpopulations
P01083784T0000|80 85|asthma
P01083784T0000|25 32|serum IgE
P01083784T0000|41 56|eosinophil counts
P01084413A0271|43 45|EMI
P01084413A0271|1 5|range
P01084413A0271|25 36|measurements
P01087288T0000|1 10|comparison
P01087288T0000|46 58|radiation dose
P01087288T0000|93 108|thyroid carcinoma
P01087288T0000|80 89|iodine-131
P01087288T0000|35 43|estimates
P01087288T0000|61 68|patients
P01088654T0001|0 8|Technique
P01088654T0001|28 35|ceramics
P01088654T0001|45 48|mass
P01090210A0417|0 3|Mean
P01090210A0417|60 65|volume
P01090210A0417|217 230|airway pressure
P01090210A0417|60 65|volume
P01090210A0417|152 156|phase
P01090210A0417|95 111|mean closing volume
P01090210A0417|9 20|lung capacity
P01090210A0417|194 198|cm H20
P01090210A0417|232 242|differences
P01090210A0417|13 20|capacity
P01090210A0417|194 198|cm H20
P01090210A0417|116 125|lung volume
P01092248T0000|15 28|zinc deficiency
P01092248T0000|7 12|status
P01092248T0000|34 45|pathogenesis
P01092248T0000|93 101|disorders
P01093055T0000|0 6|Calcium
P01093055T0000|10 29|phosphorus metabolism
P01093055T0000|39 44|uremia
P01093845A0208|0 12|Modern studies
P01093845A0208|75 84|comparison
P01093845A0208|48 58|voluntaries
P01093845A0208|148 152|dream
P01093845A0208|140 144|sleep
P01093845A0208|107 119|modifications
P01093845A0208|94 101|identity
P01093845A0208|128 135|cannabis
P01093845A0208|27 37|Delta-9-THC
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|126 131|states
P01093847A0000|82 93|neuroleptics
P01093847A0000|66 72|effects
P01093847A0000|13 18|action
P01096741X0000|29 35|animals
P01096741X0000|82 96|supplementation
P01096741X0000|10 15|growth
P01096741X0000|54 66|chickpea haulm
P01097100A0217|3 10|patients
P01097100A0217|30 37|regimens
P01098179A0167|76 92|dissolution curves
P01098179A0167|0 6|Results
P01098179A0167|105 110|assays
P01098179A0167|208 216|ointments
P01098179A0167|44 55|preparations
P01098179A0167|155 161|release
P01098179A0167|18 32|chloramphenicol
P01098179A0167|184 189|creams
P01098179A0167|171 178|activity
P01098592A0567|83 87|onset
P01098592A0567|0 8|IgG levels
P01098592A0567|63 66|days
P01098592A0567|45 51|samples
P01099693T0000|0 5|Letter
P01099693T0000|7 18|Perspectives
P01099693T0000|21 45|bone marrow transplantation
P01101272T0000|45 53|sweetners
P01101272T0000|0 9|Assessment
P01101272T0000|15 29|carcinogenicity
P01101272T0000|70 84|cyclohexylamine
P01101272T0000|57 66|Cyclamates
P01103390A0149|85 89|phase
P01103390A0149|114 124|parasitemia
P01103390A0149|53 62|occurrence
P01103390A0149|69 75|animals
P01103390A0149|101 108|increase
P01103390A0149|38 41|mice
P01103390A0149|13 21|behaviour
P01107226A0808|83 96|mg/ml dose level
P01107226A0808|8 20|amphotericin B
P01107226A0808|47 50|mice
P01107226A0808|37 41|feces
P01113908A0475|42 43|hr
P01113908A0475|15 22|increase
P01113908A0475|30 40|transferrin
P01113908A0475|90 99|experiment
P01113908A0475|59 64|values
P01113908A0475|50 55|tablet
P01116254A0000|179 188|myocardium
P01116254A0000|63 80|tracer thallium-201
P01116254A0000|194 194|%
P01116254A0000|125 128|mice
P01116254A0000|243 249|minutes
P01116254A0000|98 108|rubidium-81
P01116254A0000|194 194|%
P01116254A0000|194 194|%
P01116254A0000|48 60|concentration
P01116254A0000|20 33|administration
P01116254A0000|69 76|thallium
P01116254A0000|98 105|rubidium
P01116254A0000|48 60|concentration
P01116254A0000|82 93|potassium-43
P01116254A0000|82 90|potassium
P01116466A0185|0 17|Thromboplastin time
P01116466A0185|45 56|thrombin time
P01116466A0185|133 145|platelet count
P01116466A0185|72 77|fibrin
P01116466A0185|123 123|X
P01116466A0185|115 115|V
P01116466A0185|97 111|clotting factors
P01116466A0185|117 120|VIII
P01116466A0185|26 43|thromboplastin time
P01116466A0185|79 92|clot retraction
P01118293A0150|87 90|eyes
P01118293A0150|40 45|images
P01118293A0150|27 37|suppression
P01118293A0150|17 22|notion
P01118293A0150|3 6|data
P01118293A0150|61 67|rivalry
P01119586A0337|101 106|hearts
P01119586A0337|0 18|Glycogen utilization
P01119586A0337|74 80|lactate
P01119586A0337|122 125|flow
P01119586A0337|67 69|ATP
P01119586A0337|49 65|creatine phosphate
P01119586A0337|35 46|tissue levels
P01119658A0000|205 207|N2A
P01119658A0000|262 277|radiation therapy
P01119658A0000|177 195|lymph node metastases
P01119658A0000|3 9|records
P01119658A0000|202 203|N1
P01119658A0000|73 85|cell carcinoma
P01119658A0000|134 144|hypopharynx
P01119658A0000|95 100|cavity
P01119658A0000|211 213|N2B
P01119658A0000|125 130|larynx
P01119658A0000|53 60|patients
P01119658A0000|230 242|neck treatment
P01119658A0000|102 111|oropharynx
P01122015A0467|43 49|mumol/1
P01122015A0467|43 49|mumol/1
P01122015A0467|30 35|values
P01122015A0467|55 62|mg/100 ml
P01122015A0467|55 62|mg/100 ml
P01122015A0467|7 9|vol
P01122015A0467|12 12|%
P01123658A0000|62 66|spine
P01123658A0000|145 150|sacrum
P01123658A0000|47 56|tomography
P01123658A0000|3 9|authors
P01123658A0000|83 93|description
P01123658A0000|21 29|technique
P01123658A0000|104 110|anatomy
P01123658A0000|62 66|spine
P01123658A0000|137 139|L-4
P01124944A0830|28 38|protein diet
P01124944A0830|15 22|attitude
P01124944A0830|43 46|g/kg
P01125117A0183|112 117|groups
P01125117A0183|18 24|attacks
P01125117A0183|13 16|type
P01125117A0183|2 5|none
P01125117A0183|18 24|attacks
P01125117A0183|74 80|changes
P01125117A0183|13 16|type
P01128985A0000|101 108|patients
P01128985A0000|85 89|apnea
P01128985A0000|76 82|periods
P01128985A0000|27 32|method
P01130186A0568|73 83|tolbutamide
P01130186A0568|47 60|insulin release
P01130186A0568|21 27|patient
P01130186A0568|63 70|response
P01130531A0224|0 15|Nerve stimulation
P01130531A0224|40 48|frequency
P01130531A0224|88 94|percent
P01130531A0224|76 83|decrease
P01130531A0224|59 68|reductions
P01130531A0224|71 73|CBF
P01130531A0224|23 30|cycles/s
P01131946T0001|0 5|Effect
P01131946T0001|47 52|period
P01131946T0001|19 28|Norbiogest
P01131946T0001|65 70|organs
P01131946T0001|8 16|ingestion
P01138215T0001|0 3|Risk
P01138215T0001|31 39|fractures
P01138215T0001|20 28|treatment
P01138215T0001|6 14|infection
P01138330A0204|43 47|% NaC1
P01138330A0204|29 37|solutions
P01138330A0204|43 47|% Na C1
P01138330A0204|81 88|% peptone
P01138330A0204|6 12|pouches
P01138330A0204|59 66|% glucose
P01138330A0204|52 55|N HC1
P01138330A0204|110 130|acetylcholine chloride
P01138330A0204|98 107|% solutions
P01140184A0342|0 14|Liver microsomes
P01140184A0342|42 42|%
P01140184A0342|42 42|%
P01140184A0342|115 129|liver microsomes
P01140184A0342|48 69|epoxide hydrase activity
P01140184A0342|105 112|capacity
P01140184A0342|137 139|rat
P01141114A0188|56 59|mmHg
P01141114A0188|83 92|degrees C-v
P01141114A0188|68 70|P50
P01141114A0188|14 17|work
P01141114A0188|58 58|H
P01141114A0188|28 35|increase
P01141114A0188|155 165|temperature
P01141114A0188|131 137|effects
P01141114A0188|76 79|PH-v
P01141114A0188|99 104|Pv-CO2
P01145884T0028|34 38|study
P01147436T0000|36 49|progress report
P01147436T0000|11 33|Burkitt Lymphoma Registry
P01147502T0000|0 9|Vitrectomy
P01147502T0000|27 42|instrument system
P01148868A0284|27 38|progesterone
P01148868A0284|56 60|1/day
P01148868A0284|51 54|S.E.
P01148868A0284|12 24|clearance rate
P01150658A0683|55 61|hormone
P01150658A0683|4 11|sequence
P01150658A0683|70 71|M.
P01150658A0683|63 68|Sairam
P01156631A0658|57 62|mEq/kg
P01156631A0658|57 62|mEq/kg
P01156631A0658|77 85|treatment
P01156631A0658|3 31|mean plasma sodium concentration
P01156631A0658|152 152|P
P01156631A0658|50 51|SD
P01156631A0658|50 51|SD
P01156631A0658|77 85|treatment
P01156814T0000|0 8|Editorial
P01156814T0000|18 24|heparin
P01156814T0000|31 40|prevention
P01156814T0000|49 69|thromboembolic disease
P01157191A0536|13 22|dose levels
P01157191A0536|28 42|sodium saccharin
P01157191A0536|187 191|weeks
P01157191A0536|77 87|carcinogens
P01157191A0536|110 123|bladder tumours
P01157191A0536|46 60|sodium cyclamate
P01157191A0536|117 123|tumours
P01157614T0000|0 6|Effects
P01157614T0000|32 52|matrix task performance
P01157614T0000|19 26|salience
P01157614T0000|75 82|children
P01158512T0000|33 38|G-6-PD
P01158512T0000|19 31|dehydrogenase
P01158512T0000|40 49|deficiency
P01158838A0438|49 56|flow rate
P01158838A0438|62 67|ml/min
P01159822A0353|147 150|size
P01159822A0353|200 206|numbers
P01159822A0353|138 143|number
P01159822A0353|12 20|epithelia
P01159822A0353|91 103|invaginations
P01159822A0353|118 121|axes
P01159822A0353|39 45|animals
P01159822A0353|105 108|tilt
P01159822A0353|71 84|ultrastructure
P01159822A0353|125 132|increase
P01159822A0353|153 161|lysosomes
P01159822A0353|235 242|granules
P01159822A0353|181 186|bodies
P01168607A0672|86 100|prothrombin time
P01168607A0672|121 121|E
P01168607A0672|37 44|vitamins
P01168607A0672|124 132|intervals
P01168607A0672|10 23|administration
P01168607A0672|104 116|serum vitamins
P01168908A0000|0 14|Prostaglandins F
P01168908A0000|115 119|times
P01168908A0000|175 198|plasma progesterone levels
P01168908A0000|99 105|tissues
P01168908A0000|142 146|cycle
P01168908A0000|41 44|vein
P01168908A0000|16 18|PGF
P01168908A0000|70 79|vein plasma
P01168908A0000|53 58|artery
P01168956A0552|7 7|h
P01168956A0552|43 52|weight gain
P01168956A0552|18 21|drug
P01168956A0552|64 74|sensitivity
P01168956A0552|121 141|maximum weight decrease
P01168956A0552|105 107|day
P01168956A0552|80 87|placenta
P01168956A0552|148 152|organ
P01168956A0552|10 13|date
P01170143A0247|0 5|Groups
P01170143A0247|26 35|saline mice
P01170143A0247|70 79|conditions
P01170143A0247|99 107|cylinders
P01171020A0711|3 9|effects
P01171020A0711|26 46|nucleus accumbens septi
P01171935A0313|44 49|humans
P01171935A0313|74 81|levodopa
P01171935A0313|3 12|appearance
P01171935A0313|134 164|dopamine receptor site sensitivity
P01171935A0313|84 94|amphetamine
P01171935A0313|69 71|use
P01171935A0313|174 181|striatum
P01171935A0313|25 41|movement disorders
P01171935A0313|101 113|manifestation
P01172734T0035|0 10|Association
P01172734T0035|19 22|W-27
P01172917T0000|0 5|Letter
P01172917T0000|42 54|milk tolerance
P01172917T0000|31 39|predictor
P01172917T0000|7 27|Lactose tolerance tests
P01174873T0000|0 13|Retinoblastoma
P01174873T0000|30 36|history
P01174873T0000|16 20|study
P01174873T0000|54 58|cases
P01174873T0000|40 48|prognosis
P01176905A0094|43 50|mid-dark
P01176905A0094|59 67|mid-light
P01176905A0094|20 33|serum melatonin
P01176905A0094|10 18|melatonin
P01178153A0056|0 1|D.
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|85 91|changes
P01185956A0722|33 52|Doppler-cardiography
P01185956A0722|3 9|authors
P01185956A0722|97 108|stroke volume
P01186344A0303|145 147|ova
P01186344A0303|72 81|production
P01186344A0303|100 103|male
P01186344A0303|84 94|spermatozoa
P01186344A0303|3 12|attainment
P01186344A0303|31 35|terms
P01186344A0303|21 28|maturity
P01186344A0303|151 160|end-points
P01186344A0303|136 142|release
P01186344A0303|125 131|pattern
P01186344A0303|53 67|characteristics
P01186344A0303|179 185|process
P01190120A0832|15 26|% lengthening
P01190120A0832|73 77|hours
P01190120A0832|80 86|storage
P01190120A0832|39 56|thromboplastin time
P01190251A0335|0 6|Caution
P01190251A0335|29 31|use
P01190251A0335|39 42|dyes
P01190251A0335|46 56|lymphograms
P01191955A0077|71 77|varices
P01191955A0077|15 18|test
P01191955A0077|103 108|reflux
P01191955A0077|65 68|cent
P01191955A0077|36 47|incompetence
P01191964A0000|60 65|Graves
P01191964A0000|230 234|basis
P01191964A0000|93 98|goitre
P01191964A0000|5 10|groups
P01191964A0000|68 74|disease
P01191964A0000|93 98|goitre
P01191964A0000|13 20|patients
P01191964A0000|216 224|subgroups
P01191964A0000|135 139|years
P01191964A0000|162 175|serum thyroxine
P01191964A0000|44 56|thyroidectomy
P01191964A0000|181 185|level
P01191964A0000|177 179|T-4
P01191964A0000|253 282|serum thyrotrophin concentration
P01193458T0001|89 94|reflux
P01193458T0001|33 47|Tc sulfur colloid
P01193458T0001|7 24|isotope cystography
P01193458T0001|63 71|follow-up
P01193458T0001|51 59|detection
P01193770T0000|0 11|Air ion action
P01193770T0000|14 21|bacteria
P01194673A0652|2 9|evidence
P01194673A0652|36 46|chemography
P01201977T0000|29 45|disc sensitivities
P01201977T0000|3 16|interpretation
P01202616A0466|91 103|lamina propria
P01202616A0466|44 49|lining
P01202616A0466|123 126|loss
P01202616A0466|139 144|detail
P01202616A0466|9 21|retransfusion
P01206772T0000|1 5|study
P01206772T0000|55 64|hycanthone
P01206772T0000|36 43|patients
P01206772T0000|21 31|lymphocytes
P01206772T0000|8 18|chromosomes
P01206896T0001|45 64|emergency lung surgery
P01206896T0001|30 42|resuscitation
P01206896T0001|0 14|Characteristics
P01206896T0001|17 26|anesthesia
P01208811T0001|0 4|Study
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 75|citrate solution-blood system
P01208811T0001|26 30|state
P01209618A0409|99 104|action
P01209618A0409|0 9|Tobramycin
P01209618A0409|12 13|mg
P01209618A0409|107 120|d-tubocurarine
P01209618A0409|76 93|potentiating effect
P01209618A0409|47 55|dibecacin
P01209618A0409|12 13|mg
P01209618A0409|37 42|effect
P01211754A0192|116 123|deafness
P01211754A0192|29 37|operation
P01211754A0192|20 24|cases
P01211754A0192|60 70|improvement
P01211754A0192|74 81|patients
P01215067A0000|74 86|conductometry
P01215067A0000|98 116|meningitis purulenta
P01215067A0000|91 95|cases
P01215067A0000|91 95|cases
P01215067A0000|179 186|subjects
P01215067A0000|21 30|resistance
P01215067A0000|67 71|means
P01215067A0000|49 53|fluid
P01215067A0000|91 95|cases
P01215067A0000|127 142|meningitis serosa
P01215067A0000|153 164|encephalitis
P01217450A0295|52 56|block
P01217450A0295|2 18|Chemical occlusion
P01217450A0295|75 78|dogs
P01224116A0576|130 135|family
P01224116A0576|74 78|Russe
P01224116A0576|18 25|patients
P01224116A0576|35 54|serum immunoglobulins
P01224116A0576|80 84|Busey
P01224116A0576|63 65|IgG
P01224116A0576|88 94|Barbeau
P01225339A0590|40 43|time
P01225339A0590|17 26|occlusions
P01225339A0590|49 58|infarction
P01228258A0000|101 111|combination
P01228258A0000|116 126|Mitomycin-C
P01228258A0000|73 80|patients
P01228258A0000|135 153|Cytosine arabinoside
P01228258A0000|37 40|type
P01228258A0000|25 30|OK-432
P01228258A0000|48 53|cancer
P01228258A0000|128 131|5-FU
P01228258A0000|54 58|agent
P01228258A0000|13 23|preparation
P01228882A0437|164 171|diseases
P01228882A0437|47 60|concentrations
P01228882A0437|136 144|component
P01228882A0437|84 89|degree
P01228882A0437|113 120|response
P01228882A0437|63 80|CSF immunoglobulins
P01228882A0437|11 21|correlation
P01233561T0001|8 16|lactation
P01235347T0001|12 25|cardiotoxicity
P01235347T0001|28 37|adriamycin
P01236224T0001|8 16|pathology
P01237206A0199|0 12|Demonstration
P01237206A0199|203 206|eggs
P01237206A0199|176 184|titration
P01237206A0199|96 111|auramine staining
P01237206A0199|18 22|agent
P01237206A0199|54 60|day p.i.
P01237206A0199|198 200|hen
P01237206A0199|146 160|Coxiella content
P01237206A0199|80 86|methods
P01237206A0199|124 140|antibody technique
P01237206A0199|88 92|Stamp
P01241437A0152|71 78|morphine
P01241437A0152|42 46|NLA II
P01241437A0152|27 32|groups
P01241437A0152|3 10|patients
P01241437A0152|81 87|Micoren
P01241437A0152|60 69|nalorphine
P01241588A1470|56 60|brain
P01241588A1470|69 78|conditions
P01241588A1470|16 19|5-HT
P01241588A1470|3 13|alterations
P01241588A1470|44 50|regions
P01241588A1470|108 120|neurotoxicity
P01241588A1470|152 159|neurones
P01241588A1470|102 105|IDPN
P01241588A1470|23 34|5-HIAA levels
P01241866A0682|60 64|serum
P01241866A0682|15 30|leukocyte-counts
P01241866A0682|44 57|administration
P01241866A0682|5 12|increase
P01241866A0682|89 95|phase-2
P01241866A0682|77 82|rabbit
P01242636A0678|55 60|system
P01242636A0678|3 9|results
P01242636A0678|81 98|beryllium retention
P01243628A0286|67 70|COHb
P01243628A0286|80 80|%
P01243628A0286|17 19|end
P01243628A0286|6 10|cases
P01243628A0286|44 65|blood carboxyhemoglobin
P01243628A0286|22 29|exposure
P01243628A0286|37 41|level
P01244236A1122|3 9|results
P01244236A1122|22 29|increase
P01244236A1122|146 152|vessels
P01244236A1122|22 29|increase
P01244236A1122|138 143|number
P01244236A1122|40 48|blood flow
P01244236A1122|165 183|vasomotor reactivity
P01244236A1122|215 220|amount
P01244236A1122|243 251|thickness
P01244236A1122|101 109|gestation
P01244236A1122|146 152|vessels
P01244236A1122|229 234|muscle
P01244236A1122|229 234|muscle
P01244236A1122|78 87|resistance
P01245162A0262|0 8|Reduction
P01245162A0262|31 40|taste sense
P01245162A0262|63 66|drug
P01245162A0262|109 126|transaminase levels
P01245162A0262|11 16|dosage
P01246210A0648|73 73|%
P01246210A0648|16 24|mean ratio
P01246210A0648|3 14|calcium ratio
P01246210A0648|79 83|women
P01246210A0648|56 58|men
P01246210A0648|49 52|TBCa
P01246210A0648|73 73|%
P01247475A0000|82 94|deterioration
P01247475A0000|16 29|retinoblastoma
P01247475A0000|5 13|diagnosis
P01247475A0000|65 70|growth
P01247475A0000|48 51|fact
P01247475A0000|100 106|outlook
P01248124A0281|71 79|gestation
P01248124A0281|5 15|cholesterol
P01248124A0281|37 42|fluids
P01248124A0281|63 68|stages
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|67 75|pregnancy
P01249198A1097|80 90|GTD patients
P01249198A1097|106 120|hyperthyroidism
P01249198A1097|53 58|ranges
P01252223A0347|101 105|Winch
P01252223A0347|28 31|fear
P01252223A0347|59 75|trait correlations
P01252223A0347|3 9|authors
P01252223A0347|119 122|type
P01252223A0347|108 116|principle
P01252223A0347|35 43|pugnacity
P01252223A0347|124 138|complementarity
P01252223A0347|91 98|contrast
P01253191T0000|1 4|note
P01253191T0000|53 68|action potentials
P01253191T0000|10 43|phase-plane technique representation
P01256410T0001|1 10|activities
P01256410T0001|52 55|term
P01256410T0001|44 49|infant
P01256410T0001|16 21|factor
P01256410T0001|24 31|molecule
P01259027A0416|246 253|approach
P01259027A0416|55 62|analysis
P01259027A0416|3 9|concept
P01259027A0416|174 182|procedure
P01259027A0416|79 93|model parameters
P01259027A0416|23 37|identifiability
P01259027A0416|156 159|data
P01259027A0416|3 9|concept
P01259027A0416|192 200|extension
P01259027A0416|271 283|design problem
P01261005A0711|29 37|variation
P01261005A0711|41 51|differences
P01261005A0711|93 118|bandpass spectrophotometers
P01261005A0711|54 64|performance
P01261005A0711|78 85|bandpass
P01262596T0000|11 20|compromise
P01264640T0028|15 20|Saigon
P01264640T0028|1 4|case
P01265443A0159|148 154|stomach
P01265443A0159|55 59|pouch
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|81 90|inhibition
P01265443A0159|184 189|effect
P01265443A0159|113 125|acid secretion
P01265443A0159|173 178|saline
P01265443A0159|10 16|glucose
P01265887T0001|43 50|patients
P01265887T0001|8 26|factor VIII inhibitor
P01267446A0210|0 15|Biohydrogenation
P01267446A0210|26 29|acid
P01267446A0210|26 29|acid
P01272816A0000|102 105|47Ca
P01272816A0000|86 99|administration
P01272816A0000|134 143|absorption
P01272816A0000|3 7|study
P01272816A0000|69 76|controls
P01272816A0000|44 51|children
P01272816A0000|10 26|calcium metabolism
P01275335A0158|66 70|phase
P01275335A0158|47 49|end
P01275335A0158|35 39|semen
P01275335A0158|10 15|agents
P01275541A0405|130 137|delivery
P01275541A0405|87 95|dystrophy
P01275541A0405|120 124|weeks
P01275541A0405|45 52|newborns
P01275541A0405|21 31|CPK activity
P01276105A0313|14 28|insulin response
P01276105A0313|73 75|day
P01276105A0313|2 9|contrast
P01276105A0313|81 90|puerperium
P01276105A0313|57 61|value
P01278251A0000|73 81|materials
P01278251A0000|83 94|polyethylene
P01278251A0000|3 9|authors
P01278251A0000|73 81|materials
P01278251A0000|29 34|series
P01278251A0000|19 25|results
P01278251A0000|163 172|sensitizer
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01278251A0000|50 54|tests
P01279197T0000|28 41|homology region
P01279197T0000|69 71|use
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|10 17|analysis
P01279197T0000|74 94|saturation mutagenesis
P01279352A0297|3 6|site
P01279352A0297|29 48|bp sequence GGGGAGGAGG
P01279352A0297|8 10|PAL
P01279352A0473|91 98|proteins
P01279352A0473|74 83|mouse liver
P01279352A0473|60 69|mouse brain
P01279352A0473|131 142|PAL sequences
P01279352A0473|7 14|extracts
P01279352A0473|50 58|cell lines
P01279352A0473|181 195|target sequences
P01279352A0473|124 127|PROX
P01279352A0473|91 98|proteins
P01279352A1197|72 82|development
P01279352A1197|16 17|NF
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279352A1197|19 19|H
P01279352A1197|93 96|mice
P01279352A1197|46 51|tissue
P01279352A1197|110 123|promoter region
P01279352A1197|21 28|promoter
P01279352A1197|60 65|manner
P01279374A0396|118 123|PET122
P01279374A0396|30 34|genes
P01279374A0396|106 115|truncation
P01279374A0396|62 72|suppressors
P01279696A0862|60 68|Kishimoto
P01279696A0862|34 35|S.
P01279696A0862|57 58|E.
P01279696A0862|46 47|M.
P01279696A0862|70 71|T.
P01279696A0862|37 44|Kusubata
P01279696A0862|8 14|studies
P01279696A0862|49 55|Okumura
P01279696A0862|25 32|Hisanaga
P01280413T0001|0 8|Treatment
P01280413T0001|42 50|detection
P01280413T0001|31 38|sections
P01280413T0001|22 27|smears
P01280413T0001|53 66|microorganisms
P01280413T0001|12 19|staining
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|80 103|ThrRS/CGU operator complex
P01280807A0575|47 60|order magnitude
P01280807A0575|11 12|Kd
P01281322A0604|115 122|flow rate
P01281322A0604|18 29|relationship
P01281322A0604|51 68|percent area density
P01281322A0604|89 101|percent change
P01281322A0604|77 82|muscle
P01281472T0000|0 5|Rabbit
P01281472T0000|14 29|muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|57 73|expression pattern
P01281771T0000|38 48|cytokeratin
P01281771T0000|26 29|gene
P01282014A0275|0 6|Animals
P01282014A0275|19 23|DSP-4
P01282014A0275|51 63|motor recovery
P01282014A0275|79 89|saline group
P01282638A0934|3 17|prophylactic use
P01282638A0934|234 241|schedule
P01282638A0934|168 174|quality
P01282638A0934|36 43|patients
P01282638A0934|137 151|health care costs
P01282638A0934|90 98|agreement
P01282638A0934|36 43|patients
P01282638A0934|68 72|cycle
P01282638A0934|36 42|patient
P01282638A0934|208 219|continuation
P01282638A0934|249 260|interruption
P01282638A0934|106 114|estimates
P01282638A0934|279 292|life expectancy
P01282638A0934|23 32|medication
P01282638A0934|75 86|chemotherapy
P01282638A0934|177 180|life
P01284032A0213|0 1|AP
P01284032A0213|90 93|mmol
P01284032A0213|84 87|GDOC
P01284032A0213|47 60|concentrations
P01284032A0213|79 82|acid
P01284032A0213|90 93|mmol
P01284032A0213|25 32|infusion
P01284595A0102|84 92|sequences
P01284595A0102|115 120|insert
P01284595A0102|3 11|isolation
P01284595A0102|94 103|HTF islands
P01284595A0102|54 64|Y-231 cosmid
P01284595A0102|18 21|gene
P01284595A0102|77 79|CpG
P01284595A0102|35 48|identification
P01284828T0001|59 70|fibrinolysis
P01284828T0001|30 38|inhibitor
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|73 77|blood
P01284828T0001|119 126|prostate
P01284828T0001|47 56|parameters
P01284828T0001|80 87|patients
P01284828T0001|103 113|hypertrophy
P01285009A0000|0 13|Gene constructs
P01285009A0000|121 135|thymidine kinase
P01285009A0000|31 43|growth hormone
P01285009A0000|142 159|rat cholecystokinin
P01285009A0000|90 109|mouse metallothionein
P01285009A0000|169 185|chicken beta-actin
P01285009A0000|161 164|rCCK
P01285009A0000|251 259|micropyle
P01285009A0000|137 139|vTK
P01285009A0000|49 52|gene
P01285009A0000|45 47|hGH
P01285009A0000|111 113|mMT
P01285009A0000|214 222|cytoplasm
P01285009A0000|80 87|sequence
P01285009A0000|49 52|gene
P01285009A0000|187 189|cBA
P01285009A0000|235 244|medaka eggs
P01285358A0396|0 11|Serum gastrin
P01285358A0396|84 89|course
P01285358A0396|95 101|disease
P01285358A0396|15 23|AFP levels
P01285358A0396|65 72|interest
P01285358A0396|34 42|evolution
P01285554T0000|31 37|systems
P01285554T0000|0 8|Prospects
P01285807A0365|14 17|PaO2
P01285807A0365|42 45|mmHg
P01285807A0365|3 6|mean
P01285807A0365|42 45|mmHg
P01285807A0365|77 84|infusion
P01285807A0365|42 45|mmHg
P01285807A0365|99 103|PaCO2
P01285807A0365|14 14|P
P01285807A0365|14 14|P
P01285807A0365|11 12|SD
P01286732A0572|172 183|complication
P01286732A0572|134 150|liver cell necrosis
P01286732A0572|70 79|proportion
P01286732A0572|186 204|P. falciparum malaria
P01286732A0572|82 89|patients
P01286732A0572|6 17|hepatomegaly
P01286732A0572|36 42|enzymes
P01286732A0572|123 131|hepatitis
P01286732A0572|25 33|elevation
P01286732A0572|104 108|liver
P01286732A0572|91 101|involvement
P01287197A0761|113 118|mmol/l
P01287197A0761|210 211|iv
P01287197A0761|27 34|decrease
P01287197A0761|43 44|po
P01287197A0761|148 156|decrement
P01287197A0761|62 71|salbutamol
P01287197A0761|11 15|group
P01287197A0761|113 118|mmol/l
P01287197A0761|11 15|group
P01287197A0761|37 51|plasma potassium
P01292230A0283|42 48|filling
P01292230A0283|6 10|drugs
P01292230A0283|22 25|rate
P01294345A0591|44 57|administration
P01294345A0591|60 68|Bromergon
P01294345A0591|165 169|edema
P01294345A0591|184 199|breast tenderness
P01294345A0591|171 180|weight gain
P01294345A0591|82 89|symptoms
P01294345A0591|128 142|prolactin levels
P01294345A0591|25 35|improvement
P01294345A0591|157 163|tension
P01294345A0591|104 119|overreactiveness
P01295373A0651|41 41|%
P01295373A0651|44 44|A
P01295373A0651|3 11|magnitude
P01295373A0651|41 41|%
P01295373A0651|91 91|B
P01295373A0651|65 66|SE
P01295373A0651|46 56|% baseline RL
P01295373A0651|105 105|C
P01295373A0651|22 29|response
P01295373A0651|25 25|p
P01295373A0651|41 41|%
P01295373A0651|58 61|mean
P01295500A0366|89 96|Deficits
P01295500A0366|57 57|%
P01295500A0366|47 53|Attacks
P01295500A0366|57 57|%
P01295500A0366|9 16|patients
P01296815A0059|57 72|sequence analysis
P01296815A0059|31 34|LD78
P01296815A0059|42 50|LD78 gamma
P01296815A0059|21 24|gene
P01296815A0059|100 109|pseudogene
P01297332A0983|100 107|proposal
P01297332A0983|84 88|genes
P01297332A0983|118 134|consensus sequence
P01297332A0983|4 11|analysis
P01297332A0983|161 167|element
P01297332A0983|44 47|SCBs
P01297332A0983|26 38|consideration
P01297332T0000|68 76|cell cycle
P01297332T0000|21 31|DNA sequence
P01297332T0000|49 62|gene expression
P01297332T0000|10 17|analysis
P01298173A0153|147 156|modalities
P01298173A0153|44 53|efficiency
P01298173A0153|86 89|part
P01298173A0153|98 109|chemotherapy
P01298173A0153|168 174|measure
P01298173A0153|111 118|survival
P01298173A0153|68 77|treatments
P01298173A0153|24 30|lesions
P01298173A0153|10 16|history
P01298173A0153|128 132|death
P01298398A0461|40 55|nadolol racemate A
P01298398A0461|3 8|method
P01298398A0461|73 88|phase composition
P01298398A0461|59 64|change
P01298398A0461|25 37|determination
P01299489A0788|87 97|performance
P01299489A0788|101 108|athletes
P01299489A0788|41 48|evidence
P01299489A0788|54 59|effect
P01299489A0788|22 26|study
P01299489A0788|128 131|RDIs
P01299489A0788|62 76|supplementation
P01300914A1066|171 175|walls
P01300914A1066|5 11|absence
P01300914A1066|63 66|view
P01300914A1066|401 408|exercise
P01300914A1066|532 536|froms
P01300914A1066|275 285|arrhythmias
P01300914A1066|480 483|sign
P01300914A1066|220 228|existence
P01300914A1066|340 346|feature
P01300914A1066|697 702|stasis
P01300914A1066|389 399|stimulation
P01300914A1066|180 188|diagnosis
P01300914A1066|72 82|variability
P01300914A1066|26 33|criteria
P01300914A1066|127 132|biopsy
P01300914A1066|611 625|RV abnormalities
P01300914A1066|85 91|results
P01300914A1066|320 321|VT
P01300914A1066|448 463|amplification ECG
P01300914A1066|429 438|potentials
P01300914A1066|684 691|vaulting
P01300914A1066|191 194|ACRV
P01300914A1066|366 376|sensitivity
P01300914A1066|366 376|sensitivity
P01300914A1066|104 110|dangers
P01300914A1066|358 363|degree
P01300914A1066|26 33|criteria
P01300914A1066|220 228|existence
P01301171A0979|15 22|enhancer
P01301171A0979|6 10|cases
P01301171A0979|35 55|c-myc bearing sequences
P01301171A0979|58 67|chromosome
P01302765A0999|20 21|ad
P01302765A0999|29 30|R2
P01302765A0999|54 56|R2s
P01302765A0999|5 14|components
P01302765A0999|5 14|components
P01304515A0178|55 64|volunteers
P01304515A0178|34 45|control group
P01304515A0178|11 17|results
P01304809T0001|3 7|years
P01304809T0001|53 56|Jena
P01304809T0001|10 18|dentistry
P01304809T0001|24 50|Friedrich Schiller University
P01309244A0798|115 121|context
P01309244A0798|99 105|species
P01309244A0798|87 95|cell types
P01309244A0798|3 8|target
P01309244A0798|45 48|acts
P01309244A0798|137 144|promoter
P01309244A0798|25 33|positions
P01309244A0798|64 74|orientation
P01309587A0715|101 108|Z protein
P01309587A0715|89 95|binding
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|118 129|c-myb protein
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|11 25|transactivation
P01309593A0095|3 17|UCR core sequence
P01309593A0095|19 27|CGCCATTTT
P01309593A0095|89 108|MuLV promoter activity
P01309593A0095|52 57|factor
P01309593A0095|77 86|regulation
P01309593A1092|199 210|protein genes
P01309593A1092|132 150|immunoglobulin light
P01309593A1092|5 11|studies
P01309593A1092|119 126|elements
P01309593A1092|166 170|genes
P01309593A1092|20 24|UCRBP
P01309593A1092|119 126|elements
P01309593A1092|73 80|UCR motif
P01309593A1092|39 50|target motifs
P01309593A1092|101 115|virus P5 promoter
P01309815A0972|71 76|arrest
P01309815A0972|96 106|maintenance
P01309815A0972|71 76|arrest
P01309815A0972|39 55|signal recognition
P01309815A0972|12 25|scr1-1 mutation
P01309815A0972|130 141|AEP synthesis
P01309860A0559|11 19|sequences
P01309860A0559|32 46|integration site
P01309860A0559|11 19|sequences
P01309860A0559|103 115|mouse L1 family
P01309860A0559|11 19|sequences
P01309860A0559|62 70|% identity
P01309894A0807|56 65|nucleotide
P01309894A0807|31 41|AAV sequence
P01309894A0807|4 8|Rep78
P01309894A0807|51 54|site
P01309894A0807|12 16|Rep68
P01309910A0428|0 25|Nucleotide sequence analysis
P01309910A0428|74 85|CREB2 protein
P01309910A0428|49 55|protein
P01310154A0879|72 86|transrepression
P01310154A0879|43 51|mutations
P01310154A0879|28 28|N
P01310154A0879|89 98|FBR protein
P01310154A0879|163 181|protein modification
P01310154A0879|5 11|results
P01310154A0879|43 51|mutations
P01310154A0879|187 200|gene regulation
P01310154A0879|89 98|FBR protein
P01310178A0876|39 48|amber codon
P01310178A0876|162 186|host transcription shut-off
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310178A0876|66 75|production
P01310178A0876|30 32|gp0
P01310178A0876|110 120|polypeptide
P01310178A0876|154 159|domain
P01310879A0000|1 16|patient suffering
P01310879A0000|101 107|failure
P01310879A0000|113 121|treatment
P01310879A0000|70 86|arteriothromboses
P01310879A0000|56 58|HAT
P01310879A0000|39 54|thrombocytopenia
P01310879A0000|21 27|heparin
P01310899A0339|89 107|transmembrane domain
P01310899A0339|64 69|domain
P01310899A0339|12 28|receptor structure
P01310899A0339|133 160|serine/threonine kinase domain
P01310935T0000|59 64|enzyme
P01310935T0000|84 101|protein degradation
P01310935T0000|10 14|UbcD1
P01312005A0600|290 300|replication
P01312005A0600|0 7|Analysis
P01312005A0600|285 286|OH
P01312005A0600|61 68|cleavage
P01312005A0600|71 80|chick mtDNA
P01312005A0600|128 138|target sites
P01312005A0600|95 95|H
P01312005A0600|0 0|A
P01312005A0600|250 254|bases
P01312005A0600|49 52|MDP1
P01312005A0600|223 232|structures
P01312005A0600|173 177|tract
P01312005A0600|26 33|mt genome
P01312005A0600|278 283|origin
P01313715A0461|84 91|rp47phox
P01313715A0461|3 6|goal
P01313715A0461|54 63|retrovirus
P01313715A0461|171 190|B-lymphocyte cell line
P01313715A0461|192 198|EBV-BCL
P01313715A0461|41 51|feasibility
P01313715A0461|72 81|expression
P01313715A0461|97 100|HL60
P01313715A0461|59 63|virus
P01313715A0461|19 23|study
P01313715A0461|104 107|U937
P01313715A0461|126 134|cell lines
P01313715A0461|229 238|CGD patient
P01313846A0850|130 145|melanoma Ag MUC-18
P01313846A0850|0 9|Comparison
P01313846A0850|218 237|cell adhesion molecule
P01313846A0850|175 182|Ag family
P01313846A0850|42 48|Tactile
P01313846A0850|97 106|similarity
P01313846A0850|17 33|sequence databanks
P01313846A0850|187 204|poliovirus receptor
P01313846A0850|147 153|members
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|52 57|member
P01313894A1179|14 20|pattern
P01313894A1179|54 72|LMP2B mRNA expression
P01313894A1179|45 51|respect
P01313894A1179|119 124|tumors
P01313894A1179|78 88|transcripts
P01313894A1179|148 153|levels
P01313894A1179|111 116|subset
P01313894A1179|23 29|results
P01313909A0526|115 122|sequence
P01313909A0526|3 11|phenotype
P01313909A0526|3 12|phenotypes
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|79 83|virus
P01313909A0526|22 35|nonsense mutant
P01314457T0000|72 76|L-DNA
P01314457T0000|0 7|Analysis
P01314457T0000|85 96|conservation
P01314457T0000|68 70|HVS
P01314457T0000|44 46|kbp
P01314457T0000|49 66|herpesvirus saimiri
P01314457T0000|68 70|HVS
P01314457T0000|106 117|organization
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|55 59|virus
P01314841A0724|0 8|Treatment
P01314841A0724|27 42|burst suppression
P01314841A0724|79 82|mm Hg
P01314841A0724|89 92|mean
P01314841A0724|64 67|drop
P01314841A0724|48 50|EEG
P01314841A0724|101 108|pressure
P01314841A0724|13 18|MK-801
P01314953A1266|112 120|complexes
P01314953A1266|60 63|HAP2
P01314953A1266|2 9|contrast
P01314953A1266|90 102|hap3 mutations
P01314953A1266|77 82|domain
P01314953A1266|66 69|HAP3
P01314953A1266|11 37|gel mobility shift experiments
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|8 22|differentiation
P01315706A0000|67 85|rat L6 muscle cell line
P01316125A0176|37 39|1O2
P01316125A0176|3 12|experiment
P01316125A0176|71 74|YHPD
P01316125A0176|71 74|YHPD
P01316125A0176|66 67|OH
P01316125A0176|37 39|1O2
P01316125A0176|66 67|OH
P01316125A0176|71 74|YHPD
P01316125A0176|94 96|aid
P01316125A0176|152 155|BHPD
P01316125A0176|152 155|BHPD
P01316125A0176|118 124|ability
P01316125A0176|52 59|radicals
P01316125A0176|71 74|YHPD
P01316125A0382|54 57|YHPD
P01316125A0382|3 8|points
P01316125A0382|81 83|1O2
P01316125A0382|110 111|OH
P01316125A0382|54 57|YHPD
P01316125A0382|188 191|BHPD
P01316125A0382|46 51|damage
P01316125A0382|46 51|damage
P01316125A0382|96 103|radicals
P01316125A0382|110 111|OH
P01316125A0382|247 251|yield
P01316125A0382|46 51|damage
P01316125A0382|123 128|second
P01316125A0382|54 57|YHPD
P01316125A0382|81 83|1O2
P01316459A0311|0 3|Acad
P01316461A1083|44 51|peptides
P01316461A1083|98 101|sera
P01316461A1083|200 206|animals
P01316461A1083|23 24|S2
P01316461A1083|25 31|protein
P01316461A1083|23 31|S2 protein
P01316461A1083|127 132|horses
P01316461A1083|157 164|evidence
P01316461A1083|167 176|expression
P01316476A0842|71 80|start sites
P01316476A0842|53 55|VZV
P01316476A0842|13 25|TATA sequences
P01316476A1428|3 5|ORF
P01316476A1428|3 5|ORF
P01316476A1428|60 68|induction
P01316476A1428|7 10|gene
P01316476A1428|7 10|gene
P01316476A1428|60 68|induction
P01316476A1428|74 78|genes
P01316680A0643|17 22|IR5 ORF
P01316680A0643|143 150|H-X2-4-C
P01316680A0643|40 47|sequence
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|26 26|H
P01316680A0643|91 95|match
P01316680A0643|52 61|amino acids
P01316680A0643|101 124|consensus zinc finger motif
P01316680A0643|126 141|C-X2-4-C-X2-15-C
P01316680A0643|25 29|EHV-1
P01316900A0000|60 63|K-12
P01316900A0000|3 13|DNA sequence
P01316900A0000|19 40|sulfate activation locus
P01316903A0296|19 22|form
P01316903A0296|96 98|IIO
P01316903A0296|19 22|form
P01316903A0296|25 37|RNA polymerase
P01316903A0296|52 54|IIA
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|83 93|input enzyme
P01316903A1040|64 72|reactions
P01316903A1040|53 61|complexes
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|119 131|frk mRNA levels
P01317376A0981|45 53|Z. mobilis
P01317376A0981|81 87|glucose
P01317376A0981|64 71|fructose
P01317376A0981|109 116|increase
P01318310A0000|0 14|Plasma membranes
P01318310A0000|41 57|affinity receptors
P01318310A0000|135 145|cholesterol
P01318310A0000|84 86|HDL
P01318310A0000|65 82|density lipoprotein
P01318310A0000|107 113|removal
P01318310A0000|25 29|cells
P01318739A0410|58 62|VM-26
P01318739A0410|15 33|patients vincristine
P01318739A0410|69 81|neurotoxicity
P01318739A0410|47 56|teniposide
P01320255A0795|39 45|element
P01320255A0795|97 109|factor binding
P01320255A0795|143 155|transcription
P01320255A0795|5 11|results
P01320255A0795|74 75|L1
P01320255A0795|134 137|role
P01320255A0795|74 83|L1 sequence
P01320255A0795|39 45|element
P01320640A0336|0 9|Tumor cells
P01320640A0336|61 67|insulin
P01320640A0336|69 76|glucagon
P01320640A0336|80 82|VIP
P01320640A0336|53 59|enolase
P01321277A0342|96 98|CEF
P01321277A0342|26 28|src
P01321277A0342|42 44|ros
P01321277A0342|141 143|UR2
P01321277A0342|52 54|SRC
P01321277A0342|103 124|spindle shape morphology
P01321277A0342|19 21|end
P01321277A0342|19 21|end
P01321277A0342|56 58|ROS
P01321277A0342|71 94|chicken embryo fibroblasts
P01321277A0664|0 2|ROS
P01321277A0664|32 39|deletion
P01321277A0664|4 6|SRC
P01321277A0664|79 84|domain
P01321277A0664|0 0|R
P01321277A0664|87 89|ros
P01321280A0494|175 190|E7 fusion proteins
P01321280A0494|95 124|immunoprecipitation experiments
P01321280A0494|31 32|E6
P01321280A0494|20 25|nature
P01321280A0494|78 82|cells
P01321280A0494|36 49|E7 gene products
P01321280A0494|165 171|BPV-1 E6
P01321280A0494|11 16|number
P01321280A0494|129 136|antisera
P01321332A0970|219 225|amounts
P01321332A0970|158 165|presence
P01321332A0970|86 100|transactivation
P01321332A0970|69 71|RXR
P01321332A0970|120 127|promoter
P01321332A0970|135 152|hepatoma HepG2 cells
P01321332A0970|241 245|ARP-1
P01321332A0970|37 41|site A
P01321332A0970|9 26|transfection assays
P01321332A0970|86 100|transactivation
P01321332A0970|168 169|RA
P01321332A0970|106 114|apoAI gene
P01321336A0000|28 40|leukemia virus
P01321336A0000|3 16|enhancer region
P01321336A0000|19 21|Akv
P01321336A0000|52 72|sequence motif ACAGATGG
P01321336A0731|85 92|proteins
P01321336A0731|58 66|insertion
P01321336A0731|3 16|splice variants
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|104 113|amino acids
P01321337A0318|88 94|ability
P01321337A0318|101 105|45Ca2
P01321337A0318|43 46|mass
P01321337A0318|145 145|B
P01321337A0318|15 23|component
P01321337A0318|165 175|calcineurin
P01321337A0318|68 77|properties
P01321337A0318|147 153|subunit
P01321337A0318|196 204|antiserum
P01321337A0318|49 51|kDa
P01321337A0318|165 175|calcineurin
P01321337A1161|44 50|mutants
P01321337A1161|127 138|growth arrest
P01321337A1161|52 66|MATa cnb1 mutants
P01321337A1161|87 93|ability
P01321337A1161|26 37|MATa cna1 cna2
P01324172A0880|0 9|Antibodies
P01324172A0880|44 47|RIM1
P01324172A0880|29 35|protein
P01324172A0880|50 61|mitochondria
P01324385A0329|0 6|METHODS
P01324385A0329|29 42|anti-HHV-6-IgG
P01324385A0329|171 173|CDC
P01324385A0329|195 202|subjects
P01324385A0329|8 20|IgG antibodies
P01324385A0329|68 85|immunofluorescence
P01324385A0329|91 94|IVDA
P01324385A0329|164 168|IV-C1
P01324385A0329|152 154|age
P01324385A0329|217 228|control group
P01324385A0329|98 109|seronegative
P01324385A0329|23 27|HHV-6
P01324385A0329|150 154|stage
P01324385A0329|130 134|HIV-1
P01324404A0813|131 140|amino acids
P01324404A0813|21 36|activation domain
P01324404A0813|60 66|regions
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A1208|0 8|HNF-3 beta
P01324404A1208|102 109|activity
P01324404A1208|75 89|transactivation
P01324404A1208|121 133|participation
P01324404A1208|139 156|region II-III domain
P01324404A1208|50 55|region
P01324404A1208|50 55|region
P01324404A1208|23 31|sequences
P01324406A1250|130 138|sequences
P01324406A1250|27 52|ATPase/DNA helicase activity
P01324406A1250|72 82|maintenance
P01324406A1250|15 18|RAD5
P01324406A1250|55 63|DNA repair
P01324406A1250|94 98|rates
P01324406A1250|8 12|roles
P01324406A1250|101 111|instability
P01324639T0000|0 15|Susceptibilities
P01324639T0000|125 135|clindamycin
P01324639T0000|43 49|bacilli
P01324639T0000|52 62|amoxicillin
P01324639T0000|85 107|amoxicillin-clavulanate
P01324639T0000|64 78|amoxicillin-BRL
P01324639T0000|109 120|temafloxacin
P01325221A0870|46 54|detection
P01325221A0870|18 27|DU249 cells
P01325221A0870|133 146|chromatography
P01325221A0870|10 15|arrest
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|76 84|MBP kinase
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|32 40|synthesis
P01325386A0766|24 29|defect
P01325386A0766|49 64|heat shock protein
P01326329A0703|193 222|glucocorticoid response elements
P01326329A0703|6 19|base pair region
P01326329A0703|266 269|CREs
P01326329A0703|135 144|CACCC boxes
P01326329A0703|86 92|TATA box
P01326329A0703|109 117|sequences
P01326329A0703|71 74|lack
P01326329A0703|127 133|GC boxes
P01326329A0703|246 264|AMP response elements
P01326329A0703|157 172|activator protein
P01326329A0703|44 50|CAP site
P01326329A0703|180 184|sites
P01326329A0703|146 155|CCAAT boxes
P01326329A0703|175 178|Ap-2
P01326329A0703|224 227|GREs
P01326329A0703|99 106|presence
P01326557T0000|0 6|Cloning
P01326557T0000|74 103|chondroitin sulfate proteoglycan
P01326557T0000|28 35|neurocan
P01326557T0000|17 25|structure
P01326557T0000|106 110|brain
P01327280A0000|60 61|pH
P01327280A0000|2 5|rats
P01327280A0000|65 65|K
P01327280A0000|60 61|pH
P01327280A0000|75 88|cord dorsal horn
P01327280A0000|25 34|chloralose
P01327280A0000|125 134|electrodes
P01327280A0000|65 65|K
P01327280A0000|38 44|changes
P01327758A0000|0 10|Replication
P01327758A0000|61 72|gene products
P01327758A0000|19 34|papillomavirus-1
P01327758A0000|36 40|BPV-1
P01327758A0000|77 85|E1 protein
P01327758A0000|42 44|DNA
P01327758A0000|103 111|E2 protein
P01327967A0668|119 124|serine
P01327967A0668|42 52|sensitivity
P01327967A0668|132 142|metabolites
P01327967A0668|68 94|agent methylmethane sulfonate
P01327967A0668|105 115|requirement
P01327967A0668|11 22|inactivation
P01327967A0668|25 27|sms
P01328197A0985|27 60|MAP kinase activator/MAP kinase system
P01328197A0985|5 12|findings
P01328197A0985|79 88|components
P01328197A0985|91 119|ras signal transduction pathways
P01328219A1397|0 5|NSCL-1
P01328219A1397|26 31|number
P01328219A1397|39 47|cell lines
P01328681A0149|89 101|transcription
P01328681A0149|17 24|proteins
P01328681A0149|180 195|protein synthesis
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|108 117|activities
P01328681A0149|168 177|inhibition
P01328681A0149|197 198|A.
P01328681A0149|17 24|proteins
P01328681A0348|0 6|Ruddell
P01328681A0348|8 9|M.
P01328854T0000|42 48|element
P01328854T0000|7 15|MEF-2 site
P01328854T0000|110 135|phosphoglycerate mutase gene
P01328854T0000|93 99|subunit
P01328854T0000|60 72|transcription
P01328854T0000|156 166|muscle cells
P01328884T0000|0 17|Truncation variants
P01328884T0000|20 27|peptides
P01328884T0000|50 58|molecules
P01328884T0000|66 79|sequence motifs
P01328884T0000|40 47|MHC class
P01329039A0239|130 137|proteins
P01329039A0239|86 92|E-boxes
P01329039A0239|45 50|CANNTG
P01329039A0239|107 111|genes
P01329039A0239|11 24|E-box consensus
P01329039A0239|63 73|nucleotides
P01329039A0951|115 128|Ig kappa E2 E-box
P01329039A0951|0 17|Intermediate levels
P01329039A0951|47 58|TnI enhancers
P01329039A0951|97 105|E-box site
P01329039A0951|69 75|E-boxes
P01329039A0951|20 31|gene activity
P01329039A0951|90 92|MCK
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|27 44|gene rearrangements
P01330077A0000|99 102|ALLs
P01330077A0000|19 25|TCR beta
P01330077A0000|65 70|B-cell
P01330077A0000|89 97|leukemias
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|93 100|extracts
P01330309A1134|30 33|MyoD
P01330309A1134|51 58|proteins
P01330309A1134|37 58|myogenin fusion proteins
P01330309A1134|113 120|myotubes
P01330975T0000|46 52|myeloma
P01330975T0000|10 23|polyneuropathy
P01331057A0000|40 43|gene
P01331057A0000|82 99|cytochrome c oxidase
P01331057A0000|47 56|subunit VIb
P01331057A0000|24 28|COX12
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|3 11|structure
P01331060A0768|48 57|comparison
P01331060A0768|73 85|cDNA sequences
P01331086T0000|59 62|gene
P01331086T0000|32 56|cytochrome c oxidase subunit
P01331086T0000|121 140|transcription factors
P01331086T0000|8 23|promoter elements
P01331086T0000|90 98|ets motifs
P01331292A1425|100 106|variola
P01331292A1425|44 58|oligonucleotide
P01331292A1425|109 121|vaccinia virus
P01331292A1425|23 31|instances
P01331292A1425|78 83|region
P01331292A1425|65 71|repeats
P01331501A0397|28 35|peptides
P01331501A0397|60 68|sequences
P01331501A0397|121 124|p130
P01331501A0397|71 73|E1A
P01331501A0397|110 116|cyclin A
P01331501A0397|105 108|p107
P01331501A0397|90 100|interaction
P01331516A0103|115 125|C2 myoblasts
P01331516A0103|84 88|virus
P01331516A0103|5 11|mutants
P01331516A0103|91 112|coinfection experiments
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01332589A0666|13 20|compound
P01332589A0666|3 6|MICs
P01332589A0666|30 30|%
P01332589A0666|38 46|organisms
P01332589A0666|125 137|micrograms/ml
P01332589A0666|78 85|S. aureus
P01332964A0247|68 75|elements
P01332964A0247|10 17|promoter
P01332964A0247|23 33|RII beta gene
P01333035T0000|0 6|Mapping
P01333035T0000|45 56|alpha subunit
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|74 86|RNA polymerase
P01333047A0404|157 173|threonine residues
P01333047A0404|97 101|cells
P01333047A0404|147 152|serine
P01333047A0404|138 145|tyrosine
P01333047A0404|109 123|phosphorylation
P01333047A0404|126 135|Nck protein
P01333047A0404|53 75|growth factor stimulation
P01333047A0404|23 34|growth factor
P01333053A0110|121 124|ACTH
P01333053A0110|80 85|cortex
P01333053A0110|6 14|mechanism
P01333053A0110|138 141|cAMP
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|106 119|peptide hormone
P01333125A0000|132 137|region
P01333125A0000|74 85|conservation
P01333125A0000|1 11|combination
P01333125A0000|150 162|enteroviruses
P01333125A0000|57 63|methods
P01333125A0000|96 112|structure elements
P01333125A0000|139 141|UTR
P01333125A0000|25 40|sequence analysis
P01333125A0000|166 177|rhinoviruses
P01333317A1008|58 64|protein
P01333317A1008|87 92|factor
P01333317A1008|98 102|PRF-I
P01333317A1008|66 66|s
P01333317A1008|10 15|region
P01333317A1008|66 66|s
P01333317A1008|38 40|Sp1
P01334428A1102|0 1|Km
P01334428A1102|73 74|mM
P01334428A1102|81 94|mumol min-1 mg-1
P01334428A1102|15 24|substrates
P01334428A1102|56 58|Tyr
P01334428A1102|5 8|Vmax
P01334428A1102|73 74|mM
P01334428A1102|47 50|poly
P01334428A1102|81 94|mumol min-1 mg-1
P01334428A1102|52 54|Glu
P01334428A1102|37 43|peptide
P01334493A0289|100 107|receptor
P01334493A0289|20 23|HGFr
P01334493A0289|45 52|affinity
P01334493A0289|11 14|form
P01334493A0289|20 22|HGF
P01334493A0289|25 29|sHGFr
P01334518T0000|0 9|Strategies
P01334518T0000|33 47|hepatitis C virus
P01334518T0000|89 98|risk groups
P01334518T0000|62 82|immunodeficiency virus
P01334518T0000|13 26|blood screening
P01337142A2043|13 45|glycoprotein alpha-subunit promoter
P01337142A2043|85 89|cells
P01337142A2043|70 75|GH4 rat
P01337142A2043|114 118|WORDS
P01337142A2043|92 99|ABSTRACT
P01337142A2043|65 67|FSK
P01338867A0503|0 9|Comparison
P01338867A0503|130 142|fatiguability
P01338867A0503|186 191|system
P01338867A0503|69 78|antagonist
P01338867A0503|31 37|results
P01338867A0503|151 156|extent
P01338867A0503|168 177|activation
P01338867A0503|110 117|blockade
P01338867A0503|47 55|treatment
P01338867A0503|12 15|data
P01339125A0153|0 16|Laboratory studies
P01339125A0153|33 37|teeth
P01339125A0153|33 37|teeth
P01339125A0153|22 25|Ca45
P01339125A0153|81 90|dentifrice
P01339125A0153|114 124|bleach teeth
P01339125A0153|106 111|enamel
P01339373T0000|0 8|Structure
P01339373T0000|33 51|Arabidopsis thaliana
P01339373T0000|61 67|protein
P01339373T0000|77 93|SNF1 protein kinase
P01339373T0000|12 21|expression
P01339373T0000|25 28|gene
P01339391A0000|42 60|DNA surrounding HRAS1
P01339391A0000|34 39|region
P01339468A0272|94 101|proteins
P01339468A0272|55 59|potex
P01339468A0272|3 13|ORF1 protein
P01339468A0272|94 101|proteins
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|79 82|ORF2
P01339468A0272|110 118|analogues
P01339773A0000|1 5|total
P01339773A0000|34 39|groups
P01339773A0000|93 103|capnography
P01339773A0000|64 72|diagnosis
P01339773A0000|105 114|spirometry
P01339773A0000|127 134|analysis
P01339773A0000|11 18|patients
P01339773A0778|116 141|ventilation-perfusion ratio
P01339773A0778|72 80|gradients
P01339773A0778|33 41|pressures
P01339773A0778|3 15|relationships
P01339773A0778|49 51|CO2
P01339773A0778|103 110|increase
P01339815A1545|57 61|tests
P01339815A1545|27 33|peak VO2
P01339815A1545|13 24|correlations
P01340470A0000|67 85|RNA recognition motif
P01340470A0000|106 111|domain
P01340470A0000|91 97|Arg-Ser
P01340470A0000|25 28|rbp1
P01340470A0000|103 104|RS
P01340470A0000|13 23|protein gene
P01341119A0450|59 67|ingestion
P01341119A0450|85 97|others antacid
P01341119A0450|40 45|tumors
P01341119A0450|4 18|research studies
P01341119A0450|70 81|H2 inhibitors
P01341119A0450|34 37|kind
P01346262A0377|27 33|protein
P01346262A0377|27 33|protein
P01346262A0377|27 41|protein profiles
P01346262A0377|78 81|UC21
P01346262A0377|53 68|S. entomophila UC9
P01346262A0377|12 16|study
P01346534T0000|0 15|Characterization
P01346534T0000|71 77|protein
P01346534T0000|21 27|regulon
P01347476T0000|0 6|Mapping
P01347476T0000|47 60|sequence family
P01347476T0000|12 25|mouse ornithine
P01347664A1026|72 77|mutant
P01347664A1026|42 47|levels
P01347664A1026|4 11|mutation
P01347664A1026|50 56|CAD mRNA
P01347664A1026|60 66|protein
P01347908T0000|62 70|Parkinson
P01347908T0000|3 11|rationale
P01347908T0000|73 79|disease
P01347908T0000|37 47|stimulation
P01347908T0000|50 57|patients
P01347944A0964|91 100|regulation
P01347944A0964|10 16|studies
P01347944A0964|61 68|sequence
P01347944A0964|37 58|homeodomain binding site
P01348504A0757|68 75|distance
P01348504A0757|8 30|pol alpha-primase complex
P01348508A0313|59 68|comparison
P01348508A0313|17 25|positions
P01348508A0313|33 39|introns
P01348508A0313|136 145|literature
P01348508A0313|153 160|TGM1 gene
P01348508A0313|33 39|introns
P01348508A0313|194 197|date
P01348508A0313|112 121|activities
P01348508A0313|76 80|genes
P01348590A0000|145 153|diagnosis
P01348590A0000|54 61|lymphoma
P01348590A0000|91 98|patients
P01348590A0000|139 142|time
P01348590A0000|188 199|radiotherapy
P01348590A0000|110 120|HIV-disease
P01348590A0000|36 40|cases
P01348590A0000|161 163|use
P01348590A0000|16 23|analysis
P01348590A0000|67 72|cohort
P01348590A0000|180 185|agents
P01348590A0000|218 224|outcome
P01348590A0000|103 107|stage
P01348590A0000|125 127|CD4
P01348590A0000|26 29|data
P01349705T0000|0 6|Effects
P01349705T0000|42 47|babies
P01349705T0000|18 32|thyroid function
P01349705T0000|9 15|dioxins
P01349837T0000|0 9|cDNA clones
P01349837T0000|60 74|chaperonin HSP60
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|98 112|seed germination
P01349837T0000|40 46|Zea mays
P01349837T0000|116 124|heat shock
P01349837T0000|78 91|gene expression
P01350780A0184|0 26|Amino acid sequence comparison
P01350780A0184|87 107|gamma-glutamyl kinases
P01350780A0184|123 129|lengths
P01350780A0184|46 53|homology
P01350780A0184|64 68|yeast
P01350932A1123|115 130|disulphide bridge
P01350932A1123|85 87|Cys
P01350932A1123|15 27|glycosylation
P01350932A1123|59 79|N-glycosylation sequon
P01350932A1123|44 53|C-terminus
P01350932A1123|108 111|part
P01350932A1123|81 91|Asn-Cys-Ser
P01350932A1123|9 12|site
P01352113A0002|95 109|inhalation model
P01352113A0002|17 22|events
P01352113A0002|134 141|measures
P01352113A0002|81 83|rat
P01352113A0002|57 64|exposure
P01352113A0002|53 54|NO
P01352113A0002|37 51|nitrogen dioxide
P01352113A0231|100 102|ppm
P01352113A0231|62 78|NO2 concentrations
P01352113A0231|128 140|exposure times
P01352113A0231|116 123|mg m-3 NO2
P01352113A0231|153 155|min
P01352113A0231|105 110|ppm NO2
P01352113A0231|12 18|effects
P01353478T0000|0 10|Interaction
P01353478T0000|47 65|A20/2J B cell lymphoma
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|13 17|H-2Eb
P01354506T0000|105 111|history
P01354506T0000|67 78|cytogenetics
P01354506T0000|52 64|understanding
P01354506T0000|39 46|advances
P01354506T0000|24 31|diseases
P01354506T0000|80 93|histopathology
P01357190A0726|130 134|cells
P01357190A0726|97 103|ability
P01357190A0726|18 24|mutants
P01357190A0726|7 15|exception
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|111 116|fusion
P01357190A0726|73 85|glycoproteins
P01357528A0084|211 224|enterobacteria
P01357528A0084|3 16|subunit protein
P01357528A0084|19 23|curli
P01357528A0084|185 189|class
P01357528A0084|63 68|SEF-17
P01357528A0084|48 60|amino terminus
P01357528A0084|169 174|fibres
P01357528A0084|105 112|fimbriae
P01357528A0084|192 208|surface organelles
P01357528A0084|141 148|strain 3b
P01357528A0084|3 16|subunit protein
P01358190A0654|0 11|Substitution
P01358190A0654|56 59|loss
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|62 72|recognition
P01358190A0654|33 41|H-2E beta k
P01358190A0654|74 95|alpha chain substitution
P01358190A0654|110 115|effect
P01358592A0752|57 64|cell fate
P01358592A0752|22 28|pathway
P01358592A0752|125 130|embryo
P01358592A0752|114 119|region
P01358592A0752|89 93|state
P01358758A0000|117 127|combination
P01358758A0000|81 83|Far
P01358758A0000|182 189|enhancer
P01358758A0000|47 49|DNA
P01358758A0000|21 35|rat insulin I gene
P01358758A0000|9 15|portion
P01358758A0000|61 76|sequence elements
P01358758A0000|87 98|FLAT elements
P01358880A0251|65 88|transglutaminase sequence
P01358880A0251|10 26|amino acid sequence
P01358880A0251|38 46|% identity
P01359588A0375|73 80|elements
P01359588A0375|4 14|computation
P01359588A0375|37 43|network
P01360180A0513|88 99|recombinants
P01360180A0513|152 159|mutation
P01360180A0513|68 73|kinase
P01360180A0513|68 73|kinase
P01360180A0513|8 14|efforts
P01360180A0513|35 47|baculoviruses
P01360180A0513|144 149|domain
P01360180A1568|27 42|P68 amino terminus
P01360180A1568|82 86|dsRNA
P01360180A1568|122 131|properties
P01360180A1568|135 153|reporter gene product
P01360180A1568|84 86|RNA
P01360294A0000|57 64|subjects
P01360294A0000|45 49|women
P01360294A0000|16 22|October
P01360294A0000|4 9|August
P01360294A0000|80 85|levels
P01360294A0000|104 115|antithrombin
P01360294A0000|88 93|plasma
P01360294A0000|126 133|activity
P01363080A0710|122 130|diuretics
P01363080A0710|56 60|error
P01363080A0710|69 80|sulfonamides
P01363080A0710|6 11|acuity
P01363080A0710|95 112|agent metronidazole
P01363080A0710|143 161|anhydrase inhibitors
P01363080A0710|37 43|changes
P01363166T0001|43 51|treatment
P01363166T0001|0 14|Currents aspects
P01363166T0001|54 59|ulcers
P01363166T0001|17 37|H2 receptor antagonists
P01364100A0377|2 9|addition
P01364100A0377|55 58|unit
P01364100A0377|18 35|subrepeat structure
P01370281A0461|0 9|Sequencing
P01370281A0461|30 41|reading frame
P01370281A0461|57 63|protein
P01370446A0818|5 9|sites
P01370446A0818|26 54|keratan sulfate attachment sites
P01371181A0688|87 101|characteristics
P01371181A0688|13 20|plasmids
P01371181A0688|26 35|pLS1 family
P01371181A0688|59 63|share
P01371181A0688|54 57|pLB4
P01371181A0688|43 49|pADB201
P01371181A0688|108 117|regulation
P01371181A0688|125 135|copy numbers
P01371181A0688|37 41|pE194
P01371272A1167|0 11|Perturbation
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371272A1167|14 22|dNTP pools
P01371272A1167|38 55|frameshift fidelity
P01371275T0000|30 36|subunit
P01371275T0000|28 28|B
P01371275T0000|69 75|tissues
P01371275T0000|55 60|ATPase
P01371275T0000|50 50|H
P01371275T0000|12 21|expression
P01371413A0742|14 23|hGCSFR gene
P01371413A0742|2 9|addition
P01371413A0742|97 101|panel
P01371413A0742|146 154|cDNA probe
P01371413A0742|104 125|rodent-human hybrid DNAs
P01371413A0742|76 93|segregation pattern
P01371413A0742|51 70|Southern blot analysis
P01371863A0000|70 96|protozoan parasite Leishmania
P01371863A0000|55 64|gene family
P01372365A1202|56 56|M
P01372365A1202|70 76|sites %T
P01372365A1202|34 35|Cl
P01372365A1202|6 10|sites
P01372365A1202|105 114|conditions
P01372365A1202|37 50|concentrations
P01372365A1202|12 13|%T
P01372456A0426|0 7|Necrosis
P01372456A0426|42 42|%
P01372456A0426|16 16|h
P01372456A0426|16 16|h
P01372456A0426|92 95|area
P01372456A0426|45 50|extent
P01372456A0426|102 110|% necrosis
P01372456A0426|76 82|animals
P01372456A0426|42 42|%
P01372456A0426|22 31|TA infusion
P01372456A0426|16 16|h
P01372802A1481|47 54|residues
P01372802A1481|2 8|summary
P01372802A1481|157 165|fragments
P01372802A1481|23 24|C3
P01372802A1481|112 119|epitopes
P01372802A1481|23 24|C3
P01372802A1481|38 54|amino acid residues
P01372802A1481|110 110|D
P01372802A1481|13 20|segments
P01372802A1481|191 209|fluid-phase fragment
P01372802A1481|13 20|segments
P01372802A1481|370 376|protein
P01372802A1481|112 119|epitopes
P01372802A1481|110 110|D
P01372802A1481|155 165|C3 fragments
P01372802A1481|23 24|C3
P01372802A1481|23 24|C3
P01372900A0448|5 9|exons
P01372900A0448|5 9|exons
P01372900A0448|132 133|F.
P01372900A0448|91 112|alpha s1-casein variant A
P01372900A0448|65 81|amino acid residues
P01372900A1017|101 134|polymerase chain reaction experiments
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|37 48|organization
P01373374A0735|0 9|Homodimers
P01373374A0735|74 84|GBF3 binding
P01373374A0735|20 27|proteins
P01373374A0735|67 70|GBF1
P01373374A0735|115 122|sequence
P01373374A0735|52 61|G-box motif
P01374331A0636|44 52|start site
P01374331A0636|7 10|gene
P01374331A0636|62 79|nuclease S1 analysis
P01374392A0341|57 61|NHE-2
P01374392A0341|3 20|hydrophobicity plot
P01374392A0341|23 27|NHE-3
P01374392A0341|49 53|NHE-1
P01374398A0951|84 87|acid
P01374398A0951|79 98|amino acid composition
P01374398A0951|10 27|translation protein
P01374398A0951|127 127|%
P01374398A0951|52 54|kDa
P01374398A0951|40 43|cDNA
P01374398A0951|138 154|amino acid residues
P01374688A0471|96 110|micrograms/kg/0
P01374688A0471|4 8|group
P01374688A0471|81 85|hours
P01374688A0471|19 23|ml/kg
P01374688A0471|64 69|plasma
P01374688A0471|49 60|% pentastarch
P01374688A0471|33 46|% pentafraction
P01374688A0471|113 116|hr E.
P01375224A0152|147 162|growth regulation
P01375224A0152|55 68|transformation
P01375224A0152|71 94|chicken embryo fibroblasts
P01375224A0152|111 118|activity
P01375224A0152|21 28|evidence
P01375224A0152|129 136|proteins
P01375224A0152|41 45|v-Crk
P01375913A0484|141 147|plasmid
P01375913A0484|32 50|DNA oligonucleotides
P01375913A0484|94 120|T7 RNA polymerase promoter site
P01375913A0484|53 64|U14 snRNA gene
P01376319T0000|0 3|Gene
P01376319T0000|43 68|mannose 6-phosphate receptor
P01376319T0000|7 16|pseudogene
P01376319T0000|22 26|mouse
P01377696A0000|3 7|chick
P01377696A0000|73 78|growth
P01377696A0000|82 94|fasciculation
P01377696A0000|23 52|surface glycoprotein neurofascin
P01377696A0000|107 137|antibody perturbation experiments
P01377764A0309|60 64|layer
P01377764A0309|3 11|carcinoma
P01377764A0309|34 43|epithelium
P01377764A0309|60 64|layer
P01377818A0468|2 9|addition
P01377818A0468|79 88|C/EBP alpha
P01377818A0468|23 32|C/EBP gamma
P01377818A0468|11 19|C/EBP beta
P01377962A1012|2 9|contrast
P01377962A1012|34 41|subunits
P01377962A1012|53 56|size
P01377962A1012|11 21|tobacco GS-2
P01377962A1012|62 67|organs
P01378052A0594|87 89|N18
P01378052A0594|172 189|activator sequences
P01378052A0594|7 10|acoR
P01378052A0594|34 38|types
P01378052A0594|92 94|GTG
P01378052A0594|113 115|ACA
P01378052A0594|14 20|acoXABC
P01378052A0594|41 49|sequences
P01378052A0594|41 49|sequences
P01378052A0594|98 100|TGT
P01378052A0594|68 75|symmetry
P01378052A0594|160 163|NifA
P01378052A0594|108 110|N14
P01378052A0594|82 84|N11
P01378052A0594|153 156|NtrC
P01378052A0594|77 79|CAC
P01378052A0594|103 105|N10
P01378127A0841|42 58|calcium antagonist
P01378127A0841|95 103|responses
P01378127A0841|23 39|calcium supplement
P01378127A0841|11 17|effects
P01378431A0202|0 1|C.
P01378431A0202|14 15|M.
P01378431A0202|14 18|M.-Y.
P01378431A0202|3 5|Sun
P01378431A0202|46 47|S.
P01378431A0202|7 8|J.
P01378431A0202|20 34|Vallejo-Ramirez
P01378431A0202|7 8|J.
P01378431A0202|39 44|Inouye
P01378431A0202|39 44|Inouye
P01378431A0202|10 12|Hsu
P01378506A0884|16 34|full-deletion mutant
P01378506A0884|55 66|virus release
P01378506A0884|48 52|block
P01378506A0884|96 108|virus assembly
P01378506A0884|82 83|NC
P01378526A0535|29 45|FK506 plasma levels
P01378526A0535|82 87|effect
P01378526A0535|66 75|appearance
P01379032A0495|112 121|prednisone
P01379032A0495|40 47|steroids
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379032A0495|6 12|percent
P01379032A0495|108 109|mg
P01379032A0495|78 82|group
P01379032A0495|62 72|steroid dose
P01379032A0495|125 127|day
P01379150A0996|157 171|risk arrhythmias
P01379150A0996|119 123|drugs
P01379150A0996|43 47|agent
P01379150A0996|5 15|cibenzoline
P01379150A0996|113 117|class
P01379150A0996|143 149|therapy
P01379150A0996|126 133|patients
P01379150A0996|78 84|profile
P01380062A0097|45 55|T lymphocyte
P01380062A0097|0 7|T antigen
P01380062A0097|87 93|targets
P01380062A0097|61 79|recognition epitopes
P01380062A0097|57 59|CTL
P01380062A0097|121 123|Y-5
P01380062A0097|97 108|CTL clones Y-1
P01380062A0097|110 112|Y-2
P01380062A0097|114 116|Y-3
P01380076A0165|42 60|paired-ion technique
P01380076A0165|3 8|method
P01380076A0165|71 84|docusate sodium
P01380076A0165|32 37|column
P01380076A0165|94 103|components
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|171 190|transcription factors
P01380454A0451|216 222|members
P01380454A0451|200 208|NF-kappa B
P01380454A0451|210 212|Myb
P01380454A0451|43 51|ref-1 gene
P01380454A0451|65 82|DNA binding activity
P01380454A0451|125 144|Hela cell AP-1 proteins
P01380454A0451|105 121|Jun-Jun homodimers
P01380454A0451|24 37|protein product
P01380454A0451|228 241|ATF/CREB family
P01380716A0174|9 15|tissues
P01380716A0174|40 45|molars
P01380716A0174|77 90|calcium hydrate
P01380825A0622|0 19|Northern blot analyses
P01380825A0622|75 78|cDNA
P01380825A0622|95 101|tissues
P01380825A0622|165 172|function
P01380825A0622|128 134|protein
P01380825A0622|52 56|mRNAs
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|105 116|ABL SH2 domain
P01383690A1023|49 51|BCR
P01383690A1023|38 45|affinity
P01383695A0100|56 61|embryo
P01383695A0100|27 31|E29.1
P01383695A0100|79 86|IgM kappa
P01383695A0100|90 98|IgM lambda
P01383695A0100|12 25|EBV B-cell clone
P01384040A1043|119 123|pCF10
P01384040A1043|47 53|regions
P01384040A1043|18 27|activation
P01384040A1043|81 91|orientation
P01384165A0000|70 76|trachea
P01384165A0000|82 93|regeneration
P01384165A0000|2 5|rats
P01384165A0000|30 36|omentum
P01384165A0000|144 159|tracheal grafting
P01384165A0000|130 134|stage
P01384165A0000|20 25|effect
P01384165A0000|106 115|epithelium
P01384165A0000|50 64|vascularization
P01384229A0175|110 113|gene
P01384229A0175|57 71|oligonucleotide
P01384229A0175|197 228|chloramphenicol acetyl transferase
P01384229A0175|44 53|chicken ICS
P01384229A0175|239 245|pBLCAT2
P01384229A0175|167 182|herpes TK promoter
P01384229A0175|105 113|BF-IV gene
P01384229A0175|91 99|sequences
P01384229A0175|152 157|copies
P01384229A0175|26 29|role
P01384229A0175|230 232|CAT
P01385462A0151|107 119|determination
P01385462A0151|103 119|acid determination
P01385462A0151|58 61|runs
P01385462A0151|150 159|monoamines
P01386210A0293|100 116|GM2 gangliosidosis
P01386210A0293|43 49|therapy
P01386210A0293|70 79|depression
P01386210A0293|21 23|use
P01386210A0293|53 61|treatment
P01386210A0293|88 90|man
P01386897A0000|56 59|form
P01386897A0000|0 4|Entry
P01386897A0000|41 45|Start
P01386897A0000|128 131|CLN2
P01386897A0000|31 39|cell cycle
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|121 124|CLN1
P01386897A0000|105 111|cyclins
P01386897A0000|7 16|yeast cells
P01386897A0000|133 135|ref
P01387105A0933|29 31|DNA
P01387105A0933|117 120|loci
P01387105A0933|55 58|mice
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|36 44|backcross
P01387105A0933|95 105|cell hybrids
P01387105A0933|171 183|loci Cycb1-rs1
P01387105A0933|241 241|X
P01387105A0933|186 194|Cycb1-rs9
P01387105A0933|135 140|cyclin
P01387105A0933|151 159|sequences
P01387105A0933|208 223|mouse chromosomes
P01387105A0933|77 83|strains
P01388160A1102|156 162|Ser-107
P01388160A1102|5 11|residue
P01388160A1102|5 18|residue Glu-381
P01388160A1102|68 81|epsilon peptide
P01388160A1102|166 172|Ser-108
P01388160A1102|106 120|peptide sequence
P01388160A1102|21 24|beta
P01388160A1102|148 154|Ser-106
P01388160A1102|139 145|choices
P01389362T0000|0 8|Porcelain
P01389362T0000|17 28|bond strength
P01389362T0000|34 47|dentin adhesive
P01389573A1071|82 83|P2
P01389573A1071|0 3|TBPf
P01389573A1071|16 23|quotient
P01389573A1071|90 91|A2
P01389573A1071|79 80|P1
P01389573A1071|29 38|difference
P01389573A1071|61 71|measurement
P01389573A1071|0 3|TBPf
P01389573A1071|87 88|A1
P01389585A0825|95 100|choice
P01389585A0825|32 50|Prisma Universal Bond
P01389585A0825|18 27|Scotchbond
P01389585A0825|73 92|dentine bonding agents
P01391001A0583|99 105|methods
P01391001A0583|41 45|total
P01391001A0583|67 75|ATB method
P01391001A0583|50 50|%
P01391001A0583|26 38|yeasts species
P01392012A0228|19 29|vasopressin
P01392012A0228|85 92|Dekanski
P01392012A0228|33 47|oxytocin content
P01392012A0228|108 115|activity
P01392012A0228|63 75|pressor effect
P01392012A0228|144 147|Hays
P01392012A0228|132 140|van Dongen
P01392277A0000|28 33|status
P01392277A0000|0 7|Comments
P01392277A0000|163 165|DIN
P01392277A0000|96 105|connection
P01392277A0000|57 61|water
P01392277A0000|154 161|standard
P01392277A0000|64 76|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|167 169|No.
P01392277A0000|113 126|KOK regulations
P01392277A0000|36 46|regulations
P01392358A0389|4 8|reply
P01392358A0389|21 36|telephone contact
P01392358A0389|39 48|home visits
P01394200A0592|84 103|rebound lymphocytosis
P01394200A0592|3 16|treatment group
P01394200A0592|181 185|cells
P01394200A0592|107 118|upregulation
P01394200A0592|124 140|subset markers CD25
P01394200A0592|33 48|T-cell activation
P01394200A0592|142 152|interleukin
P01394200A0592|166 171|CD45RO
P01394200A0592|62 72|lymphopenia
P01394200A0592|154 161|receptor
P01394655A0615b|84 87|tube
P01394655A0615b|0 13|Urease activity
P01394655A0615b|55 58|urea
P01394655A0615b|89 91|S/N
P01394655A0615b|79 80|ng
P01394655A0615b|101 118|Jack bean meal urease
P01394655A0615b|34 50|ammonia production
P01394655A0615b|26 31|amount
P01395755A1023|84 95|oxygen uptake
P01395755A1023|105 110|ml/min
P01395755A1023|137 150|oxygen delivery
P01395755A1023|220 224|L/min
P01395755A1023|105 110|ml/min
P01395755A1023|66 72|methods
P01395755A1023|91 91|p
P01395755A1023|91 91|p
P01395755A1023|204 209|output
P01395755A1023|220 224|L/min
P01395755A1023|105 110|ml/min
P01395755A1023|24 34|differences
P01395755A1023|105 110|ml/min
P01395755A1023|91 91|p
P01396432A0388|29 37|functions
P01396432A0388|13 17|range
P01396432A0388|82 91|assessment
P01396432A0388|94 110|memory performance
P01396432A0388|61 67|seizure
P01396444A0934|128 135|activity
P01396444A0934|58 66|condition
P01396444A0934|45 51|alveoli
P01396444A0934|3 13|experiments
P01396444A0934|95 110|activation states
P01396444A0934|172 179|recovery
P01396444A0934|29 39|micromilieu
P01396444A0934|164 169|degree
P01396444A0934|72 73|AM
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|146 155|competitor
P01396572A0320|87 88|CG
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|126 131|Z-form
P01396572A0320|114 120|segment
P01396572A0320|107 111|dG-dC
P01396583A0204|1 11|cDNA library
P01396583A0204|14 24|tumour cells
P01396583A0204|67 71|probe
P01396583A0204|42 52|interleukin
P01396592A1113|41 46|target
P01396592A1113|97 110|SCL gene product
P01396592A1113|128 136|regulator
P01396592A1113|28 34|SCL gene
P01396592A1113|3 13|experiments
P01396592A1113|148 162|differentiation
P01396592A1113|62 86|transcription factor GATA-1
P01396601A0986|98 105|homology
P01396601A0986|2 9|contrast
P01396601A0986|45 49|Stl2p
P01396601A0986|30 35|Sec12p
P01396601A0986|68 71|size
P01396601A0986|21 27|domains
P01396601A0986|37 41|Stl1p
P01398068A0948|0 8|Complexes
P01398068A0948|98 111|RGC DNA sequence
P01398068A0948|57 67|p53 proteins
P01398068A0948|45 50|his273
P01398068A0948|37 42|his175
P01398071A0526|81 88|activity
P01398071A0526|34 40|strains
P01398071A0526|5 15|temperature
P01398071A0526|58 65|extracts
P01398071A0526|152 154|III
P01398071A0526|77 88|BRF1 activity
P01398071A0526|130 143|RNA polymerases
P01398073A0986|89 99|stimulation
P01398073A0986|54 65|TFIID protein
P01398073A0986|5 11|results
P01398073A0986|109 125|activation domains
P01398073A0986|143 150|promoter
P01398074A0697|44 46|RNA
P01398074A0697|54 61|yeast RNA
P01398074A0697|3 14|gene sequence
P01398074A0697|75 100|RNase MRP enzyme preparations
P01398074A1081|41 51|replacement
P01398074A1081|84 92|viability
P01398074A1081|3 17|RNase MRP RNA gene
P01398074A1081|120 123|role
P01398074A1081|3 10|RNase MRP
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398098A0770|73 83|polypeptide
P01398098A0770|28 31|mRNA
P01398098A0770|47 57|translation
P01398104A0834|59 65|protein
P01398104A0834|39 43|ssDNA
P01398104A0834|17 21|CBF-A
P01398104A0834|30 36|CArG box
P01398104A0834|9 15|results
P01398104A0834|101 106|factor
P01398106A0754|0 7|Cleavage
P01398106A0754|170 178|overhangs
P01398106A0754|110 115|bottom
P01398106A0754|186 194|OH termini
P01398106A0754|48 49|bp
P01398106A0754|34 39|I-CreI
P01398106A0754|91 94|exon
P01398106A0754|63 81|intron insertion site
P01398106A0754|119 125|strands
P01398106A0754|101 103|top
P01398106A0754|48 49|bp
P01398106A0754|27 32|enzyme
P01398140A0488|87 88|bp
P01398140A0488|16 28|Xenopus U7 gene
P01398140A0488|87 88|bp
P01398140A0488|104 106|PSE
P01398140A0488|63 68|motifs
P01398140A0488|125 132|location
P01399206A0375|3 9|results
P01399206A0375|35 55|collagenase inhibitors
P01399206A0375|115 134|epidermolysis bullosa
P01399206A0375|24 30|reports
P01399206A0375|78 93|blister formation
P01400217T0000|72 82|involvement
P01400217T0000|58 61|traF
P01400217T0000|29 61|IncP alpha plasmid transfer genes traF
P01400217T0000|65 68|traG
P01400217T0000|91 106|phage sensitivity
P01400217T0000|10 17|analysis
P01400396A1265|3 10|promoter
P01400396A1265|97 106|activation
P01400396A1265|109 126|protein kinase C beta
P01400396A1265|35 47|phorbol esters
P01400401A0065|42 47|muscle
P01400401A0065|13 32|AMP deaminase variants
P01400401A0065|59 60|E1
P01400401A0065|2 7|humans
P01400401A0065|68 78|erythrocyte
P01400401A0065|50 50|L
P01400401A0065|137 144|criteria
P01400401A0065|65 66|E2
P01400401A0065|52 56|liver
P01400401A0065|14 14|M
P01400401A0065|101 107|variety
P01400401A0854|106 115|expression
P01400401A0854|0 18|Western blot analyses
P01400401A0854|75 82|extracts
P01400401A0854|128 136|AMPD3 cDNA
P01400401A0854|40 55|immunoreactivity
P01400775A0435|5 11|results
P01400775A0435|52 61|salsolinol
P01400775A0435|37 49|N-methylation
P01400775A0435|95 99|brain
P01400775A0435|66 83|N-methylsalsolinol
P01402647A0114|0 11|DR1 molecules
P01402647A0114|43 51|cell lines
P01402647A0114|80 95|peptide sequences
P01402647A0114|110 121|phage surface
P01403222A0391|73 85|blood donation
P01403222A0391|101 111|transfusion
P01403222A0391|4 10|article
P01403222A0391|45 49|woman
P01403222A0391|36 39|care
P01403391T0000|7 16|hepatitis B
P01403391T0000|34 41|children
P01404401A0740|85 99|chloroplast gene
P01404401A0740|30 42|reading frames
P01404401A0740|9 21|ATPase cluster
P01404612A0303|72 79|proteins
P01404612A0303|26 28|Ads
P01404612A0303|93 109|vaccine candidates
P01404612A0303|53 55|HIV
P01406630A0545|0 8|Alignment
P01406630A0545|70 76|binding
P01406630A0545|137 151|binding analysis
P01406630A0545|185 203|sequence specificity
P01406630A0545|22 30|sequences
P01406630A0545|114 121|proteins
P01406630A0545|114 121|proteins
P01406630A0545|165 176|DNA sequences
P01406630A0545|50 66|consensus sequence
P01406630A0965|68 74|binding
P01406630A0965|96 102|protein
P01406630A0965|68 74|binding
P01406630A0965|30 40|kappa B motif
P01406630A0965|79 85|respect
P01406630A0965|152 167|NF-kappa B complex
P01406630A0965|12 14|p50
P01406656A1075|96 98|DNA
P01406656A1075|15 19|clone
P01406656A1075|129 139|fibroblasts
P01406656A1075|70 71|kb
P01406656A1075|70 71|kb
P01406656A1075|121 126|levels
P01406656A1075|53 56|gene
P01406656A1075|39 48|mouse alpha
P01406656A1075|163 165|ras
P01406677A0000|150 168|nucleotide positions
P01406677A0000|122 129|analysis
P01406677A0000|205 213|start site
P01406677A0000|87 99|myoglobin gene
P01406677A0000|231 244|luciferase gene
P01406677A0000|140 148|sequences
P01406677A0000|23 37|control elements
P01406677A0000|67 76|expression
P01406688A0898|0 17|Sequencing analysis
P01406688A0898|85 90|region
P01406688A0898|98 107|amino acids
P01406688A0898|54 69|nonsense mutation
P01406688A0898|34 44|rap1t allele
P01406703A1435|58 65|H-2RIIBP
P01406703A1435|18 21|cDNA
P01406703A1435|47 52|region
P01406703A1435|149 153|cells
P01406703A1435|73 91|hormone receptor cDNA
P01406703A1435|12 28|Y1 cell cDNA library
P01407286A0427|101 106|traces
P01407286A0427|0 6|Autopsy
P01407286A0427|146 164|tyrosine hydroxylase
P01407286A0427|61 71|integration
P01407286A0427|48 52|cells
P01407286A0427|135 142|reaction
P01407286A0427|79 83|brain
P01407286A0427|23 30|survival
P01408090A0572|54 61|arteries
P01408090A0572|17 32|TEE visualization
P01408090A0572|3 11|technique
P01408137A0974|114 117|% G+C
P01408137A0974|85 86|bp
P01408137A0974|17 22|region
P01408137A0974|3 10|sequence
P01408137A0974|45 45|%
P01408137A0974|32 41|G+C content
P01408137A0974|102 110|mRNA start
P01408219A0670|105 112|analysis
P01408219A0670|60 62|PGL
P01408219A0670|43 58|lymph-adenopathy
P01408219A0670|89 93|nodes
P01408219A0670|67 75|nontender
P01408219A0670|129 139|hyperplasia
P01408219A0670|10 17|patients
P01408474A0531|0 12|PaO2 threshold
P01408474A0531|47 60|sensor catheter
P01408474A0531|35 44|indwelling
P01409581A0206|99 102|site
P01409581A0206|18 20|E26
P01409581A0206|68 75|factor PU
P01409581A0206|34 38|v-ets
P01409643A0618|147 153|protein
P01409643A0618|233 235|TMF
P01409643A0618|178 181|mass
P01409643A0618|99 109|TATA element
P01409643A0618|187 189|kDa
P01409643A0618|122 135|identification
P01409643A0618|7 26|lambda gt11 expression
P01409643A0618|226 231|factor
P01409643A0618|77 97|immunodeficiency virus
P01409643A0618|99 109|TATA element
P01409643A0618|38 53|oligonucleotides
P01410071T0000|0 10|Blood levels
P01410071T0000|13 21|melatonin
P01410071T0000|86 108|platelet serotonin uptake
P01410071T0000|33 40|cortisol
P01410071T0000|56 63|relation
P01410071T0000|45 53|prolactin
P01410071T0000|23 31|serotonin
P01410071T0000|78 83|rhythm
P01413984A0737|144 155|antithrombin
P01413984A0737|54 64|cholesterol
P01413984A0737|122 131|fibrinogen
P01413984A0737|30 46|FA supplementation
P01413984A0737|66 79|HDL cholesterol
P01413984A0737|114 120|glucose
P01413984A0737|160 188|plasminogen activator inhibitor
P01413984A0737|219 250|von Willebrand factor concentration
P01413984A0737|133 142|factor VIII
P01413984A0737|19 24|effect
P01413984A0737|190 215|tissue plasminogen activator
P01413984A0737|96 100|apo A1
P01413984A0737|289 301|blood pressure
P01413984A0737|108 112|HbA1C
P01413984A0737|81 94|LDL cholesterol
P01413984A0737|262 265|time
P01413984A0737|102 103|Lp
P01414219A0319|42 52|differences
P01414219A0319|85 88|time
P01414219A0319|59 82|peak plasma concentrations
P01414219A0319|55 57|AUC
P01414219A0319|69 81|concentration
P01414219A0319|149 151|ERY
P01414219A0319|112 114|OXC
P01414219A0319|10 19|volunteers
P01418272A1072|39 41|CEA
P01418272A1072|26 36|sensitivity
P01418272A1072|16 21|cutoff
P01418272A1072|6 10|ng/mL
P01418272A1072|47 47|%
P01418494T0000|8 13|spikes
P01418494T0000|26 33|function
P01418542A0000|3 8|effect
P01418542A0000|56 65|arrhythmia
P01418542A0000|19 36|beta-glycyrrhetate
P01418542A0000|38 40|SGA
P01418542A0000|11 16|sodium
P01418834A0987|42 42|P
P01418834A0987|125 128|mm Hg
P01418834A0987|71 83|blood pressure
P01418834A0987|42 42|P
P01418834A0987|65 68|fall
P01418834A0987|12 29|hematocrit decrease
P01418834A0987|39 39|H
P01418860A0797|12 20|diltiazem
P01418860A0797|3 9|effects
P01418860A0797|111 115|cases
P01418860A0797|12 20|diltiazem
P01418860A0797|48 59|potentiation
P01418860A0797|165 186|calcium channel blockade
P01418860A0797|193 196|role
P01418860A0797|204 215|interactions
P01418860A0797|12 20|diltiazem
P01419945A1386|0 11|Localization
P01419945A1386|25 30|plexus
P01419945A1386|116 120|sites
P01419945A1386|76 87|interscalene
P01419945A1386|38 52|nerve stimulator
P01420177A1065|42 44|Ser
P01420177A1065|0 11|Substitution
P01420177A1065|28 30|Gly
P01420177A1065|81 94|protein kinases
P01420177A1065|68 75|residues
P01420177A1065|20 24|Val33
P01420177A1065|136 143|activity
P01420177A1065|106 111|enzyme
P01420177A1065|34 38|Gly28
P01420223T0000|0 11|Significance
P01420223T0000|32 52|latissimus dorsi muscle
P01420223T0000|17 26|biopsy site
P01420223T0000|56 66|fiber typing
P01420363A0818|142 153|consensus TRE
P01420363A0818|98 107|competitor
P01420363A0818|16 22|AP1 site
P01420363A0818|3 6|TIMP
P01420363A0818|142 153|consensus TRE
P01420363A0818|160 167|addition
P01420363A0818|111 117|binding
P01420363A0818|130 136|factors
P01420363A0818|51 64|c-Fos/c-Jun AP1
P01420363A0818|37 41|motif
P01420363A0818|127 136|AP1 factors
P01420363T0000|0 10|Involvement
P01420363T0000|58 72|tissue inhibitor
P01420363T0000|40 49|regulation
P01420363T0000|19 34|PEA3 binding sites
P01420363T0000|96 101|TIMP-1
P01420363T0000|103 115|transcription
P01420363T0000|75 94|metalloproteinases-1
P01420363T0000|13 15|AP1
P01420579A0292|131 141|vaccination
P01420579A0292|42 47|calves
P01420579A0292|84 93|SN antibody
P01420579A0292|95 99|month
P01420579A0292|5 21|serum neutralizing
P01420579A0292|52 52|%
P01420579A0292|23 24|SN
P01420579A0292|26 33|antibody
P01420579A0292|52 52|%
P01421145A1190|0 12|Fractionation
P01421145A1190|135 144|leaf tissue
P01421145A1190|27 34|extracts
P01421145A1190|37 65|heparin-agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|27 34|extracts
P01421390T0000|90 104|body irradiation
P01421390T0000|141 165|bone marrow transplantation
P01421390T0000|206 213|lymphoma
P01421390T0000|74 79|factor
P01421390T0000|115 126|chemotherapy
P01421390T0000|11 15|trial
P01421390T0000|187 194|leukemia
P01421609A1067|54 59|trauma
P01421609A1067|5 8|data
P01421609A1067|108 114|support
P01421609A1067|64 66|CPB
P01421609A1067|24 27|DMVA
P01422265A0263|112 115|IgG4
P01422265A0263|85 88|IgG1
P01422265A0263|186 200|coeliac patients
P01422265A0263|153 169|subclass responses
P01422265A0263|32 45|coeliac disease
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|129 137|magnitude
P01422265A0263|107 110|IgG3
P01422265A0263|76 83|controls
P01422265A0263|102 105|IgG2
P01423454A0309|86 95|vasculitis
P01423454A0309|0 10|Examination
P01423454A0309|184 192|treatment
P01423454A0309|120 127|activity
P01423454A0309|70 78|diagnosis
P01423454A0309|133 139|disease
P01423454A0309|106 114|indicator
P01423454A0309|38 49|contribution
P01423454A0309|152 164|effectiveness
P01423454A0309|13 16|ANCA
P01423738A0639|121 127|rhythms
P01423738A0639|69 75|rabbits
P01423738A0639|3 3|h
P01423738A0639|20 31|pinealectomy
P01423738A0639|10 13|hand
P01423738A0639|129 140|mean delta tau
P01423738A0639|104 115|deceleration
P01424674A0000|43 49|disease
P01424674A0000|84 96|cicatrization
P01424674A0000|11 20|pemphigoid
P01425653T0000|88 92|women
P01425653T0000|15 20|levels
P01425653T0000|60 76|oxygen consumption
P01425653T0000|3 9|effects
P01425653T0000|23 39|caffeine ingestion
P01425921A1286|161 164|V1J1
P01425921A1286|17 24|features
P01425921A1286|71 84|lysine deletion
P01425921A1286|38 53|amino acid changes
P01425921A1286|153 158|region
P01425921A1286|103 119|consensus sequence
P01426635A0496|18 22|ZFH-2
P01426635A0496|76 84|serotonin
P01426635A0496|63 65|DDC
P01426635A0496|34 36|CNS
P01426635A0496|9 15|profile
P01426635A0496|88 102|dopamine neurons
P01427034A0440|42 53|protein genes
P01427034A0440|141 142|bp
P01427034A0440|120 131|DNA sequences
P01427034A0440|145 150|length
P01427034A0440|9 15|introns
P01427034A0440|9 15|introns
P01427034A0440|90 97|S13 genes
P01427457A0000|131 143|sodium heparin
P01427457A0000|177 186|thrombosis
P01427457A0000|100 113|calcium heparin
P01427457A0000|149 157|treatment
P01427457A0000|33 37|trial
P01427457A0000|49 49|h
P01427457A0000|188 190|DVT
P01427457A0000|76 77|SC
P01427457A0000|51 58|efficacy
P01428490A0671|158 161|past
P01428490A0671|30 39|pet allergy
P01428490A0671|119 124|asthma
P01428490A0671|61 67|attacks
P01428490A0671|149 152|pets
P01428490A0671|135 142|children
P01428490A0671|70 78|shortness
P01428490A0671|81 86|breath
P01428490A0671|48 52|cough
P01428490A0671|54 59|wheeze
P01428490A0671|10 19|prevalence
P01428513A0440|45 51|persons
P01429596A1669|88 121|18K agglutination-aggregation factor
P01429596A1669|123 129|18K-LAF
P01429596A1669|55 67|hemagglutinin
P01429596A1669|5 9|basis
P01429596A1669|23 32|properties
P01429624A0328|87 94|activity
P01429624A0328|3 7|shift
P01429624A0328|55 58|loss
P01429624A0328|97 111|adenylylcyclase
P01429624A0328|61 66|guanyl
P01429624A0328|26 36|temperature
P01429714A0730|0 3|Clin
P01429724A0664|83 88|Gly451
P01429724A0664|46 50|Nmt1p
P01429724A0664|3 6|data
P01429724A0664|67 71|Ile59
P01429724A0664|92 97|Leu455
P01429724A0664|75 79|Phe96
P01429724A0664|38 43|domain
P01429740A1065|70 75|domain
P01429740A1065|122 127|E2 gene
P01429740A1065|92 96|exons
P01429740A1065|39 49|presequence
P01429768T0000|61 65|alloy
P01429768T0000|5 22|neutrophil response
P01429768T0000|45 48|F-75
P01429768T0000|35 42|exposure
P01429836A0457|0 9|Disruption
P01429836A0457|96 108|Vps1p function
P01429836A0457|49 56|kinetics
P01429836A0457|12 23|microtubules
P01429836A0457|67 80|protein sorting
P01429836A0457|39 46|fidelity
P01429836A0457|12 23|microtubules
P01429836A1205|13 17|Vps1p
P01429836A1205|73 86|protein sorting
P01429836A1205|98 102|cells
P01429836A1205|45 50|domain
P01429836A1205|7 10|form
P01431380A0244|169 176|antibody
P01431380A0244|116 122|vectors
P01431380A0244|31 39|tick fauna
P01431380A0244|169 176|antibody
P01431380A0244|106 110|ticks
P01431380A0244|296 299|JSFR
P01431380A0244|164 167|SFGR
P01431380A0244|65 68|area
P01431380A0244|164 167|SFGR
P01431380A0244|14 26|field research
P01431380A0244|390 395|organs
P01431380A0244|215 222|findings
P01431380A0244|246 256|patient sera
P01431380A0244|416 420|gland
P01431380A0244|334 341|electron
P01431380A0244|106 110|ticks
P01431380A0244|106 110|ticks
P01431380A0244|179 182|mice
P01431380A0244|147 162|group rickettsiae
P01431380A0244|355 366|observations
P01431380A0244|305 318|hemolymph cells
P01431380A0244|201 213|tick emulsions
P01431380A0244|152 162|rickettsiae
P01431602A0229|20 24|macro
P01431602A0229|93 108|microliters HClO4
P01431602A0229|9 14|method
P01431602A0229|62 81|micrograms phosphorus
P01431602A0229|36 51|sensitivity range
P01431602A0229|26 30|assay
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|88 104|polyhedrosis virus
P01431809T0000|36 43|analysis
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 80|Spodoptera exigua
P01432453T0000|0 9|Validation
P01432453T0000|30 45|system definition
P01432453T0000|21 27|systems
P01433391A0594|98 102|value
P01433391A0594|57 63|neurons
P01433391A0594|127 133|kittens
P01433391A0594|40 46|density
P01433391A0594|3 13|consequence
P01433391A0594|20 26|rearing
P01433391A0594|66 69|area
P01433391A0594|66 69|area
P01433502A1163|72 76|cells
P01433502A1163|5 11|results
P01433502A1163|32 36|class
P01433502A1163|162 170|repressor
P01433502A1163|111 116|levels
P01433502A1163|90 93|part
P01433502A1163|138 143|factor
P01433502A1163|38 53|enhancer activity
P01433524A0788|92 101|activities
P01433524A0788|7 12|domain
P01433524A0788|51 53|IE1
P01433524A0788|39 48|amino acids
P01435698A0000|2 6|order
P01435698A0000|135 146|implantation
P01435698A0000|68 74|changes
P01435698A0000|95 104|production
P01435698A0000|114 123|harvesting
P01435698A0000|53 61|vein graft
P01435698A0000|23 40|blood compatibility
P01435698A0000|77 88|prostacyclin
P01435698A0000|63 65|AVG
P01435698A0000|90 93|PGI2
P01436261A0145|133 145|disappearance
P01436261A0145|0 25|Subcutaneous administration
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|181 196|calcitonin levels
P01436261A0145|121 129|diarrhoea
P01436261A0145|52 61|octreotide
P01436261A0145|154 165|incontinence
P01436261A0145|108 118|improvement
P01436261A0145|66 75|micrograms
P01437562A0462|129 132|gene
P01437562A0462|100 117|nucleotide sequence
P01437562A0462|30 36|protein
P01437562A0462|49 61|C.fasciculata
P01437562A0462|8 17|antibodies
P01437562A0462|80 83|size
P01437562A0462|39 46|extracts
P01437562A0462|64 72|agreement
P01438224A0749|49 50|J.
P01438287T0000|59 63|genes
P01438287T0000|14 27|vaccinia vector
P01441120T0000|0 2|Use
P01441120T0000|16 23|minerals
P01441818T0001|0 13|Interferon type
P01441818T0001|27 39|body reactions
P01441818T0001|56 74|Klebsiella infection
P01443047A0773|29 49|differentiation status
P01443047A0773|7 13|changes
P01443047A0773|79 94|Id-SCL expression
P01443047A0773|64 74|association
P01443745T0000|58 66|midazolam
P01443745T0000|46 53|sedation
P01443745T0000|33 42|anesthesia
P01443745T0000|11 21|interaction
P01443748A1190|3 10|pressure
P01443748A1190|43 54|excitability
P01443748A1190|60 67|tadpoles
P01443748A1190|128 136|movements
P01443748A1190|25 30|atm abs
P01446132A0328|3 13|air embolism
P01446132A0328|63 74|complication
P01446132A0328|37 42|filter
P01446828A1088|13 16|ADH5
P01446828A1088|100 103|NF-1
P01446828A1088|86 88|Sp1
P01446828A1088|5 10|region
P01446828A1088|94 98|LF-A1
P01446828A1088|105 109|NF-A2
P01446828A1088|25 45|consensus binding sites
P01446828A1088|114 118|NF-E1
P01446828A1088|90 92|AP2
P01446828A1088|77 84|proteins
P01447139A0208|0 1|V.
P01447189A1546|85 92|granules
P01447189A1546|57 64|activity
P01447189A1546|5 8|data
P01447189A1546|108 118|lymphocytes
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|33 46|serine protease
P01447189T0000|15 21|cloning
P01447189T0000|0 11|Purification
P01447189T0000|73 75|rat
P01447189T0000|83 100|killer cell leukemia
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|30 43|serine protease
P01447189T0000|62 69|granules
P01448107A0361|80 86|absence
P01448107A0361|47 58|derepression
P01448107A0361|24 36|GCN2 mutations
P01448107A0361|89 107|amino acid starvation
P01448107A0361|61 74|GCN4 expression
P01448806A0135|0 13|Administration
P01448806A0135|16 21|growth
P01448806A0135|16 28|growth hormone
P01448806A0135|62 75|bone maturation
P01448917A0775|314 323|polymerase
P01448917A0775|0 10|Comparisons
P01448917A0775|199 206|proteins
P01448917A0775|230 232|58K
P01448917A0775|286 298|24K proteinase
P01448917A0775|199 205|protein
P01448917A0775|340 352|cleavage sites
P01448917A0775|47 54|sequence
P01448917A0775|241 248|helicase
P01448917A0775|47 54|sequence
P01448917A0775|44 45|aa
P01448917A0775|184 186|set
P01448917A0775|155 162|CPSMV RNA
P01448917A0775|211 228|proteinase cofactor
P01448917A0775|47 65|sequence information
P01448917A0775|281 284|RNAs
P01448917A0775|250 252|VPg
P01448917A0775|123 142|clover mottle virus RNA
P01448917A0775|81 87|CPMV RNA
P01448917A0775|303 305|87K
P01448917A0775|27 42|amino acid residue
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|14 20|utility
P01449183A0795|28 43|transferrin assay
P01449183A0795|73 85|fluid otorrhea
P01449183A0795|2 9|addition
P01449183A0795|23 26|beta
P01449183A0795|49 57|diagnosis
P01449301A0710|0 15|Cold cardioplegia
P01449301A0710|57 61|hours
P01449301A0710|46 52|minutes
P01449301A0710|35 38|mm Hg
P01450815A0337|29 32|IPRK
P01450815A0337|13 23|diatrizoate
P01450815A0337|3 10|addition
P01450815A0337|69 71|RPF
P01450815A0337|148 155|decrease
P01450815A0337|111 118|increase
P01450815A0337|61 66|change
P01450815A0337|75 77|GFR
P01451771A0619|189 196|husbands
P01451771A0619|203 207|wives
P01451771A0619|27 41|family variables
P01451771A0619|174 185|health scores
P01451771A0619|137 151|scaling analysis
P01451771A0619|95 112|components analysis
P01451771A0619|153 155|MDS
P01451771A0619|67 70|data
P01451771A0619|114 116|PCA
P01451771A0619|12 19|analyses
P01452037A0000|266 279|gap amber mutant
P01452037A0000|124 147|triosephosphate isomerase
P01452037A0000|208 218|gene cluster
P01452037A0000|91 96|kinase
P01452037A0000|118 121|part
P01452037A0000|66 70|GAPDH
P01452037A0000|98 100|PGK
P01452037A0000|149 151|TIM
P01452037A0000|13 17|genes
P01452037A0000|167 190|Bacillus megaterium DSM319
P01452037A0000|220 228|gap operon
P01452037A0000|232 246|complementation
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452584T0000|73 85|Lindberg Award
P01452584T0000|34 37|role
P01452584T0000|21 29|exotoxin A
P01452584T0000|53 64|wound healing
P01452584T0000|40 50|retardation
P01452703A0782|0 16|Laboratory studies
P01452703A0782|130 135|bodies
P01452703A0782|87 90|case
P01452703A0782|130 135|bodies
P01452703A0782|151 159|ELISA kits
P01452703A0782|56 59|kits
P01452703A0782|139 140|ml
P01452703A0782|139 140|ml
P01454518A0336|86 92|homolog
P01454518A0336|175 180|probes
P01454518A0336|29 35|domains
P01454518A0336|135 158|stringency hybridizations
P01454518A0336|78 81|gene
P01454518A0336|61 72|conservation
P01454518A0336|10 21|significance
P01454518A0336|191 199|ERCC3 cDNA
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|61 63|NAD
P01454819A0000|97 98|EC
P01454819A0000|34 45|modification
P01454819A0000|48 55|proteins
P01454819A0000|130 139|hydrolases
P01454819A0000|173 181|reactions
P01454819A0000|186 206|ADP-ribosylation cycle
P01454819A0000|97 98|EC
P01454819A0000|65 95|arginine ADP-ribosyltransferases
P01456888A0074|261 268|sequence
P01456888A0074|58 67|HIV-1 group
P01456888A0074|32 39|capacity
P01456888A0074|7 12|reason
P01456888A0074|170 177|vaccinia
P01456888A0074|42 52|derivatives
P01456888A0074|17 24|particle
P01456888A0074|132 148|expression systems
P01456888A0074|161 168|bacteria
P01456888A0074|182 194|baculoviruses
P01456888A0074|227 240|core protein p55
P01456888A0074|76 92|core antigen p55 gag
P01456888A0074|281 308|myristylation consensus signal
P01457380A0000|101 113|ttk transcript
P01457380A0000|3 11|tramtrack
P01457380A0000|55 62|proteins
P01457380A0000|17 20|gene
P01457380A0000|81 88|splicing
P01457380A0000|13 15|ttk
P01457695T0000a|0 6|Removal
P01457695T0000a|30 41|hemodialysis
P01457695T0000a|45 58|hemofiltration
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|65 68|year
P01457695T0000b|0 6|Removal
P01457695T0000b|30 41|hemodialysis
P01457695T0000b|45 58|hemofiltration
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|65 68|year
P01458170A0155|0 9|Adapromine
P01458170A0155|115 117|EEG
P01458170A0155|32 39|decrease
P01458170A0155|82 95|theta-activity
P01458170A0155|163 174|wave activity
P01458170A0155|185 189|range
P01458170A0155|132 140|hippocamp
P01458170A0155|98 109|power spectra
P01458170A0155|45 53|amplitude
P01458170A0155|67 70|peak
P01458170A0155|180 183|beta
P01458170A0155|132 140|hippocamp
P01458170A0155|148 155|increase
P01458170A0155|123 128|cortex
P01458170A0155|123 128|cortex
P01459447A0484|28 32|clone
P01459447A0484|57 61|yeast
P01459447A0484|69 75|library
P01459447A0484|5 13|sequences
P01459447A0484|47 51|genes
P01459451A0478|18 31|antirepression
P01459451A0478|124 130|embryos
P01459451A0478|68 83|co-antirepressor
P01459451A0478|51 56|factor
P01459885A0705|13 32|haloperidol treatment
P01459885A0705|41 47|changes
P01459885A0705|83 90|increase
P01459885A0705|118 121|beta
P01459885A0705|93 97|alpha
P01459885A0705|7 10|days
P01459885A0705|104 111|decrease
P01459885A0705|63 67|delta
P01459921A0000|198 203|cis C18
P01459921A0000|186 190|acids
P01459921A0000|77 86|experiment
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|36 51|Hampshire wethers
P01459921A0000|164 167|flow
P01459921A0000|192 196|C18:2
P01459921A0000|127 142|calcium linoleate
P01460054A0478|9 11|ICS
P01460054A0478|96 99|part
P01460054A0478|45 54|amino acids
P01460054A0478|105 120|DNA binding domain
P01460054A0478|9 13|ICSBP
P01460054A0478|152 164|amino terminus
P01460054A0968|89 93|genes
P01460054A0968|109 113|cells
P01460054A0968|10 14|ICSBP
P01460054A0968|66 73|activity
P01460772T0001|1 4|case
P01460772T0001|14 23|hepatitis C
P01460772T0001|65 83|interferon treatment
P01460772T0001|35 48|hypothyroidism
P01462786T0000|0 20|Dynamic decision making
P01462786T0000|36 49|complex systems
P01462786T0000|27 33|control
P01464329T0000|61 79|prophase chromosomes
P01464329T0000|45 51|regions
P01464329T0000|19 25|protein
P01464606A0344|59 63|cells
P01464606A0344|82 98|detergent extracts
P01464606A0344|66 79|chromatography
P01464606A0344|161 164|EDTA
P01464606A0344|30 37|integrin
P01464606A0344|19 23|alpha
P01464606A0344|150 156|elution
P01464606A0344|125 146|fragment affinity column
P01464606A0344|10 16|amounts
P01464606A0344|102 112|fibronectin
P01464606A0344|25 28|beta
P01467088T0075|0 8|Abstracts
P01467828A0542|29 39|involvement
P01467828A0542|100 108|ischaemia
P01467828A0542|162 171|antagonism
P01467828A0542|5 11|results
P01467828A0542|140 148|receptors
P01467828A0542|112 122|reperfusion
P01467828A0542|78 84|effects
P01467828A0542|52 65|opioid peptides
P01468625A0282|16 19|LEU2
P01468625A0282|48 56|frequency
P01468625A0282|131 136|manner
P01468625A0282|8 14|library
P01468625A0282|86 90|cases
P01468625A0282|23 31|HIS3 cDNAs
P01468625A1080|30 34|times
P01468625A1080|30 34|times
P01468625A1080|39 42|NSR1
P01468625A1080|11 14|ACT1
P01469042A0355|72 98|mouse centromere satellite DNA
P01469042A0355|5 14|CENP-B gene
P01469042A0355|148 158|interaction
P01469042A0355|87 95|satellite
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|192 209|centromere function
P01469042A0355|180 183|kind
P01469042A0355|37 43|species
P01469047A1606|15 21|portion
P01469047A1606|27 36|tail domain
P01469047A1606|98 104|protein
P01469047A1606|61 86|% amino acid sequence identity
P01469047A1606|109 118|mouse brain
P01469047A1606|140 156|acid decarboxylase
P01469047A1606|53 58|shares
P01469047A1606|38 39|aa
P01470243A0871|224 228|means
P01470243A0871|141 148|increase
P01470243A0871|31 32|Ht
P01470243A0871|20 20|p
P01470243A0871|115 115|%
P01470243A0871|165 168|home
P01470243A0871|231 243|haemodilution
P01470243A0871|106 111|months
P01470243A0871|151 162|independence
P01470243A0871|13 20|subgroup
P01470243A0871|39 41|l/l
P01470243A0871|69 77|reduction
P01470243A0871|265 279|viscosity effect
P01470243A0871|91 99|mortality
P01470243A0871|115 115|%
P01470243A0871|9 9|n
P01470243A0871|213 221|viscosity
P01470243A0871|69 77|reduction
P01470243A0871|16 20|group
P01470243A0871|248 254|albumin
P01470243A0871|115 115|%
P01470243A0871|115 115|%
P01470741T0062|0 11|Distribution
P01470741T0062|36 41|course
P01471602A0362|14 16|use
P01471602A0362|103 111|coenzyme A
P01471602A0362|34 37|acid
P01471602A0362|121 139|reductase inhibitors
P01471602A0362|34 38|acids
P01471602A0362|30 49|bile acid sequestrants
P01471602A0362|234 238|drugs
P01471602A0362|113 119|HMG-CoA
P01471602A0362|20 27|benefits
P01471602A0362|216 226|conjunction
P01471602A0362|200 209|approaches
P01471602A0362|144 151|probucol
P01473196A1016|19 30|reabsorption
P01473196A1016|51 59|clearance
P01473207A0582|61 70|hypoplasia
P01473207A0582|33 40|placenta
P01473207A0582|45 57|prematuration
P01473207A0582|20 27|findings
P01473234A1001|0 10|Green pepper
P01473234A1001|65 77|acid formation
P01473234A1001|65 68|acid
P01474990A0000|14 18|pTt21
P01474990A0000|30 32|DNA
P01474990A0000|84 98|trypomastigotes
P01474990A0000|172 187|epimastigote cDNA
P01474990A0000|68 78|Trypanosoma
P01474990A0000|8 12|clone
P01474990A0000|84 97|trypomastigote
P01474990A0000|144 150|library
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01476376T0000|7 10|urea
P01476376T0000|24 29|urease
P01476376T0000|52 59|pH-meter
P01477021A0394|42 68|serum prolactin concentration
P01477021A0394|0 6|RESULTS
P01477021A0394|13 20|AGA group
P01477021A0394|95 103|gestation
P01477021A0394|105 105|P
P01477021A0394|105 105|P
P01478672A0795|3 12|phage clone
P01478672A0795|22 29|junction
P01478672A0795|79 86|sequence
P01478672A0795|37 53|alpha satellite DNA
P01480183A0000|14 19|region
P01480183A0000|30 44|lactoferrin gene
P01480183A0000|82 88|library
P01480183A1689|102 106|mouse
P01480183A1689|22 31|mechanisms
P01480183A1689|37 50|estrogen action
P01480183A1689|64 88|lactoferrin gene expression
P01480470A0323|0 5|BiP670
P01480470A0323|21 23|Ca2
P01480470A0323|50 59|activities
P01480470A0323|25 33|ionophore
P01482912A0617|14 32|registration updates
P01482912A0617|60 75|data dependencies
P01482912A0617|3 5|CEM
P01482912A0617|78 82|rules
P01482912A0617|102 119|relational database
P01482912A0617|88 96|interface
P01482912A0617|38 47|HL7 message
P01483755A0000|130 135|muscle
P01483755A0000|45 47|MRI
P01483755A0000|101 110|metabolism
P01483755A0000|119 127|structure
P01483755A0000|86 90|study
P01483755A0000|30 32|MRS
P01483755A0000|70 79|techniques
P01483755A0000|37 43|imaging
P01483755A0000|8 28|resonance spectroscopy
P01483771A1335|22 23|NA
P01483771A1335|46 70|plasma epinephrine response
P01483771A1335|38 43|change
P01485648A0000|100 105|Sweden
P01485648A0000|200 207|patients
P01485648A0000|45 48|test
P01485648A0000|69 90|Pharmacia Diagnostics AB
P01485648A0000|171 180|comparison
P01485648A0000|185 188|RAST
P01485648A0000|92 98|Uppsala
P01485648A0000|126 136|measurement
P01485648A0000|192 197|groups
P01485648A0000|50 67|Pharmacia CAP System
P01485648A0000|27 31|value
P01485648A0000|156 168|IgE antibodies
P01486836A0774|0 7|Patients
P01486836A0774|26 36|differences
P01486836A0774|197 198|T4
P01486836A0774|112 113|T1
P01486836A0774|140 141|T2
P01486836A0774|91 109|discrimination tasks
P01486836A0774|49 69|visuomotor performance
P01486836A0774|39 47|attention
P01486836A0774|160 161|T3
P01486836A0774|17 19|VPA
P01486836A0774|77 80|span
P01486836A0774|77 80|span
P01486836A0774|49 69|visuomotor performance
P01486836A0774|26 36|differences
P01487144A0505|14 24|gene segment
P01487144A0505|68 69|bp
P01487144A0505|136 147|myeloma cells
P01487144A0505|48 54|signals
P01487144A0505|107 129|transcription terminator
P01487144A0505|90 97|sequence
P01487144A0505|46 46|A
P01487144A0505|38 44|mu m poly
P01487144A0505|151 166|L cell fibroblasts
P01490493A0416|69 86|triglyceride levels
P01490493A0416|39 54|serum cholesterol
P01490493A0416|15 25|examination
P01490493A0416|3 6|part
P01490493A0416|61 65|lipid
P01492463T0001|0 4|Alena
P01492463T0001|40 44|wages
P01492463T0001|15 20|Prague
P01492463T0001|62 66|ocean
P01492463T0001|8 12|nurse
P01492463T0001|49 52|trip
P01493864A0619|58 70|pre-treatment
P01493864A0619|0 14|Dopamine neurons
P01493864A0619|75 83|GBR-12909
P01493864A0619|17 24|subjects
P01493864A0619|37 42|6-OHDA
P01495069A0392|0 3|DIBA
P01495069A0392|92 95|DFAT
P01495069A0392|78 87|percentage
P01495069A0392|51 55|value
P01496348A0000|0 5|Caries
P01496348A0000|57 63|mankind
P01496348A0000|47 54|diseases
P01496348A0000|9 20|parodontitis
P01496784A0939|58 62|cause
P01496784A0939|71 75|death
P01496784A0939|3 9|results
P01496784A0939|16 20|study
P01496784A0939|36 51|strongyloidiasis
P01497582A0593|127 134|placenta
P01497582A0593|116 121|embryo
P01497582A0593|58 67|infections
P01497582A0593|30 38|pregnancy
P01497582A0593|19 27|disorders
P01497582A0593|73 78|mother
P01497582A0593|86 94|pathogens
P01497582A0593|49 55|effects
P01497582A0593|12 16|group
P01498607A0000|29 33|boxes
P01498607A0000|79 109|parsley chalcone synthase promoter
P01498607A0000|9 27|nucleotide sequences
P01498607A0000|60 73|responsiveness
P01499213A0185|98 101|fall
P01499213A0185|141 154|L2-L3 disk space
P01499213A0185|3 6|case
P01499213A0185|115 122|fracture
P01499213A0185|43 52|ochronosis
P01499213A0185|90 94|spine
P01499213A0185|65 84|hyperextension injury
P01499213A0185|36 38|man
P01499616A0136|27 34|foreskin
P01499616A0136|96 104|induction
P01499616A0136|169 180|foreskin flap
P01499616A0136|63 63|g
P01499616A0136|7 15|blood flow
P01499616A0136|144 146|tip
P01499616A0136|107 116|anesthesia
P01499616A0136|87 87|%
P01499616A0136|87 87|%
P01502157A0000|0 4|ME1a1
P01502157A0000|71 100|P2 transcription initiation sites
P01502157A0000|61 67|c-MYC P1
P01502157A0000|115 124|P2 activity
P01502157A0000|26 42|factor binding site
P01504178T0000|13 17|years
P01504178T0000|46 54|visionary
P01504178T0000|56 62|complex
P01504178T0000|20 29|prevention
P01504178T0000|38 44|country
P01504853A0299|59 65|species
P01504853A0299|36 49|mating behavior
P01504853A0299|9 12|LHRH
P01505488A0231|41 43|EVL
P01505488A0231|22 29|patients
P01505488A0231|53 58|period
P01505488A0231|76 79|July
P01505488A0231|63 68|August
P01505516A0928|56 68|valine residue
P01505516A0928|29 34|lysine
P01505516A0928|20 23|acid
P01505516A0928|76 84|formation
P01505516A0928|47 53|alanine
P01505516A0928|103 108|dimers
P01506705A0282|16 27|hemodynamics
P01506705A0282|6 14|V-A bypass
P01506746A0476|0 18|Greater rupture force
P01506746A0476|40 43|pigs
P01506746A0476|40 43|pigs
P01509798A0520|38 38|%
P01509798A0520|38 38|%
P01509798A0520|2 8|rest AFF
P01509798A0520|52 53|AT
P01509798A0520|62 64|UEA
P01509798A0520|33 34|UT
P01509798A0520|38 38|%
P01511231A0085|42 45|year
P01511231A0085|98 111|placebo patches
P01511231A0085|32 40|relapsers
P01511231A0085|17 29|smoking habits
P01511231A0085|88 95|nicotine
P01511231A0085|62 82|smoking cessation trial
P01511950T0000|37 46|population
P01511950T0000|0 7|Exposure
P01511950T0000|58 62|Japan
P01511950T0000|86 93|antibody
P01511950T0000|96 119|hepatitis B surface antigen
P01511950T0000|64 75|significance
P01511950T0000|49 56|Hisayama
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|37 46|population
P01512259A0867|105 109|furin
P01512259A0867|97 101|times
P01512259A0867|19 28|phenomenon
P01512259A0867|104 110|Dfurin2
P01512259A0867|61 73|cysteine motif
P01512654A0503|73 85|KLH challenges
P01512654A0503|146 152|latency
P01512654A0503|118 131|threshold level
P01512654A0503|22 30|phosphate
P01512654A0503|61 62|ES
P01512654A0503|61 62|ES
P01512654A0503|39 53|saline injection
P01512654A0503|10 13|hand
P01512941A0000|102 111|comparison
P01512941A0000|45 56|levofloxacin
P01512941A0000|63 69|DR-3355
P01512941A0000|166 169|NFLX
P01512941A0000|48 56|ofloxacin
P01512941A0000|58 61|LVFX
P01512941A0000|154 164|norfloxacin
P01512941A0000|146 149|OFLX
P01512941A0000|130 133|CPFX
P01512941A0000|116 128|ciprofloxacin
P01513114A1133|56 58|KTA
P01513114A1133|69 76|ABSTRACT
P01513114A1133|44 47|year
P01513114A1133|62 65|mg/d
P01513114A1133|49 51|SPK
P01513114A1133|7 27|serum creatinine levels
P01513114A1133|91 95|WORDS
P01513213A0231|0 15|Model predictions
P01513213A0231|128 134|HIP data
P01513213A0231|40 44|years
P01513213A0231|44 51|survival
P01513213A0231|94 102|exception
P01513213A0231|44 61|survival experience
P01513213A0231|64 68|women
P01513213A0231|22 27|accord
P01513213A0231|74 81|HIP trial
P01513213A0231|64 68|women
P01516427T0000|56 67|tuberculosis
P01516427T0000|23 32|tomography
P01516427T0000|38 46|diagnosis
P01516829A0113|119 125|complex
P01516829A0113|28 31|SNF5
P01516829A0113|81 90|activation
P01516829A0113|36 47|SNF6 function
P01516829A0113|23 26|SNF2
P01516829A0460|85 94|activation
P01516829A0460|97 107|target genes
P01516829A0460|131 143|lexA operators
P01516829A0460|33 46|fusion proteins
P01516829A0460|70 73|SNF5
P01516829A0460|78 81|SNF6
P01516829A0460|65 68|SNF2
P01516829A0460|10 18|LexA-GAL4
P01518396T0000|0 7|George T.
P01518833A0397|1 21|lambda gt10 cDNA library
P01518833A0397|71 77|spinach
P01518833A0397|40 43|poly
P01518833A0397|0 0|A
P01518833A0397|63 68|leaves
P01518833A0397|48 50|RNA
P01518849A0165|0 1|NE
P01518849A0165|44 57|microorganisms
P01518849A0165|150 184|alpha 1-proteinase inhibitor complexes
P01518849A0165|5 7|PR3
P01518849A0165|19 29|destruction
P01518849A0165|94 107|protein elastin
P01518849A0165|188 202|elastin peptides
P01518849A0165|131 140|activities
P01518926T0000|8 13|topics
P01518926T0000|25 39|ultrasonography
P01522699A0092|0 6|Methods
P01522699A0092|29 34|recall
P01522699A0092|51 64|recipe analysis
P01522699A0092|36 46|menu weights
P01523111A0769|0 6|Factors
P01523111A0769|86 93|body mass
P01523111A0769|38 40|age
P01523111A0769|21 29|afterdrop
P01523111A0769|56 66|temperature
P01524549A0241|99 109|association
P01524549A0241|73 82|occurrence
P01524549A0241|33 38|growth
P01524549A0241|4 15|GH deficiency
P01524549A0241|55 61|stature
P01524549A0241|136 139|time
P01524549A0241|90 96|puberty
P01524549A0241|152 160|GH therapy
P01524549A0241|4 15|GH deficiency
P01525153A0359|133 139|Gilbert
P01525153A0359|2 9|contrast
P01525153A0359|31 34|form
P01525153A0359|84 103|K cation concentration
P01525153A0359|125 127|Sen
P01525153A0359|11 11|d
P01525153A0359|54 70|monomer structures
P01525153A0359|25 29|T2G4T
P01525153A0359|129 130|D.
P01525153A0359|11 11|d
P01525153A0359|141 142|W.
P01525153A0359|13 18|T2AG3T
P01525966T0000|25 30|stones
P01526658A0454|0 2|IFI
P01526658A0454|82 82|T
P01526658A0454|54 58|cells
P01526658A0454|5 8|mRNA
P01526658A0454|64 72|cell lines
P01526658A0454|86 94|B lineages
P01526690T0000|18 23|action
P01526690T0000|36 46|lymphocytes
P01526690T0000|26 33|warfarin
P01527020A0511|55 58|gene
P01527020A0511|140 146|rat gene
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01527020A0511|94 97|exon
P01527020A0511|94 98|exons
P01527020A0511|11 19|junctions
P01527020A0511|75 83|positions
P01529530T0000|60 65|effect
P01529530T0000|39 46|evidence
P01529530T0000|24 37|gene expression
P01529530T0000|68 74|ouabain
P01529530T0000|92 116|ISGF3 transcription complex
P01529530T0000|77 86|activation
P01531086A0127|16 27|reading frame
P01531086A0127|3 6|cDNA
P01531086A0127|67 73|protein
P01531086A0127|33 42|amino acids
P01531214A0885|69 82|administration
P01531214A0885|15 18|mice
P01531214A0885|31 34|g/kg
P01531214A0885|9 12|LD50
P01531214A0885|21 26|RP-170
P01531214A0885|37 40|i.v.
P01531214A0885|31 34|g/kg
P01531632A0000|11 18|proteins
P01531632A0000|149 157|GAR domain
P01531632A0000|172 178|glycine
P01531632A0000|82 90|nucleolin
P01531632A0000|140 144|motif
P01531632A0000|111 114|NSR1
P01531632A0000|182 197|arginine residues
P01531632A0000|34 42|nucleolus
P01531632A0000|92 102|fibrillarin
P01531632A0000|11 18|proteins
P01531632A0000|104 107|SSB1
P01532229A1264|87 91|MEF-2
P01532229A1264|58 62|HF-1a
P01532229A1264|179 189|muscle cells
P01532229A1264|68 79|muscle factor
P01532229A1264|149 158|expression
P01532229A1264|81 85|HF-1b
P01532229A1264|124 130|pathway
P01532229A1264|22 29|evidence
P01532229A1264|9 13|study
P01532229A1264|51 56|factor
P01532796A0107|70 74|alpha
P01532796A0107|0 8|Mutations
P01532796A0107|57 58|F1
P01532796A0107|41 44|step
P01532796A0107|17 20|gene
P01532796A0107|146 147|S.
P01532796A0107|137 144|Ackerman
P01532796A0107|104 115|mitochondria
P01532796A0107|78 89|beta subunits
P01532796A0107|47 54|assembly
P01532796A0107|126 135|aggregates
P01532914A0067|0 6|Expense
P01532914A0067|16 18|use
P01532914A0067|122 128|studies
P01532914A0067|21 38|hepatitis B vaccines
P01532914A0067|104 111|strategy
P01532914A0067|62 73|immunization
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|60 72|meta-analyses
P01533760T0000|29 32|risk
P01533760T0000|48 54|results
P01533760T0000|35 46|breast cancer
P01535242A0557|43 48|GM-CSF
P01535242A0557|16 23|MAC cells
P01535242A0557|28 33|growth
P01535242A0557|5 5|h
P01535242A0557|36 40|M-CSF
P01535242A0557|9 14|FDC-P1
P01535242A0557|80 88|c-fms mRNA
P01535242A0557|67 77|degradation
P01535242A0557|102 116|factor switching
P01536153A0574|29 38|difference
P01536153A0574|145 148|dust
P01536153A0574|89 105|animal food workers
P01536153A0574|74 81|symptoms
P01536153A0574|208 214|dyspnea
P01536153A0574|195 197|IgE
P01536153A0574|44 53|prevalence
P01536153A0574|129 137|skin tests
P01536153A0574|153 161|fish flour
P01536575A1213|174 179|CYPIA1
P01536575A1213|80 86|element
P01536575A1213|35 42|position
P01536575A1213|64 69|dioxin
P01536575A1213|134 146|transcription
P01536575A1213|89 96|sequence
P01536575A1213|12 18|finding
P01536575A1213|189 193|genes
P01536575A1213|249 260|hydrocarbons
P01536575A1213|123 131|induction
P01536575A1213|152 172|cytochrome P450IA1 gene
P01536575A1213|204 228|detoxification/activation
P01536575A1213|25 32|presence
P01537334A0507|26 40|mouse chromosome
P01537334A0507|15 23|TRP-2 maps
P01537334A0507|3 6|gene
P01537334A0507|60 82|coat colour mutation slaty
P01537334A0507|49 54|region
P01537845A0571|45 48|rate
P01537845A0571|20 30|c-myb clones
P01537845A0571|108 116|cell cycle
P01537845A0571|34 39|change
P01537845A0571|51 72|c-myb gene transcription
P01537845A0571|75 87|mRNA stability
P01538401A1244|100 106|binding
P01538401A1244|158 169|DNA fragments
P01538401A1244|119 124|latter
P01538401A1244|3 26|base-pair oligonucleotide
P01538401A1244|17 27|nucleotides
P01538401A1244|60 67|S RNA gene
P01538403A1058|162 177|complex formation
P01538403A1058|28 31|eUSF
P01538403A1058|28 31|eUSF
P01538403A1058|35 39|TFIID
P01538403A1058|213 220|TATA-box
P01538403A1058|184 202|H5 promoter mutations
P01538403A1058|83 98|protein fractions
P01538403A1058|49 70|transcription complexes
P01538403A1058|12 25|reconstitution
P01539996A0588|112 121|similarity
P01539996A0588|1 10|comparison
P01539996A0588|25 32|sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|52 57|enzyme
P01539996A0588|263 270|residues
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|16 32|amino acid sequence
P01539996A0588|130 141|conservation
P01539996A0588|245 252|presence
P01539996A0588|276 284|C terminus
P01539996A0588|104 104|%
P01539996A0588|147 156|Ser residue
P01539996A0588|52 57|enzyme
P01541556A1040|73 89|lipid modification
P01541556A1040|101 113|Cys-22 residue
P01541556A1040|54 60|protein
P01541556A1040|13 21|palmitate
P01541577A0000|58 73|Stanford Hypnotic
P01541577A0000|15 16|Ss
P01541577A0000|2 10|volunteer
P01541577A0000|82 86|Scale
P01541577A0000|95 100|Morgan
P01541577A0000|35 52|volunteer hearing Ss
P01541577A0000|104 105|J.
P01541577A0000|88 91|SHCS
P01542565A0220|59 71|protein L7/L12
P01542565A0220|28 45|% amino acid identity
P01542565A0220|6 22|tobacco L12 protein
P01542565T0000|35 44|protein L12
P01542565T0000|35 41|protein
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|98 106|isolation
P01542565T0000|128 137|cDNA clones
P01542565T0000|110 125|sequence analysis
P01542565T0000|64 79|characterization
P01542565T0000|160 168|precursor
P01542667A0125|15 23|IFN-gamma
P01542667A0125|3 6|gene
P01542667A0125|135 144|expression
P01542667A0125|3 6|gene
P01542667A0125|106 113|activity
P01542667A0125|61 75|enhancer element
P01542686A0000|121 123|p65
P01542686A0000|99 106|identity
P01542686A0000|134 143|NF-kappa B.
P01542686A0000|21 40|polypeptide component
P01542686A0000|125 131|subunit
P01542686A0000|9 15|cloning
P01542686A0000|62 84|p75 nucleoprotein complex
P01542730A1982|203 209|devices
P01542730A1982|86 96|development
P01542730A1982|144 150|support
P01542730A1982|198 201|DDDR
P01542730A1982|234 239|number
P01542730A1982|109 117|DDD pacing
P01542730A1982|40 45|pacing
P01542730A1982|74 77|risk
P01542730A1982|99 105|AV block
P01542730A1982|247 254|patients
P01542730A1982|185 196|dual-chamber
P01542730A1982|55 61|patient
P01542730A1982|279 283|WORDS
P01542730A1982|257 264|ABSTRACT
P01543909A0787|44 45|Lg
P01543909A0787|30 38|K562 cells
P01543909A0787|117 131|characteristics
P01543909A0787|201 215|ferritin subunit
P01543909A0787|150 153|gene
P01543909A0787|144 153|pseudogene
P01543909A0787|53 57|clone
P01544854A0699|29 37|WR-168643
P01544854A0699|5 9|drugs
P01544854A0699|48 56|protector
P01544854A0699|62 64|DMF
P01544918A1240|0 15|Characterization
P01544918A1240|240 242|kDa
P01544918A1240|294 300|RI alpha
P01544918A1240|178 195|gel electrophoresis
P01544918A1240|240 242|kDa
P01544918A1240|39 71|8-azido-cAMP photoaffinity labeling
P01544918A1240|143 155|sodium dodecyl
P01544918A1240|75 90|immunoreactivity
P01544918A1240|197 204|SDS-PAGE
P01544918A1240|255 275|RII alpha dephosphoform
P01544918A1240|240 242|kDa
P01544918A1240|230 236|RII beta
P01544918A1240|128 140|mobility shift
P01544918A1240|216 227|subunit sizes
P01544918A1240|23 31|R subunits
P01544928A1252|0 9|Comparison
P01544928A1252|156 168|cassette model
P01544928A1252|117 124|splicing
P01544928A1252|59 63|mRNAs
P01544928A1252|82 92|transcripts
P01544928A1252|136 143|pre-mRNA
P01544928A1252|22 32|DNA sequence
P01545523A0000|105 121|antistreptolysin O
P01545523A0000|16 30|quantifications
P01545523A0000|69 69|C
P01545523A0000|96 101|factor
P01545523A0000|50 57|testings
P01545523A0000|78 84|protein
P01545787A0345|72 76|DNase
P01545787A0345|14 21|enhancer
P01545787A0345|98 104|NFIL-2B
P01545787A0345|31 35|sites
P01545787A0345|78 87|footprints
P01545787A0345|89 94|NFAT-1
P01545792A0000|29 33|MLC-2
P01545792A0000|120 129|regulation
P01545792A0000|135 144|expression
P01545792A0000|35 46|gene promoter
P01545792A0000|10 27|myosin light chain-2
P01545792A0000|91 99|sequences
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|75 84|regulation
P01545792A0492|43 50|elements
P01545792A0492|87 108|MLC-2 gene transcription
P01545797A0587|0 18|Disruption mutations
P01545797A0587|43 50|SLK1 gene
P01545797A0587|97 101|cells
P01545797A0587|60 66|mutants
P01545797A0587|81 88|degrees C
P01545797A0587|122 130|degrees C.
P01545797A0587|52 55|slk1
P01545806T0000|32 36|yeast
P01545806T0000|19 26|analysis
P01545806T0000|49 72|recombination genes REC102
P01545806T0000|76 86|REC107/MER2
P01545818A0696|159 172|v-Src SH2 domain
P01545818A0696|3 6|p130
P01545818A0696|57 64|v-Src SH2
P01545818A0696|135 141|binding
P01545818A0696|36 43|proteins
P01545818A0696|114 123|Rat-2 cells
P01545818A0696|10 12|p62
P01545818A0696|57 61|v-Src
P01546522A0000|0 7|Probable
P01546522A0000|133 135|man
P01546522A0000|103 118|resonance imaging
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|149 157|remission
P01546522A0000|49 51|PML
P01546522A0000|174 181|lymphoma
P01546522A0000|85 91|picture
P01546522A0000|70 74|basis
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547775A1024|5 8|data
P01547775A1024|150 162|PLRV replicase
P01547775A1024|122 124|RNA
P01547775A1024|35 46|significance
P01547775A1024|75 82|position
P01547775A1024|141 144|site
P01547775A1024|52 61|frameshift
P01547787A0548|0 19|Proprotein processing
P01547942A0120|29 46|dimerization domain
P01547942A0120|48 58|zipper probe
P01547942A0120|121 127|CHOP-10
P01547942A0120|113 119|protein
P01547942A0120|77 81|clone
P01547942A0120|12 14|LAP
P01547957A1083|119 124|region
P01547957A1083|259 262|GL81
P01547957A1083|198 208|DNA fragment
P01547957A1083|67 76|aa sequence
P01547957A1083|143 146|CYP1
P01547957A1083|198 200|DNA
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|134 140|portion
P01547957A1083|250 252|PCR
P01547957A1083|150 153|CYP2
P01547957A1083|177 182|genome
P01547957A1083|226 248|polymerase chain reaction
P01547957A1083|276 284|substrate
P01548756A1102|72 80|EHS-1 loci
P01548756A1102|146 150|locus
P01548756A1102|109 119|band pattern
P01548756A1102|122 134|chimpanzee DNA
P01548756A1102|49 51|DNA
P01548756A1102|49 51|DNA
P01548756A1102|24 28|EHS-1
P01548756A1102|9 21|hybridization
P01548756A1102|153 167|rhesus monkey DNA
P01548891A0635|50 57|patients
P01548891A0635|132 132|P
P01548891A0635|3 7|level
P01548891A0635|50 57|patients
P01548891A0635|38 44|hormone
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|62 77|thyroid carcinoma
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|58 62|stage
P01549118A0000|126 147|hermaphrodite intestine
P01549118A0000|83 92|regulation
P01549118A0000|53 55|sex
P01549123A0480|27 34|sequence
P01549123A0480|56 62|protein
P01549123A0480|3 10|MET4 gene
P01549123A0480|105 114|activators
P01549123A0480|75 80|family
P01549123A0480|86 89|bZIP
P01549125A0140|43 46|IAPP
P01549125A0140|3 11|functions
P01549125A0140|35 41|insulin
P01549125A0140|106 121|DNA binding assays
P01549125A0140|93 102|expression
P01549125A0140|22 29|portions
P01549125A0140|51 65|beta GK promoters
P01549129A0356|75 86|interactions
P01549129A0356|121 123|Src
P01549129A0356|108 118|functioning
P01549129A0356|21 27|domains
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|69 71|DNA
P01549346A0000|24 45|transcription activator
P01549465A0122|87 89|Ser
P01549465A0122|76 81|region
P01549465A0122|52 61|amino acids
P01549465A0122|8 33|transactivation experiments
P01549465A0122|93 95|Val
P01549465A0122|83 85|Gly
P01549465A0122|129 142|discrimination
P01551176A0000|0 7|GR63178A
P01551176A0000|58 71|pyrroloquinone
P01551176A0000|34 44|mitoquidone
P01551176A0000|24 31|analogue
P01551568A1476|0 19|Marker rescue analysis
P01551568A1476|32 34|ts8
P01551568A1476|79 87|Rif domain
P01551568A1476|61 64|rpoB
P01551568A1476|52 58|segment
P01551898A1084|128 140|culture medium
P01551898A1084|116 125|LAPP/liter
P01551898A1084|28 32|yeast
P01551898A1084|99 104|levels
P01551898A1084|4 9|vector
P01551898A1084|63 72|expression
P01551898A1084|112 113|mg
P01551898A1084|90 96|protein
P01551910A0313|0 18|Competition analysis
P01551910A0313|117 136|transcription factors
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|80 90|interaction
P01551910A0978|43 50|sequence
P01551910A0978|4 11|DNA motif
P01552052A0139|117 125|mg/kg/day
P01552052A0139|0 8|OBJECTIVE
P01552052A0139|86 93|patients
P01552052A0139|98 106|psoriasis
P01552052A0139|69 83|serum creatinine
P01552052A0139|56 66|alterations
P01552052A0139|45 53|frequency
P01552052A0139|128 139|cyclosporine
P01552052A0139|13 17|study
P01552457T0000|30 42|periodontitis
P01552457T0000|0 22|Intrapocket chemotherapy
P01552457T0000|86 94|ofloxacin
P01552457T0000|96 100|PT-01
P01552457T0000|70 75|insert
P01552662A0398|15 23|blood flow
P01552662A0398|28 32|probe
P01552662A0398|70 75|artery
P01552662A0398|25 26|BF
P01552662A0398|77 79|LAD
P01552853A1377|58 67|yop regulon
P01552853A1377|44 52|induction
P01552853A1377|5 15|temperature
P01552853A1377|19 22|virF
P01553407T0000|0 7|Problems
P01553407T0000|31 34|area
P01553407T0000|49 62|risk assessment
P01554334A0000|131 139|Committee
P01554334A0000|161 169|Australia
P01554334A0000|20 35|gamma-interferon
P01554334A0000|47 57|assay system
P01554334A0000|81 92|tuberculosis
P01554334A0000|95 100|cattle
P01554334A0000|37 45|IFN-gamma
P01554334A0000|64 72|diagnosis
P01554334A0000|142 152|Agriculture
P01554334A0000|156 158|use
P01555556A0565|0 13|Control Tmuscle
P01555556A0565|69 74|W.kg-1
P01555556A0565|40 48|control Wi
P01555556A0565|27 34|degrees C
P01555556A0565|63 64|SD
P01555556A0565|50 52|max
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|133 142|catabolite
P01556068A0000|146 166|ammonium ion repression
P01556068A0000|91 98|tyramine
P01556068A0000|112 120|compounds
P01556068A0000|62 77|monoamine oxidase
P01556068A0000|51 59|synthesis
P01556111A0241|25 31|plasmid
P01556111A0241|13 19|regions
P01557217A0272|33 39|lesions
P01557217A0272|73 77|h p.i.
P01557411A1282|13 19|D1A gene
P01557411A1282|97 105|promoters
P01557411A1282|32 39|category
P01557411A1282|67 71|genes
P01558942A1369|7 18|observations
P01558942A1369|49 53|genes
P01559209T0000|15 25|CNS students
P01559209T0000|0 12|Preceptorship
P01559209T0000|40 44|study
P01560021A0379|32 42|differences
P01560021A0379|109 115|rat gene
P01560021A0379|21 25|basis
P01560021A0379|63 78|brain AE3 variants
P01560774A0885|14 21|fragment
P01560774A0885|6 7|kb
P01560774A0885|60 67|fliA gene
P01562659A0676|0 10|Institution
P01562659A0676|61 73|amphotericin B
P01562659A0676|123 135|dexamethasone
P01562659A0676|152 161|situations
P01562659A0676|172 182|association
P01562659A0676|198 210|CNS vasculitis
P01562659A0676|277 294|C. immitis infection
P01562659A0676|45 58|administration
P01562659A0676|198 200|CNS
P01562659A0676|185 193|C. immitis
P01562659A0676|213 224|encephalitis
P01562659A0676|45 58|administration
P01562659A0676|263 274|confirmation
P01563343A0548|0 11|Lac operators
P01563343A0548|98 104|control
P01563343A0548|55 65|CAB promoter
P01563343A0548|37 45|positions
P01563343A0548|82 88|plasmid
P01563635T0000|0 13|Overproduction
P01563635T0000|15 26|purification
P01563635T0000|78 91|deletion mutant
P01563635T0000|30 45|characterization
P01563635T0000|48 71|M.HinfI methyltransferase
P01564653A0307|33 36|lens
P01564653A0307|7 15|companies
P01564653A0307|27 30|type
P01565093A0179|98 105|hospital
P01565093A0179|85 88|BLLs
P01565093A0179|17 23|October
P01565093A0179|4 8|March
P01565093A0179|69 83|blood lead levels
P01565093A0179|208 211|ADPH
P01565093A0179|195 206|Public Health
P01565093A0179|136 160|disease surveillance system
P01565093A0179|176 192|Alabama Department
P01565093A0179|37 43|persons
P01565882A0737|151 151|%
P01565882A0737|119 125|RD image
P01565882A0737|54 62|ReI images
P01565882A0737|57 61|image
P01565882A0737|23 37|perfusion defect
P01565882A0737|87 91|types
P01565882A0737|14 20|changes
P01565882A0737|93 96|Type
P01565882A0737|239 240|Ib
P01565882A0737|93 96|Type
P01565882A0737|151 151|%
P01565882A0737|119 125|RD image
P01565882A0737|173 181|subgroups
P01565882A0737|49 50|RD
P01565882A0737|23 38|perfusion defects
P01565882A0737|151 151|%
P01565882A0737|221 222|Ia
P01565882A0737|23 37|perfusion defect
P01566576A0605|0 3|Keck
P01566576A0605|5 8|C.J.
P01567649A0139|134 140|infancy
P01567649A0139|16 16|%
P01567649A0139|18 24|infants
P01567649A0139|47 56|hemorrhage
P01567649A0139|117 126|evaluation
P01567649A0139|92 96|palsy
P01568960A1129|95 107|corner vessels
P01568960A1129|82 90|blood flow
P01568960A1129|67 72|output
P01568960A1129|126 136|VA/Q regions
P01568960A1129|9 17|mechanism
P01568960A1129|40 47|pressure
P01569015A0120|15 19|FRAME
P01569015A0120|83 91|direction
P01569015A0120|21 28|analysis
P01569015A0120|67 70|ORFs
P01569015A0120|83 91|direction
P01569015A0120|53 65|reading frames
P01569102A0708|0 5|Domain
P01569102A0708|57 63|repeats
P01569102A0708|31 41|LDL receptor
P01569102A0708|104 112|cysteines
P01569102A0708|75 86|conservation
P01569344A0404|13 31|HTLV-I/II prevalence
P01569344A0404|58 60|age
P01569344A0404|148 156|Baltimore
P01569344A0404|6 11|cities
P01569344A0404|68 80|New Orleans age
P01569344A0404|22 31|prevalence
P01569344A0404|158 158|P
P01569581A0482|14 21|evidence
P01569581A0482|26 30|model
P01569581A0482|183 212|translation initiation frequency
P01569581A0482|118 126|base-pair
P01569581A0482|92 101|start codon
P01569581A0482|107 110|fold
P01569581A0482|64 74|nucleotides
P01569581A0482|38 41|mRNA
P01569581A0482|135 161|translation initiation region
P01569584A0672|0 16|Hybridization data
P01569584A0672|101 105|6F6.3
P01569584A0672|29 33|6F6.2
P01569584A0672|73 85|m6F6 cDNA clone
P01569584A0672|93 97|6F6.1
P01569584A0672|142 146|genes
P01569584A0672|29 33|6F6.2
P01569945A0529|100 102|kDa
P01569945A0529|3 10|SEN1 gene
P01569945A0529|92 95|mass
P01569945A0529|75 81|protein
P01569945A0529|37 48|reading frame
P01572549A0000|100 107|products
P01572549A0000|0 21|Protein tyrosine kinases
P01572549A0000|145 161|signal transducers
P01572549A0000|67 72|virtue
P01572549A0000|55 64|cell growth
P01572549A0000|46 52|control
P01572549A0000|120 128|oncogenes
P01572549A0000|168 188|growth factor receptors
P01572549A0000|23 26|PTKs
P01572549A0000|191 200|components
P01572549A0000|88 97|appearance
P01573270A0000|69 80|immunization
P01573270A0000|28 33|series
P01573270A0000|3 8|IA4 mAb
P01573270A0000|54 63|BALB/c mice
P01573270A0000|136 138|LAK
P01573270A0000|152 170|EBV-B lymphocyte line
P01573270A0000|89 96|HLA class
P01573270A0000|129 134|killer
P01573270A0000|36 45|antibodies
P01577056A0178|60 71|theophylline
P01577056A0178|83 85|day
P01577056A0178|121 127|placebo
P01577056A0178|169 181|washout period
P01577056A0178|137 143|periods
P01577056A0178|35 39|study
P01577056A0178|90 99|omeprazole
P01577056A0178|44 51|subjects
P01577056A0178|73 74|mg
P01577056A0178|73 79|mg.kg-1
P01577056A0178|152 155|days
P01577056A0178|83 85|day
P01577056A0178|152 155|days
P01577740A1111|0 14|Primer extension
P01577740A1111|29 45|S1 nuclease mapping
P01577740A1111|18 25|mung bean
P01577740A1111|112 127|Northern analyses
P01577740A1111|63 90|transcription initiation sites
P01577819A0709|59 64|number
P01577819A0709|67 73|repeats
P01577819A0709|10 29|PRP-precursor alleles
P01577819A0709|76 83|domain C.
P01579472A1018|76 81|manner
P01579472A1018|16 30|enhancer element
P01579472A1018|36 41|region
P01579537A0000|31 34|uses
P01579537A0000|59 68|neurotoxin
P01579537A0000|37 50|botulinum toxin
P01579537A0000|11 15|years
P01580738T0001|0 8|Allagille
P01580738T0001|11 18|syndrome
P01580738T0001|42 48|ascites
P01581409A0398|101 107|results
P01581409A0398|0 10|Sensitivity
P01581409A0398|87 96|comparison
P01581409A0398|14 24|specificity
P01581409A0398|69 84|DPC AlaSTAT System
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|122 125|test
P01581409A0398|113 116|skin
P01581577A1186|0 4|PSI-G
P01581577A1186|37 40|gene
P01581577A1186|8 12|PSI-K
P01581577A1186|37 51|gene duplication
P01581965A0388|30 35|domain
P01581965A0388|182 192|GAP activity
P01581965A0388|5 14|C-terminus
P01581965A0388|120 129|n-chimerin
P01581965A0388|48 56|sequences
P01581965A0388|20 26|protein
P01581965A0388|134 139|rho GAP
P01581965A0388|85 118|breakpoint cluster region gene product
P01581965A0388|200 206|GTPases
P01582413A0192|173 182|DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0192|85 90|region
P01582413A0192|135 140|domain
P01582413A0192|108 114|helices
P01582413A0192|54 63|amino acids
P01582413A0192|39 46|clusters
P01582413A0192|13 23|mutagenesis
P01582413A0759|0 11|Dimerization
P01582413A0759|14 18|Myf-5
P01582413A0759|51 60|protein E12
P01582413A0759|111 125|transactivation
P01582413A0759|80 87|affinity
P01582413A0759|91 93|DNA
P01582413A0759|141 150|DNA binding
P01582500A0178|25 29|sleep
P01582500A0178|12 22|rhythmicity
P01583819A0377|57 58|Hz
P01583819A0377|0 2|SEA
P01583819A0377|46 47|HZ
P01583819A0377|31 37|filters
P01583819A0377|64 75|Simson method
P01584812T0000|15 24|expression
P01584812T0000|100 124|transcription factor NGFI-C
P01584812T0000|74 77|gene
P01584812T0000|33 41|structure
P01584812T0000|57 68|localization
P01585014A0000|347 350|I.U.
P01585014A0000|233 236|days
P01585014A0000|2 11|experiment
P01585014A0000|67 73|hormone
P01585014A0000|23 28|effect
P01585014A0000|392 419|mg follicle stimulating hormone
P01585014A0000|277 280|time
P01585014A0000|134 139|season
P01585014A0000|331 341|combination
P01585014A0000|283 291|ovulation
P01585014A0000|23 29|effects
P01585014A0000|382 385|PMSG
P01585014A0000|78 91|micrograms GnRH
P01585014A0000|119 131|sponge removal
P01585014A0000|203 212|lupin grain
P01585014A0000|32 40|treatment
P01585014A0000|421 425|FSH-P
P01585014A0000|32 40|treatment
P01585014A0000|160 165|spring
P01585014A0000|359 380|mare serum gonadotrophin
P01585014A0000|21 21|h
P01585014A0000|152 157|autumn
P01585014A0000|303 312|Merino ewes
P01585014A0000|233 236|days
P01585014A0000|45 57|gonadotrophin
P01585014A0000|108 131|progestagen sponge removal
P01585014A0000|152 157|autumn
P01586901A0000|117 122|window
P01586901A0000|43 50|patients
P01586901A0000|86 90|drugs
P01586901A0000|9 20|interactions
P01586901A0000|68 78|medications
P01587267A1144|87 92|enzyme
P01587267A1144|73 81|structure
P01587267A1144|99 105|cloning
P01587267A1144|3 14|sequence data
P01587267A1144|135 138|gene
P01587267A1144|109 118|expression
P01587267A1144|33 46|interpretation
P01587267A1144|52 56|X-ray
P01587267A1144|166 176|mutagenesis
P01587763A0402|61 66|scheme
P01587763A0402|86 87|hr
P01587763A0402|71 79|fractions
P01587763A0402|5 19|body irradiation
P01587763A0402|108 111|days
P01587763A0402|93 95|day
P01588270A1029|95 96|.9
P01588270A1029|1 9|reduction
P01588270A1029|124 126|DBP
P01588270A1029|45 47|end
P01588270A1029|53 57|study
P01588270A1029|103 106|mmHg
P01588270A1029|108 108|P
P01588270A1029|12 24|blood pressure
P01588315A0356|204 207|maps
P01588315A0356|0 5|AgMNPV
P01588315A0356|131 137|viruses
P01588315A0356|59 75|promoter structure
P01588315A0356|33 38|OpMNPV
P01588315A0356|96 103|sequence
P01588315A0356|181 188|relation
P01588315A0356|79 88|polyhedrin
P01588315A0356|170 178|direction
P01588315A0356|111 124|polyhedrin gene
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|52 56|terms
P01588913A0000|127 134|P. putida
P01588913A0000|1 4|gene
P01588913A0000|81 93|transcription
P01588913A0000|35 42|dnaA gene
P01588961A0000|0 3|STP1
P01588961A0000|41 47|removal
P01588961A0000|19 27|yeast gene
P01588961A0000|89 96|families
P01588961A0000|61 69|sequences
P01588961A0000|129 137|pre-tRNAs
P01588963A1153|42 51|conditions
P01588963A1153|10 19|antibodies
P01588963A1153|77 88|Cdc25 protein
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|49 62|gene expression
P01589576A0170|144 145|T3
P01589576A0170|107 108|ns
P01589576A0170|87 96|components
P01589576A0170|101 113|time constants
P01589576A0170|3 13|decay curves
P01589576A0170|46 58|superposition
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|126 127|ps
P01589576A0170|126 127|ps
P01589576A0170|129 130|T2
P01589576A0170|116 117|T1
P01592545A0726|26 26|p
P01592545A0726|54 61|patients
P01592545A0726|21 33|blood pressure
P01592545A0726|54 61|patients
P01592545A0726|51 51|%
P01592545A0726|40 46|average
P01592545A0726|51 51|%
P01594554A0845|129 136|function
P01594554A0845|41 43|CCK
P01594554A0845|32 36|roles
P01594554A0845|94 108|feedback control
P01594554A0845|5 11|results
P01594554A0845|47 63|trypsin inhibitors
P01596007A0908|30 35|Stages
P01596007A0908|57 66|proportion
P01596007A0908|225 229|WORDS
P01596007A0908|83 89|gamma OH
P01596007A0908|83 94|gamma OH study
P01596007A0908|203 210|ABSTRACT
P01596007A0908|106 106|%
P01596007A0908|46 48|REM
P01596007A0908|187 189|SWS
P01596007A0908|121 134|control studies
P01596007A0908|10 15|events
P01596007A0908|106 106|%
P01597170A0000|82 88|group Co
P01597170A0000|191 196|hr/day
P01597170A0000|34 41|mg/m3 Co2
P01597170A0000|5 11|rabbits
P01597170A0000|34 41|mg/m3 Co2
P01597170A0000|62 69|mg/m3 Cr3
P01597170A0000|177 185|days/week
P01597170A0000|147 149|air
P01597170A0000|67 68|Cr
P01597170A0000|151 162|control group
P01597170A0000|67 68|Cr
P01597170A0000|76 78|NO3
P01597170A0000|45 49|CoCl2
P01597170A0000|82 88|group Co
P01597170A0000|169 174|months
P01597272A0077|40 57|withdrawal symptoms
P01597272A0077|2 6|women
P01597272A0077|22 30|methadone
P01597462A0457|44 47|gene
P01597462A0457|0 9|Disruption
P01597462A0457|26 30|CDC14
P01600531A0483|26 26|%
P01600531A0483|8 11|flow
P01600531A0483|32 46|phosphocreatine
P01600531A0483|60 71|control group
P01600531A0483|26 26|%
P01601181A0842|82 89|mesoderm
P01601181A0842|3 16|60A transcripts
P01601181A0842|55 66|gastrulation
P01601181A0842|48 52|onset
P01601181A0842|20 26|protein
P01601181A0842|104 111|germ band
P01601869A1389|59 63|E-box
P01601869A1389|150 159|activation
P01601869A1389|30 35|region
P01601869A1389|175 188|BC3H1 myoblasts
P01601869A1389|7 13|segment
P01601869A1389|30 35|region
P01603088A1121|45 46|TR
P01603088A1121|5 11|results
P01603088A1121|113 118|manner
P01603088A1121|83 92|repression
P01603088A1121|70 79|activation
P01605038T0001|0 8|Influence
P01605038T0001|59 62|rats
P01605038T0001|44 50|effects
P01605038T0001|17 26|regulation
P01605038T0001|53 56|GABA
P01607223A0000|145 153|liposomes
P01607223A0000|177 187|vasculature
P01607223A0000|69 73|pulse
P01607223A0000|45 51|release
P01607223A0000|45 60|release technique
P01607223A0000|6 19|investigations
P01607223A0000|76 85|laser light
P01608239T0001|13 20|barriers
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|64 88|Albizzia julibrissin DURAZZ
P01611699A0000|54 61|stem bark
P01612085A0624|65 70|U.ml-1
P01612085A0624|3 21|serum erythropoietin
P01612085A0624|24 24|P
P01612085A0624|49 59|triathletes
P01612085A0624|111 125|distance runners
P01612085A0624|23 25|EPO
P01612085A0624|27 40|concentrations
P01612085A0624|65 70|U.ml-1
P01613640A0158|3 18|coating materials
P01613640A0158|66 74|poloxamer
P01613640A0158|23 32|poloxamine
P01613640A0158|23 32|poloxamine
P01613640A0158|82 85|Brij
P01613640A0158|23 32|poloxamine
P01615049A0000|3 8|eating
P01615049A0000|43 47|ad lib
P01615049A0000|60 69|h light/12 h
P01615049A0000|35 39|goats
P01615049A0000|74 78|cycle
P01615049A0000|12 27|drinking patterns
P01615182A0206|102 103|mg
P01615182A0206|47 51|amoxy
P01615182A0206|41 57|sputum amoxycillin
P01615182A0206|28 38|improvement
P01615182A0206|102 103|mg
P01615182A0206|108 118|bromhexeine
P01615182A0206|47 51|amoxy
P01615182A0206|47 51|amoxy
P01615182A0206|76 92|combination tablet
P01615182A0206|10 14|study
P01615182A0206|102 103|mg
P01615182A0206|65 70|levels
P01615493A0408|3 4|HC
P01615493A0408|37 37|%
P01615493A0408|18 30|antigen levels
P01615493A0408|25 30|levels
P01615493A0408|64 71|daughter
P01615493A0408|7 14|activity
P01615493A0408|37 37|%
P01615493A0975|0 9|Argatroban
P01615493A0975|98 102|sites
P01615493A0975|40 49|conditions
P01615493A0975|80 95|thrombin activity
P01615493A0975|68 77|inhibition
P01615493A0975|36 37|HC
P01615493A0975|113 122|wall damage
P01616475A0756|86 98|family history
P01616475A0756|54 61|patients
P01616475A0756|42 45|NFPD
P01616475A0756|5 11|results
P01616475A0756|32 39|validity
P01616475A0756|54 61|patients
P01616475A0756|48 61|CP/NCA patients
P01616475A0756|149 173|panic disorder presentation
P01616475A0756|101 113|panic disorder
P01617242T0000|0 13|FDA regulations
P01617242T0000|17 29|growth factors
P01617242T0000|40 47|products
P01617776A0343|27 32|system
P01617776A0343|74 83|infarction
P01617776A0343|74 83|infarction
P01617776A0343|128 132|heart
P01617776A0343|151 154|role
P01617776A0343|112 122|innervation
P01617776A0343|128 132|heart
P01617776A0343|50 60|arrhythmias
P01617776A0343|210 213|days
P01617776A0343|186 192|reentry
P01617776A0343|27 32|system
P01617801A0088|0 5|DESIGN
P01617801A0088|98 106|captopril
P01617801A0088|82 88|minutes
P01617801A0088|57 62|supine
P01617801A0088|7 22|Serum aldosterone
P01617801A0088|110 111|mg
P01617801A0088|26 44|plasma renin activity
P01618027A1108|14 24|transcripts
P01618027A1108|131 136|probes
P01618027A1108|148 156|remainder
P01618027A1108|168 173|region
P01618027A1108|34 37|size
P01618027A1108|67 73|profile
P01618027A1108|104 114|E10 fragment
P01618243T0000|37 46|volunteers
P01618243T0000|11 27|amine pressor tests
P01618256A0521|61 74|micrograms.l-1
P01618256A0521|61 74|micrograms.l-1
P01618256A0521|3 6|mean
P01618256A0521|51 56|regime
P01618256A0521|81 81|%
P01618256A0521|51 57|regimen
P01618256A0521|26 38|concentration
P01619114A0383|67 85|Mini Speech Processor
P01619114A0383|35 38|SMSP
P01619114A0383|19 29|performance
P01619114A0383|36 38|MSP
P01619114A0383|11 15|study
P01619642A0131|4 10|parents
P01620118A0470|179 185|chicken
P01620118A0470|59 63|kappa
P01620118A0470|30 36|ability
P01620118A0470|194 198|cells
P01620118A0470|89 98|activation
P01620118A0470|142 147|repeat
P01620118A0470|109 129|immunodeficiency virus
P01620118A0470|11 18|proteins
P01620129A0417|144 145|J.
P01620129A0417|71 85|promoter element
P01620129A0417|20 30|interaction
P01620129A0417|138 142|cells
P01620129A0417|105 113|cell cycle
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|40 51|factor HiNF-D
P01620610A1070|159 167|sequences
P01620610A1070|2 11|conclusion
P01620610A1070|172 175|rule
P01620610A1070|185 196|MTI subregion
P01620610A1070|45 62|expression problems
P01620610A1070|31 32|TI
P01620610A1070|127 135|mutations
P01620610A1070|101 106|vector
P01620781A0611|147 153|stimuli
P01620781A0611|121 128|reversal
P01620781A0611|200 206|members
P01620781A0611|174 181|position
P01620781A0611|113 114|A5
P01620781A0611|66 72|control
P01620781A0611|95 96|B2
P01620781A0611|89 90|A1
P01620781A0611|15 22|subjects
P01620781A0611|41 49|sequences
P01620781A0611|101 102|A3
P01620781A0611|216 220|class
P01620781A0611|41 48|sequence
P01620781A0611|78 82|words
P01620781A0611|107 108|B4
P01621584A0183|0 5|UF-021
P01621584A0183|118 121|mmHg
P01621584A0183|16 23|solution
P01621584A0183|97 108|IOP reduction
P01621584A0183|69 75|rabbits
P01621584A0183|35 35|%
P01621584A0183|63 66|eyes
P01621584A0183|140 146|IOP rise
P01623900A0670|87 95|excretion
P01623900A0670|232 250|norepinephrine level
P01623900A0670|34 41|activity
P01623900A0670|5 17|blood pressure
P01623900A0670|314 329|dF administration
P01623900A0670|263 285|norepinephrine excretion
P01623900A0670|65 76|plasma levels
P01623900A0670|165 170|supine
P01623900A0670|191 204|blood pressures
P01623900A0670|98 111|norepinephrine
P01623900A0670|136 142|Pl group
P01623900A0670|156 159|drop
P01623900A0670|307 311|month
P01623900A0670|53 59|changes
P01624425A0907|67 85|consensus amino acids
P01624425A0907|49 61|substitutions
P01624425A0907|9 15|protein
P01624425A0907|38 44|mutants
P01624425A0907|21 29|azido-ATP
P01625131A0452|28 36|stoma site
P01625131A0452|15 20|biopsy
P01625131A0452|63 71|rejection
P01625131A0452|45 48|risk
P01625527A0000|166 189|maintenance haemodialysis
P01625527A0000|5 24|blood serotonin levels
P01625527A0000|16 16|n
P01625527A0000|16 16|n
P01625527A0000|87 101|failure patients
P01625527A0000|16 16|n
P01625527A0000|51 55|group
P01625527A0000|209 223|transplantation
P01625527A0000|44 55|control group
P01625527A0000|118 133|treatment regimen
P01625527A0000|16 16|n
P01625527A0000|118 126|treatment
P01625527A0000|16 16|n
P01626372T0000|0 6|Tissues
P01626372T0000|47 52|growth
P01626372T0000|97 102|levels
P01626372T0000|35 43|thymidine
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626372T0000|10 17|exudates
P01626372T0000|64 71|bacteria
P01626372T0000|77 84|presence
P01626430A1112|87 91|yeast
P01626430A1112|3 12|homologies
P01626430A1112|20 24|RAD16
P01626430A1112|95 109|Drosophila genes
P01626430A1112|34 37|SNF2
P01626430A1112|26 30|RAD54
P01626440A0449|28 50|instrument disinfectants
P01626440A0449|79 81|day
P01626440A0449|6 25|application solutions
P01626631A0557|145 153|elevation
P01626631A0557|45 56|disturbances
P01626631A0557|5 16|Rett syndrome
P01626631A0557|123 128|system
P01626631A0557|168 172|level
P01626631A0557|62 70|brain stem
P01627106A0320|134 151|isolation frequency
P01627106A0320|63 64|S.
P01627106A0320|63 84|S. enteritidis challenge
P01627106A0320|33 59|nitrofurazone administration
P01627106A0320|108 118|differences
P01627106A0320|10 19|experiment
P01627828A0475|27 34|blotting
P01627828A0475|2 10|agreement
P01627828A0475|49 57|SmN probes
P01627828A0475|65 69|bands
P01627828A0475|156 162|SmN gene
P01627828A0475|102 111|pseudogene
P01627828A0475|37 44|mouse DNA
P01627830A0000|83 86|CKI2
P01627830A0000|16 29|casein kinase-1
P01627830A0000|3 7|cDNAs
P01627830A0000|76 79|CKI1
P01627830A0000|51 66|yeast cDNA library
P01628201A0824|0 12|Incidence rate
P01628201A0824|72 78|minimum
P01628201A0824|39 42|year
P01628201A0824|39 42|year
P01628201A0824|95 102|datasets
P01628806A1347|99 112|helicase region
P01628806A1347|44 46|ORF
P01628806A1347|44 46|ORF
P01628806A1347|53 53|Y
P01628806A1347|11 27|sequence variation
P01628904A0386|42 49|kilobase
P01628904A0386|54 59|insert
P01628904A0386|8 16|screening
P01628904A0386|51 52|kb
P01628904A0386|25 29|clone
P01629768A0131|0 6|Lesions
P01629768A0131|42 45|acid
P01629768A0131|53 55|SOC
P01629768A0131|17 33|pressure injection
P01629768A0131|89 105|glass micropipette
P01630454A0635|44 52|regulator
P01630454A0635|17 22|region
P01630454A0635|55 74|Act1 promoter activity
P01630454A0635|6 9|poly
P01630454A0635|11 15|dA-dT
P01630455A0448|13 19|protein
P01630455A0448|27 37|NFIL-1 beta A
P01630455A0448|80 90|DNA sequence
P01630455A0448|121 132|TATA box motif
P01630455A0448|156 168|IL-1 beta genes
P01630455A0448|39 45|NF beta A
P01630569A0605|29 37|remission
P01630569A0605|43 47|tumor
P01630569A0605|21 23|AmB
P01630569A0605|7 19|amphotericin B
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|119 125|Gossett
P01633435A0743|15 21|protein
P01633435A0743|3 7|DRF-2
P01633435A0743|97 102|Buskin
P01633435A0743|84 89|factor
P01633435A0743|106 113|Hauschka
P01633435A0743|91 95|MEF-2
P01633435A0743|25 39|characteristics
P01633816A0667|56 60|exons
P01633816A0667|183 199|S1 nuclease mapping
P01633816A0667|95 101|opn gene
P01633816A0667|157 179|primer extension analysis
P01633816A0667|10 11|kb
P01633816A0667|136 144|start site
P01633816A0667|22 34|EcoRI fragment
P01633816A0667|84 89|region
P01633816A0667|12 16|clone
P01634308A0191|0 24|Cardiovascular risk factors
P01634308A0191|51 60|techniques
P01634400A1101|0 14|Production costs
P01634400A1101|36 44|operating
P01634400A1101|23 26|feed
P01634400A1101|55 75|replacement stock costs
P01634464A0163|96 99|rise
P01634464A0163|55 62|reaction
P01634464A0163|107 117|haemorrhage
P01634464A0163|65 88|penicillin administration
P01634464A0163|9 15|patient
P01634464A0163|26 43|factor VII inhibitor
P01634861A1336|86 101|lactate clearance
P01634861A1336|33 42|oxygen debt
P01634861A1336|33 52|oxygen debt hypothesis
P01634861A1336|8 15|contrast
P01636339A0200|0 6|Account
P01636339A0200|132 136|fungi
P01636339A0200|71 75|mucus
P01636339A0200|120 128|fragments
P01636339A0200|100 111|pollen grains
P01636339A0200|91 98|crystals
P01636339A0200|39 46|elements
P01636339A0200|52 57|smears
P01636714A0845|143 145|CLP
P01636714A0845|99 104|serosa
P01636714A0845|3 9|results
P01636714A0845|67 72|cortex
P01636714A0845|56 60|liver
P01636714A0845|1 1|h
P01636714A0845|48 50|MBF
P01636714A0845|48 50|MBF
P01636714A0845|40 44|areas
P01636714A0845|74 79|spleen
P01637758A0532|2 9|addition
P01637758A0532|138 138|%
P01637758A0532|30 34|women
P01637758A0532|161 163|% CI
P01637758A0532|65 74|dilatation
P01637758A0532|152 153|OR
P01637758A0532|176 176|P
P01637758A0532|18 27|proportion
P01637758A0532|103 113|examination
P01637758A0532|48 52|group
P01637758A0532|78 79|cm
P01637758A0532|119 128|labour ward
P01637758A0532|138 138|%
P01639092A0776|0 4|Lewis
P01639092A0776|6 7|N.
P01639724A0452|1 12|control group
P01639724A0452|19 23|women
P01639724A0452|45 58|contraceptives
P01639724A0452|33 37|years
P01639724A0452|60 70|Nordette-28
P01639724A0452|102 110|pill cycle
P01639724A0452|90 94|times
P01639724A0452|25 27|age
P01640778A0485|20 25|method
P01640778A0485|34 41|MLPA test
P01640778A0485|76 84|screening
P01641628A0869|68 73|groups
P01641628A0869|3 12|modalities
P01641628A0869|21 35|reference values
P01641628A0869|21 35|reference values
P01641628A0869|49 56|subjects
P01641628A0869|108 115|research
P01641628A0869|100 105|points
P01642060A0471|73 80|patients
P01642060A0471|44 57|Phthalocyanine
P01642060A0471|121 127|FIGO III
P01642060A0471|111 119|carcinoma
P01642060A0471|11 21|application
P01643943A0300|55 57|TFR
P01643943A0300|38 41|67Ga
P01643943A0300|11 27|lung cancer tissues
P01644751A0590|100 114|msgB gene product
P01644751A0590|8 19|reading frame
P01644751A0590|67 82|sequence analysis
P01644796A0374|6 10|study
P01644796A0374|75 80|medium
P01644796A0374|88 92|cells
P01644796A0374|52 56|furin
P01644814A0068|72 77|T cells
P01644814A0068|3 7|virus
P01644814A0068|30 32|tax
P01644814A0068|55 69|immortalization
P01644814A0068|22 28|protein
P01644821A1259|219 234|butyrate response
P01644821A1259|58 68|CAT activity
P01644821A1259|71 81|fusion genes
P01644821A1259|100 108|sequences
P01644821A1259|100 108|sequences
P01644821A1259|8 15|butyrate
P01644821A1259|195 204|PSG1-I gene
P01644821A1259|183 189|regions
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|99 108|accordance
P01644831A0824|2 12|examination
P01644831A0824|135 141|mutants
P01644831A0824|149 156|portions
P01644831A0824|55 60|NGFI-B
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|18 21|role
P01644831A0824|76 83|activity
P01644831A0824|125 133|receptors
P01644831A0824|76 83|activity
P01645902A1462|114 115|TK
P01645902A1462|83 88|region
P01645902A1462|139 149|syn mutation
P01645902A1462|119 120|UL
P01645902A1462|166 175|expression
P01645902A1462|37 39|Syn
P01645902A1462|114 115|TK
P01645902A1462|63 66|gene
P01645902A1462|15 21|results
P01645902A1462|41 45|locus
P01645902A1462|178 185|activity
P01645902A1462|63 67|genes
P01645902A1462|77 78|gH
P01645902A1462|101 108|portions
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|88 89|Mr
P01645905A0341|42 54|vaccinia virus
P01645905A0341|118 128|degradation
P01645905A0341|160 176|breakdown products
P01645905A0341|134 143|C-terminus
P01645905A0341|83 86|mass
P01645905A0341|58 61|TGEV
P01645905A0341|0 0|N
P01646157A0414|88 97|nucleotide
P01646157A0414|29 52|alpha-GalNAc cDNA sequence
P01646157A0414|187 196|alpha-Gal A
P01646157A0414|110 126|amino acid homology
P01646157A0414|41 44|cDNA
P01646157A0414|139 139|%
P01646157A0414|166 185|alpha-galactosidase A
P01646487A0874|0 7|Patients
P01646487A0874|85 85|T
P01646487A0874|23 30|activity
P01646487A0874|81 83|IgM
P01646487A0874|36 36|X
P01646487A0874|64 70|content
P01646487A0874|89 100|B lymphocytes
P01646487A0874|127 137|neutrophils
P01646487A0874|73 75|IgA
P01646487A0874|23 30|activity
P01646487A0874|77 79|IgG
P01646487A0874|23 30|activity
P01646487A0874|150 157|patients
P01646487A0874|51 58|decrease
P01646753A0336|3 8|reason
P01646753A0336|20 24|oxide
P01646753A0336|184 185|V.
P01646753A0336|170 176|N2O/N2O
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|88 104|reduction proceeds
P01646753A0336|167 168|EO
P01646753A0336|114 116|N2O
P01647070A0232|9 11|JCV
P01647070A0232|47 60|DNA replication
P01647070A0232|34 44|SV40 origins
P01647070A0232|9 20|JCV T antigens
P01647656A0000|175 187|regurgitation
P01647656A0000|43 50|receptor
P01647656A0000|3 10|relation
P01647656A0000|73 80|function
P01647656A0000|135 150|LV volume overload
P01647656A0000|95 102|patients
P01647656A0000|70 71|LV
P01647656A0000|114 118|years
P01647813A0512|41 47|protein
P01647813A0512|135 144|expression
P01647813A0512|126 132|control
P01647813A0512|9 18|transcript
P01647813A0512|53 62|complexity
P01647813A0512|76 79|need
P01648142A1170|108 108|P
P01648142A1170|2 9|patients
P01648142A1170|32 39|survival
P01648142A1170|56 58|arm
P01648142A1170|108 108|P
P01648142A1170|21 27|disease
P01648142A1170|133 137|PE arm
P01648142A1170|32 39|survival
P01648142A1170|32 39|survival
P01648142A1170|101 106|CAV arm
P01648530A0000|14 20|M region
P01648530A0000|42 48|Xenopus
P01648530A0000|184 187|eggs
P01648530A0000|56 72|actin gene promoter
P01648530A0000|133 161|actin-beta-globin reporter gene
P01648530A0000|113 122|expression
P01649173A0160|72 82|nucleotides
P01649173A0160|2 9|addition
P01649173A0160|72 82|nucleotides
P01649173A0160|51 60|attenuator
P01649173A0160|109 130|transcription start site
P01649173A0160|51 60|attenuator
P01649173A0160|51 60|attenuator
P01649318A0734|0 5|EBNA-2
P01649318A0734|22 32|CD23 element
P01649318A0734|74 123|herpes simplex virus TK promoter transcription start site
P01649318A0734|53 56|mRNA
P01649318A1222|5 15|experiments
P01649318A1222|126 134|cell genes
P01649318A1222|111 123|transcription
P01649318A1222|50 64|cell DNA fragment
P01649318A1222|79 86|evidence
P01649318A1222|33 38|EBNA-2
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|29 49|myeloperoxidase levels
P01649539T0000|20 25|lipids
P01649539T0000|62 68|surgery
P01649835A0822|97 104|affinity
P01649835A0822|71 78|increase
P01649835A0822|154 161|Ro5-4864
P01649835A0822|84 90|density
P01649835A0822|42 51|COS-7 cells
P01649835A0822|116 127|binding sites
P01649835A0822|97 104|affinity
P01649835A0822|109 110|PK
P01649835A0822|106 107|3H
P01649835A0822|27 37|PBR/IBP cDNA
P01650524A0837|146 151|A63162
P01650524A0837|87 90|dose
P01650524A0837|116 138|5-LO inhibitors phenidone
P01650524A0837|188 197|colchicine
P01650524A0837|173 185|dexamethasone
P01650524A0837|61 66|cavity
P01650524A0837|70 83|LTB4 production
P01650524A0837|140 144|BW A4C
P01650524A0837|34 45|permeability
P01650524A0837|10 14|phase
P01650524A0837|156 158|ICI
P01650557T0000|99 114|transplant donors
P01650557T0000|49 58|assessment
P01650557T0000|22 43|latex agglutination test
P01650557T0000|10 16|results
P01650557T0000|61 89|cytomegalovirus antibody status
P01651232A0152|85 87|UTP
P01651232A0152|4 7|mRNA
P01651232A0152|91 98|thio-UTP
P01651232A0152|34 48|uridine residues
P01651232A0152|76 82|mixture
P01651918A0000|151 164|bisphosphatase
P01651918A0000|99 127|rat testis fructose-6-phosphate
P01651918A0000|138 147|fructose-2
P01651918A0000|80 96|amino acid sequence
P01651918A0000|40 52|cDNA fragments
P01651918A0000|131 136|kinase
P01652372A0153|29 46|localization signal
P01652372A0153|100 104|entry
P01652372A0153|16 19|SWI5
P01652372A0153|120 126|protein
P01652372A0153|48 50|NLS
P01652372A0153|74 77|cell
P01652515A0379|119 120|DA
P01652515A0379|89 103|microinjections
P01652515A0379|2 9|contrast
P01652515A0379|35 55|avoidance conditioning
P01652515A0379|22 30|deviation
P01652515A0379|129 133|level
P01652515A0379|143 153|neostriatum
P01652515A0379|65 75|haloperidol
P01652755A1492|214 222|promoters
P01652755A1492|119 120|RB
P01652755A1492|43 51|HeLa cells
P01652755A1492|276 278|MHC
P01652755A1492|18 40|transfection experiments
P01652755A1492|214 222|promoters
P01652755A1492|155 158|IL-6
P01652755A1492|79 117|retinoblastoma susceptibility gene product
P01652755A1492|171 175|c-fos
P01652755A1492|155 158|IL-6
P01652755A1492|53 66|overexpression
P01652755A1492|191 200|beta-actin
P01653173A0619|215 234|preinitiation complex
P01653173A0619|201 209|formation
P01653173A0619|143 168|HPV-18 P105 promoter template
P01653173A0619|85 103|P105 promoter TATA box
P01653173A0619|183 189|extract
P01653173A0619|4 13|repression
P01653173A0619|57 60|site
P01653173A0619|44 45|E2
P01653173A0619|32 38|binding
P01653173A0619|125 137|preincubation
P01653236A0895|40 61|glucocorticoid receptor
P01653236A0895|14 16|p50
P01653236A0895|40 61|glucocorticoid receptor
P01653236A0895|64 69|L cells
P01653236A0895|19 29|association
P01653236A0895|123 139|hamster ovary cells
P01653238A1062|222 235|promoter region
P01653238A1062|163 178|growth factor beta
P01653238A1062|104 126|transcription factor AP-1
P01653238A1062|61 67|element
P01653238A1062|49 51|TPA
P01653238A1062|53 68|response elements
P01653238A1062|181 188|TGF-beta
P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|131 147|consensus sequence
P01653238A1062|93 97|sites
P01653238A1715|0 2|TPA
P01653238A1715|6 13|TGF-beta
P01653238A1715|59 64|enzyme
P01653238A1715|38 47|activities
P01653918A0286|70 76|corneas
P01653918A0286|32 39|pressure
P01653918A0286|56 61|cornea
P01653918A0286|80 87|strength
P01653918A0286|105 124|corneal pain threshold
P01654349A0327|33 33|K
P01654349A0327|0 9|Feed intake
P01654349A0327|38 43|NaHCO3
P01654349A0327|33 35|KCl
P01654349A0327|75 78|gain
P01654349A0327|38 58|NaHCO3 supplementation
P01655126T0000|0 18|Extraction procedure
P01655126T0000|87 89|HBr
P01655126T0000|67 73|tissues
P01655126T0000|94 102|tropolone
P01655126T0000|25 35|measurement
P01655126T0000|79 85|toluene
P01655126T0000|38 54|butyltin compounds
P01655713A0294|25 30|region
P01655713A0294|95 97|Tn1
P01655713A0294|69 77|phenotype
P01655713A0294|6 10|study
P01655713A0294|95 97|Tn1
P01655713A0294|80 85|strain
P01655713A0294|125 132|mutation
P01655713A0294|89 92|exs1
P01656220T0000|0 2|axl
P01656220T0000|17 20|gene
P01656220T0000|79 100|receptor tyrosine kinase
P01656220T0000|52 64|leukemia cells
P01656221A1319|103 118|tyrosine residues
P01656221A1319|14 31|amino acid sequences
P01656221A1319|0 8|Alignment
P01656221A1319|43 49|Tyr-766
P01656221A1319|67 73|regions
P01656221A1319|81 85|FGFRs
P01656221A1319|141 150|FGFR family
P01656221A1319|129 135|members
P01656235A0946|83 92|CCAAT motif
P01656235A0946|47 54|analysis
P01656235A0946|22 28|element
P01656235A0946|64 69|region
P01656675A0236|0 16|Capnography curves
P01656675A0236|24 31|patients
P01656675A0236|21 31|HVS patients
P01656675A0236|68 77|complaints
P01656675A0236|90 97|controls
P01657246A0325|3 29|transcription initiation site
P01657246A0325|77 79|Met
P01657246A0325|52 53|bp
P01657249A1019|115 131|region determinant
P01657249A1019|38 40|VH4
P01657249A1019|18 19|CA
P01657249A1019|18 19|CA
P01657249A1019|46 51|chains
P01657249A1019|139 146|VH4-HV2a
P01657249A1019|38 40|VH4
P01657415A0837|0 13|Intron K1 cox1.2
P01657415A0837|68 75|K. lactis
P01657415A0837|58 65|location
P01657594A0472|71 74|cgs1
P01657594A0472|79 82|cgs2
P01657594A0472|39 59|complementation groups
P01657594A0472|23 29|mutants
P01657969A1420|134 139|enzyme
P01657969A1420|123 128|change
P01657969A1420|48 59|interactions
P01657969A1420|8 18|alterations
P01657969A1420|77 98|amino acid substitutions
P01657969A1420|157 173|calmodulin binding
P01658356A1369|87 92|FeLV-C
P01658356A1369|117 129|3201B cell line
P01658356A1369|161 166|levels
P01658356A1369|3 9|results
P01658356A1369|55 64|generation
P01658356A1369|19 30|coexpression
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|192 196|mRNAs
P01658356T0000|116 122|viruses
P01658356T0000|101 110|activities
P01658356T0000|0 12|Recombination
P01658356T0000|50 50|C
P01658356T0000|26 47|leukemia virus subgroup B
P01658356T0000|64 74|env elements
P01658375A0854|119 123|genes
P01658375A0854|197 215|consensus sequence GT
P01658375A0854|3 21|nucleotide sequences
P01658375A0854|183 184|GC
P01658375A0854|172 180|LAT intron
P01658375A0854|34 37|ends
P01658375A0854|78 88|transcripts
P01658375A0854|45 51|introns
P01658375A0854|143 152|difference
P01658375A0854|34 36|end
P01658468A0123|68 75|hamsters
P01658468A0123|39 49|C. kutscheri
P01658468A0123|114 120|culture
P01658468A0123|96 103|attempts
P01658468A0123|28 36|isolation
P01658468A0123|148 152|sites
P01658468A0123|61 66|cavity
P01658468A0123|10 15|months
P01658741A1047|97 101|locus
P01658741A1047|3 10|strategy
P01658741A1047|47 64|nucleotide sequence
P01658741A1047|93 95|ADE
P01658741A1047|36 44|kilobases
P01659685T0000|14 22|promoters
P01659685T0000|60 74|Dd ras expression
P01659685T0000|45 51|regions
P01659685T0000|77 89|Dictyostelium
P01660486A1756|204 217|gene expression
P01660486A1756|147 163|control mechanisms
P01660486A1756|173 182|PKC pathway
P01660486A1756|3 9|results
P01660486A1756|68 91|aminoglycoside resistance
P01660486A1756|49 62|gene cotransfer
P01660486A1756|105 110|marker
P01660486A1756|40 47|cell type
P01660486A1756|192 201|activation
P01660925T0000|0 15|Transfer RNA genes
P01660925T0000|135 141|regions
P01660925T0000|98 111|consensus boxes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|80 87|elements
P01661369A0825|117 124|moieties
P01661369A0825|71 78|presence
P01661369A0825|93 100|capacity
P01661369A0825|20 28|strE genes
P01661369A0825|50 55|probes
P01661369A0825|13 16|strD
P01662609A0398|71 77|R.HgiCI
P01662609A0398|18 29|polypeptides
P01662609A0398|6 10|genes
P01662609A0398|35 44|amino acids
P01662609A0398|46 52|M.HgiCI
P01662609A0398|35 44|amino acids
P01662794A0640|0 9|Expression
P01662794A0640|15 21|wt1 gene
P01662794A0640|69 78|kDa protein
P01662794A0640|147 154|antisera
P01662794A0640|48 57|COS-1 cells
P01662794A0640|34 45|transfection
P01662807A1182|3 8|factor
P01662807A1182|81 89|infection
P01662807A1182|51 65|SV40 chromosomes
P01662807A1182|24 33|TR promoter
P01662884A1029|15 22|mg b.i.d.
P01662884A1029|0 11|Temafloxacin
P01662884A1029|46 49|days
P01662884A1029|105 115|prostatitis
P01662884A1029|77 85|treatment
P01664192A1577|42 49|ED90 dose
P01664192A1577|16 22|effects
P01664192A1577|52 61|vecuronium
P01669611A0142|99 106|diseases
P01669611A0142|71 85|pleuropneumonia
P01669611A0142|3 9|patient
P01669611A0142|47 54|aneurysm
P01669611A0142|60 64|aorta
P01669611A0142|24 28|fever
P01671675A0483|71 77|pCAD142
P01671675A0483|41 44|pair
P01671675A0483|197 210|CAD polypeptide
P01671675A0483|46 47|bp
P01671675A0483|46 47|bp
P01671675A0483|184 191|amino end
P01671675A0483|166 177|cDNA sequence
P01671675A0483|49 58|cDNA insert
P01671675A0483|124 139|sequence analysis
P01671675A0483|101 120|hybridization methods
P01671675A0483|12 21|clone pKB11
P01671675A0905|28 51|Northern blotting analysis
P01671675A0905|4 13|conclusion
P01671675A0905|68 73|region
P01671675A0905|76 82|CAD gene
P01673220A0578|67 76|bol3 allele
P01673220A0578|32 41|cDNA clones
P01673220A0578|64 65|Sn
P01673220A0578|11 19|isolation
P01674177T0001|0 18|Histamine-2 blockade
P01674177T0001|21 29|psoriasis
P01674242A0358|57 57|%
P01674242A0358|3 11|clearance
P01674242A0358|247 256|etintidine
P01674242A0358|301 310|furosemide
P01674242A0358|178 188|norfloxacin
P01674242A0358|423 431|influenza
P01674242A0358|312 320|frusemide
P01674242A0358|361 371|allopurinol
P01674242A0358|290 299|nifedipine
P01674242A0358|350 359|viloxazine
P01674242A0358|412 421|disulfiram
P01674242A0358|157 165|ofloxacin
P01674242A0358|231 234|acid
P01674242A0358|236 245|cimetidine
P01674242A0358|343 348|agents
P01674242A0358|130 142|roxithromycin
P01674242A0358|270 278|verapamil
P01674242A0358|452 461|interferon
P01674242A0358|398 410|thiabendazole
P01674242A0358|79 90|erythromycin
P01674242A0358|385 396|idrocilamide
P01674242A0358|92 105|troleandomycin
P01674242A0358|280 288|diltiazem
P01674242A0358|466 473|caffeine
P01674242A0358|144 151|enoxacin
P01674242A0358|258 268|propranolol
P01674242A0358|436 450|BCG-vaccination
P01674242A0358|167 176|pefloxacin
P01674242A0358|475 491|half-life increase
P01674242A0358|107 127|triacetyloleandomycin
P01674242A0358|153 165|ciprofloxacin
P01674242A0358|373 383|ticlopidine
P01674242A0358|215 220|T-3262
P01674369A0417|53 67|restriction site
P01674369A0417|16 22|element
P01674369A0417|75 81|cloning
P01674662A0000|3 3|n
P01674662A0000|176 179|AIDS
P01674662A0000|176 179|AIDS
P01674662A0000|33 45|heroin addicts
P01674662A0000|195 197|ARC
P01674662A0000|64 70|disease
P01674662A0000|140 144|study
P01674662A0000|245 253|relevance
P01674662A0000|218 224|factors
P01674662A0000|163 173|progression
P01674662A0000|3 3|n
P01674662A0000|187 193|complex
P01674662A0000|104 118|lymphadenopathy
P01674817A0862|2 9|homology
P01674817A0862|79 87|data banks
P01674817A0862|25 29|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|60 67|proteins
P01674817A0862|25 29|RNA14
P01674817T0000|14 23|yeast RNA14
P01674817T0000|0 8|Mutations
P01674817T0000|69 84|sequence analysis
P01674817T0000|116 127|RNA15 protein
P01674817T0000|27 36|RNA15 genes
P01674817T0000|55 67|mRNA decay rate
P01674817T0000|105 110|domain
P01675154T0000|42 54|bypass surgery
P01675154T0000|22 29|patients
P01675154T0000|10 19|infarction
P01675424A0991|41 52|H-NR sequence
P01675424A0991|15 24|difference
P01675424A0991|55 64|comparison
P01675424A0991|35 37|NAD
P01675424A0991|67 82|NADH-NR sequences
P01675424A0991|104 121|pyridine nucleotide
P01675424A0991|39 39|P
P01675424A0991|129 132|site
P01675637T0033|73 80|activity
P01675637T0033|41 46|region
P01675637T0033|84 105|receptor dimer formation
P01675637T0033|7 25|amino acid difference
P01675763A1389|6 13|benefits
P01675763A1389|64 68|liter
P01675763A1389|71 75|entry
P01675763A1389|25 32|children
P01675763A1389|37 39|CD4
P01678287A1308|15 37|Antp TATAA binding protein
P01678287A1308|78 82|cells
P01678287A1308|160 167|function
P01678287A1308|78 82|cells
P01678287A1308|101 112|homeobox gene
P01678392A0648|99 107|cmH2O l-1 s
P01678392A0648|41 43|Ros
P01678392A0648|5 21|% confidence values
P01678392A0648|68 78|variability
P01678392A0648|33 38|change
P01678392A0648|23 25|2SD
P01679068A0000|154 163|Klebsiella
P01679068A0000|129 135|strains
P01679068A0000|27 35|care units
P01679068A0000|46 46|%
P01679068A0000|54 58|value
P01679068A0000|8 14|infants
P01679068A0000|166 180|Enterobacter spp
P01679068A0000|60 64|range
P01679124A1368|60 65|dorsal
P01679124A1368|120 125|levels
P01679124A1368|170 182|MS/HSI animals
P01679124A1368|37 40|loss
P01679124A1368|11 17|studies
P01679124A1368|143 144|NE
P01679124A1368|43 54|ChAT activity
P01679124A1368|185 192|ABSTRACT
P01679124A1368|96 102|animals
P01679124A1368|151 167|dorsal hippocampus
P01679124A1368|207 211|WORDS
P01679124A1368|76 85|hippocampi
P01679124A1368|128 141|norepinephrine
P01679749A1171|3 14|localization
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01679749A1171|120 127|diseases
P01679749A1171|106 112|studies
P01679749A1171|92 96|tools
P01679749A1171|21 37|proteoglycan locus
P01679749A1171|77 81|RFLPs
P01679749A1171|48 53|genome
P01679749A1171|60 71|availability
P01681075A0429|99 111|determination
P01681075A0429|6 8|min
P01681075A0429|131 141|metabolites
P01681075A0429|117 128|tissue levels
P01681075A0429|144 149|energy
P01681075A0429|68 77|myocardium
P01681075A0429|6 8|min
P01681075A0429|45 63|pimobendan injection
P01681075A0429|153 174|carbohydrate metabolism
P01681075A0429|11 29|dobutamine injection
P01682484A0680|14 21|stenosis
P01682484A0680|28 35|contrary
P01682484A0680|69 72|dose
P01682484A0680|178 194|lactate metabolism
P01682484A0680|156 167|hemodynamics
P01682484A0680|142 148|LCX flow
P01682484A0680|50 59|procaterol
P01682484A0680|116 126|dysfunction
P01682509A0539|97 106|T-cell line
P01682509A0539|13 20|evidence
P01682509A0539|53 56|IE55
P01682509A0539|45 48|IE72
P01682509A0539|32 43|proteins IE86
P01682509A0539|108 113|HUT-78
P01682509A0539|88 93|HIV LTR
P01682542A0690|71 78|location
P01682542A0690|118 128|individuals
P01682542A0690|82 92|counselling
P01682542A0690|44 51|strategy
P01682542A0690|3 9|country
P01682542A0690|22 34|HIV prevalence
P01684791A0000|60 89|chicken glutamine synthetase gene
P01684791A0000|29 54|glucocorticoid inducibility
P01684791A0000|13 19|element
P01686909A0299|28 36|excretion
P01686909A0299|79 87|bretylium
P01686909A0299|66 76|elimination
P01686909A0299|105 108|acid
P01686909A0299|11 18|increase
P01686909A0299|115 120|kidney
P01687050T0000|30 49|fluid immunoglobulin G
P01687050T0000|51 53|IgG
P01687050T0000|10 14|value
P01687050T0000|78 85|diseases
P01688841A0430|0 9|Expression
P01688841A0430|41 44|invJ
P01688841A0430|15 19|genes
P01688841A0430|31 34|invE
P01688841A0430|49 52|invK
P01688841A0430|21 24|ipaB
P01688841A0430|36 39|invG
P01688841A0430|89 101|regulator virF
P01688841A0430|26 29|ipaC
P01688972A0803|9 10|VT
P01688972A0803|37 43|patient
P01690703A0285|0 9|Venkatesan
P01690703A0285|14 15|D.
P01690728A1166|3 10|presence
P01690728A1166|161 183|polymerase chain reaction
P01690728A1166|82 92|fibroblasts
P01690728A1166|72 73|kb
P01690728A1166|58 70|kilobase pairs
P01690728A1166|35 49|mRNA transcripts
P01690728A1166|129 153|S1 nuclease protection assay
P01690728A1166|103 127|Northern blot hybridization
P01690812A0000|30 32|DNA
P01690812A0000|15 15|%
P01690812A0000|98 101|S RNA
P01690812A0000|126 129|type
P01690812A0000|111 124|gene insertions
P01690812A0000|34 37|rDNA
P01690812A0000|126 129|type
P01690812A0000|39 43|units
P01691184A0995|127 142|precursor protein
P01691184A0995|0 4|Gap b3
P01691184A0995|81 96|cleavage products
P01691184A0995|18 34|polypeptide chains
P01691184A0995|108 121|disulfide bonds
P01691184A0995|36 37|Mr
P01692135A0783|172 176|mouse
P01692135A0783|142 152|mRNA species
P01692135A0783|184 194|killer cells
P01692135A0783|93 104|CRNK-16 cells
P01692135A0783|77 81|mRNAs
P01692135A0783|13 19|Fc gamma
P01692135A0783|11 34|rtFc gamma R alpha cDNA clone
P01692837A0390|131 139|kilobases
P01692837A0390|4 8|genes
P01692837A0390|71 76|region
P01692837A0390|31 37|introns
P01692837A0390|109 112|mRNA
P01692837A0390|81 93|kilobase pairs
P01692837A0390|22 26|exons
P01692962A0980|29 33|alpha
P01692962A0980|74 76|CHO
P01692962A0980|61 72|hamster ovary
P01692962A0980|6 15|expression
P01692962A0980|110 122|cAMP synthesis
P01692962A0980|140 160|protein kinase activity
P01692962A0980|40 51|s polypeptide
P01692962A0980|78 82|cells
P01694009A0112|97 107|polypeptide
P01694009A0112|4 7|exon
P01694009A0112|56 61|region
P01694009A0112|4 7|exon
P01694009A0112|78 91|signal sequence
P01694014A0716|0 8|Treatment
P01694014A0716|40 43|U937
P01694014A0716|11 11|h
P01694014A0716|118 132|RNA hybridizable
P01694014A0716|107 112|levels
P01694014A0716|48 76|phorbol 12-myristate 13-acetate
P01694014A0716|23 36|cell lines HL-60
P01694014A0716|135 142|LD78 cDNA
P01694014A0716|78 80|PMA
P01694280A0000|75 82|cisterns
P01694280A0000|57 66|ventricles
P01694280A0000|23 37|ventriculoscope
P01694280A0000|41 51|observation
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|84 100|amino acid sequence
P01694525A0000|24 32|epimerase
P01694525A0000|106 115|N-terminus
P01695098A1116|0 7|Serum IgG
P01695098A1116|31 38|patients
P01695116A0078|45 47|CR1
P01695116A0078|3 9|patient
P01695116A0078|94 99|months
P01695116A0078|35 43|remission
P01695116A0078|65 76|chemotherapy
P01695314A0762|14 15|NS
P01695314A0762|18 30|glucose levels
P01695314A0762|8 12|mg/dl
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|88 103|diabetes mellitus
P01695314T0000|31 37|control
P01695314T0000|82 85|type
P01695314T0000|54 79|calcium antagonist treatment
P01695322A0000|0 4|Wnt-1
P01695322A0000|86 95|tumor virus
P01695322A0000|6 10|int-1
P01695322A0000|66 68|DNA
P01695322A0000|47 55|insertion
P01695322A0000|74 78|mouse
P01695322A0000|23 30|oncogene
P01695378A1406|0 8|Induction
P01695378A1406|98 105|FKBP mRNA
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|25 30|T cells
P01695378A1406|91 95|level
P01695378A1406|11 16|Jurkat
P01695905A0480|42 50|intestine
P01695905A0480|0 8|GLUT5 mRNA
P01695905A0480|98 110|adipose tissue
P01695905A0480|29 34|levels
P01695905A0480|29 34|levels
P01695905A0480|88 93|muscle
P01695905A0480|73 78|kidney
P01697611A0738|61 67|growths
P01697611A0738|20 25|tumors
P01697683T0000|0 13|Identification
P01697683T0000|17 32|characterization
P01697683T0000|38 45|promoter
P01697683T0000|52 65|cytotactin gene
P01697928A1214|227 235|promoters
P01697928A1214|57 61|Ly-6E
P01697928A1214|79 87|consensus
P01697928A1214|49 54|region
P01697928A1214|22 37|sequence homology
P01697928A1214|197 206|alpha/beta
P01697928A1214|115 129|response element
P01698761A1059|177 182|mucoid
P01698761A1059|15 31|DNA rearrangements
P01698761A1059|43 48|region
P01698761A1059|160 169|conversion
P01698761A1059|99 105|histone
P01698761A1059|149 155|strains
P01698761A1059|124 127|AlgP
P01698761A1059|113 121|structure
P01698761A1059|197 205|phenotype
P01698761A1059|65 71|repeats
P01698772A0238|6 7|J.
P01699944A1538|117 131|promoter element
P01699944A1538|59 80|CArG box binding proteins
P01699944A1538|164 173|c-fos genes
P01699944A1538|149 159|alpha-actin
P01699944A1538|5 11|results
P01699944A1538|137 140|VLC1
P01700272A0838|0 14|Polyadenylation
P01700272A0838|17 21|B4 RNA
P01700272A0838|94 99|number
P01700272A0838|49 58|maturation
P01700272A0838|74 81|residues
P01700272A0838|126 136|recruitment
P01701088A1335|0 11|Co-existence
P01701088A1335|29 36|elements
P01701088A1335|29 36|elements
P01701088A1335|77 84|CCAAT box
P01701088A1335|64 74|AP-2 element
P01702361A0621|86 107|angiogenesis inhibitors
P01702361A0621|55 64|deposition
P01702361A0621|18 23|agents
P01702361A0621|9 15|studies
P01702361A0621|35 51|collagen synthesis
P01702426A0196|31 34|gene
P01702426A0196|19 24|region
P01702426A0196|138 153|acid synthase gene
P01702426A0196|61 70|regulation
P01702426A0196|76 85|expression
P01702426A1006|4 6|set
P01702426A1006|43 44|kb
P01702426A1006|122 129|fragment
P01702426A1006|10 17|DNA clone
P01702426A1006|9 18|cDNA clones
P01702426A1006|61 91|lambda-ZAP goose liver cDNA library
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|37 46|expression
P01702432A1296|95 106|pollen tissue
P01702432A1296|77 82|clones
P01702432A1296|52 56|genes
P01702972A0613|116 120|cDNAs
P01702972A0613|131 139|G0S30 cDNA
P01702972A0613|33 40|DNA blots
P01702972A0613|84 91|patterns
P01702972A0613|56 64|subfamily
P01702972A0613|7 23|cDNA hybridization
P01702972A0613|94 98|bands
P01702972A0613|67 76|G0S19 genes
P01702972A0613|72 76|genes
P01703335T0000|19 27|disorders
P01703335T0000|74 85|observations
P01703335T0000|61 62|FK
P01703335T0000|94 113|transplant population
P01703335T0000|40 56|immunosuppression
P01703632T0000|42 52|polypeptide
P01703632T0000|30 33|gene
P01703632T0000|57 63|regions
P01703632T0000|91 98|proteins
P01703632T0000|13 22|suppressor
P01707659A0458|60 66|HLA-5.4
P01707659A0458|55 58|gene
P01707659A0458|91 94|Ch28
P01707659A0458|76 89|chimpanzee gene
P01707800A0354|15 17|N20
P01707800A0354|61 73|parallel shift
P01707800A0354|96 109|conduction time
P01707800A0354|138 140|N11
P01707800A0354|122 135|onset latencies
P01707800A0354|80 84|peaks
P01707800A0354|11 34|N13-N20 interpeak interval
P01708098A0922|43 48|series
P01708098A0922|173 180|receptor
P01708098A0922|18 40|complex DNA binding assays
P01708098A0922|141 142|GR
P01708098A0922|62 86|alpha promoter DNA sequences
P01708098A0922|152 161|control GRE
P01708098A0922|102 110|basepairs
P01708771A1215|0 20|Sequence determination
P01708771A1215|31 38|peptides
P01708771A1215|132 136|Asn72
P01708771A1215|73 77|Asn65
P01708771A1215|122 127|others
P01708771A1215|81 86|Asn109
P01708771A1215|52 57|Asn120
P01708771A1215|105 113|molecules
P01708774A0203|59 72|promoter region
P01708774A0203|3 13|DNA sequence
P01708774A0203|24 35|AP-1 activity
P01709486A0000|48 61|proto-oncogene
P01709486A0000|9 16|mutation
P01709486A0000|63 67|c-kit
P01709486A0000|39 39|W
P01709933T0000|0 8|Isolation
P01709933T0000|33 35|rat
P01709933T0000|55 65|polypeptide
P01709933T0000|47 50|gene
P01709933T0000|93 98|statin
P01709933T0000|67 69|pS1
P01709933T0000|12 27|characterization
P01710766A0349|72 90|amino acids C terminal
P01710766A0349|3 10|proteins
P01710766A0349|32 38|absence
P01710766A0349|55 62|sequence
P01710766A0349|22 29|presence
P01710766A0349|109 123|initiation codon
P01710768A1172|84 90|pattern
P01710768A1172|3 9|results
P01710768A1172|167 181|gamma interferon
P01710768A1172|108 117|expression
P01710768A1172|123 132|HLA-B7 gene
P01710768A1172|36 44|sequences
P01710768A1172|62 63|kb
P01710768A1172|139 145|ability
P01710768A1172|129 132|gene
P01710768A1172|25 33|existence
P01710979T0000|40 50|association
P01710979T0000|3 5|SH2
P01710979T0000|55 62|tyrosine
P01710979T0000|92 95|p110
P01710979T0000|21 27|pp60src
P01710979T0000|9 18|SH3 domains
P01710979T0000|77 88|proteins p130
P01710985A0315|0 3|Chem
P01711041A0348|87 87|%
P01711041A0348|69 81|C5 alpha-chain
P01711041A0348|46 49|gene
P01711041A0348|5 10|clones
P01711041A0348|93 102|beta-chain
P01711041A0962|30 38|kilobases
P01711041A0962|3 15|C5 alpha-chain
P01711041A0962|30 38|kilobases
P01711041A0962|51 55|exons
P01711041A0962|60 69|beta-chain
P01711041A0962|51 55|exons
P01711048T0000|114 135|osteogenesis imperfecta
P01711048T0000|28 35|position
P01711048T0000|69 74|COL1A2
P01711048T0000|94 104|RNA splicing
P01711048T0000|64 67|gene
P01711048T0000|25 25|G
P01711048T0000|51 59|pro-alpha
P01711048T0000|12 19|mutation
P01711048T0000|38 43|intron
P01712296A0157|29 33|genes
P01712296A0157|3 21|nucleotide sequences
P01712296A0157|76 95|amino acid differences
P01712296A0157|50 58|positions
P01713213A0000|42 66|pim-1 proto-oncogene shares
P01713213A0000|3 9|protein
P01713213A0000|183 211|protein tyrosine kinase activity
P01713213A0000|138 148|Pim-1 enzyme
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|76 83|homology
P01713213A0000|24 31|sequence
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|97 109|fusion product
P01713213A0488|54 66|vector pGEX-2T
P01713213A0488|17 25|pim-1 cDNA
P01713213A0488|148 150|GST
P01713213A0488|123 146|glutathione S-transferase
P01714322A0969|44 50|kDa hsps
P01714322A0969|4 9|report
P01714322A0969|53 57|maize
P01714322A0969|90 94|genes
P01714322A0969|61 68|products
P01714358A0990|55 77|wheat etioplast membranes
P01714358A0990|83 90|gamma 32P
P01714358A0990|5 18|kDa polypeptide
P01714358A0990|92 94|ATP
P01714452A0559|116 120|sites
P01714452A0559|0 7|Homology
P01714452A0559|131 152|carbohydrate attachment
P01714452A0559|97 106|threonines
P01714452A0559|35 35|%
P01714452A0559|47 58|repeat domain
P01714452A0559|20 26|protein
P01714452A0559|73 84|conservation
P01714452A0559|87 93|serines
P01714902A0221|158 171|TCR stimulation
P01714902A0221|189 213|histocompatibility complex
P01714902A0221|100 106|CD3 zeta
P01714902A0221|130 152|interleukin-2 production
P01714902A0221|2 9|addition
P01714902A0221|88 98|cell surface
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01715593A0838|28 30|hrs
P01715593A0838|4 14|desipramine
P01715593A0838|56 66|brain levels
P01715593A0838|4 14|desipramine
P01715593A0838|36 54|fluoxetine injection
P01715975A0885|17 20|CYP1
P01715975A0885|57 61|cells
P01715975A0885|8 14|effects
P01716292A0000|186 192|DR alpha
P01716292A0000|155 159|DRB/H
P01716292A0000|26 32|regions
P01716292A0000|53 72|T cell allorecognition
P01716292A0000|162 168|Eb genes
P01716292A0000|195 203|H-2E alpha
P01716292A0000|93 98|series
P01716292A0000|35 41|HLA-DR1
P01716292A0000|134 141|products
P01716292A0000|10 17|analysis
P01716292A0000|112 120|cell lines
P01716629A0000|15 24|cDNA clones
P01716629A0000|52 76|matrix glycoprotein undulin
P01717718A1255|31 37|Gag-Pol
P01717718A1255|115 126|conformation
P01717718A1255|55 64|activation
P01717718A1255|38 45|PR domain
P01717718A1255|31 45|Gag-Pol PR domain
P01717718A1255|67 68|RT
P01717718A1255|55 64|activation
P01717718A1255|67 68|RT
P01717718A1255|151 162|prerequisite
P01717718A1255|38 39|PR
P01717718A1255|12 25|point mutations
P01717833A1223|72 85|granulosa cells
P01717833A1223|41 43|CRE
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|102 112|CREB protein
P01717833A1223|61 69|forskolin
P01717833T0000|0 9|Regulation
P01717833T0000|88 104|rat granulosa cells
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|72 83|transfection
P01717833T0000|54 66|monophosphate
P01717833T0000|39 47|adenosine
P01717925A0477|129 134|region
P01717925A0477|58 60|DNA
P01717925A0477|0 9|Comparison
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|104 105|bp
P01717925A0477|74 91|sequence similarity
P01717994T0000|0 6|Cloning
P01717994T0000|73 77|yeast
P01717994T0000|15 18|cDNA
P01717994T0000|40 45|kinase
P01717994T0000|83 90|mutation
P01717994T0000|48 62|complementation
P01718043A0384|14 26|osteomyelitis
P01718043A0384|1 1|n
P01718043A0384|2 9|patients
P01718043A0384|63 73|sensitivity
P01718043A0384|63 73|sensitivity
P01718043A0384|48 58|PMN elastase
P01718043A0384|121 148|erythrocyte sedimentation rate
P01718043A0384|78 78|%
P01718043A0384|35 41|empyema
P01718043A0384|78 78|%
P01718983A1640|85 88|Cell
P01718983A1640|0 1|E.
P01718983A1640|3 9|Hession
P01718983A1640|32 33|B.
P01718983A1640|55 63|Chi-Rosso
P01718983A1640|35 40|Tizard
P01718983A1640|65 66|G.
P01718983A1640|11 12|C.
P01718983A1640|71 74|Lobb
P01718983A1640|14 17|Goff
P01718983A1640|42 43|R.
P01718983A1640|45 50|Newman
P01718983A1640|19 20|D.
P01718983A1640|22 30|Griffiths
P01718983A1640|32 33|B.
P01718983A1640|42 43|R.
P01719684A0494|148 164|sphincter function
P01719684A0494|26 33|increase
P01719684A0494|69 76|prostate
P01719684A0494|8 14|results
P01719684A0494|52 60|receptors
P01720555A1087|54 66|alfalfa organs
P01720555A1087|25 36|B2 transcript
P01720843A1506|27 41|sulfhydryl group
P01720843A1506|72 87|enzyme inhibitors
P01720843A1506|5 11|results
P01720843A1506|127 146|nitrovasodilator EDRF
P01720843A1506|106 111|effect
P01720843A1506|51 61|angiotensin
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|18 19|FK
P01721261T0000|25 42|transplant patients
P01721884A0962|255 276|RNase H crystal structure
P01721884A0962|160 172|investigators
P01721884A0962|86 91|RNase H
P01721884A0962|86 91|RNase H
P01721884A0962|43 48|region
P01721884A0962|211 218|helices O
P01721884A0962|211 217|helices
P01721884A0962|43 48|region
P01721884A0962|93 98|domain
P01721884A0962|207 209|Pol
P01721884A0962|72 84|ribonuclease H
P01721884A0962|26 30|match
P01721884A0962|207 207|P
P01721884A0962|249 249|D
P01722319A0849|0 7|Analysis
P01722319A0849|118 137|N-glycosylation sites
P01722319A0849|89 95|domains
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|20 36|amino acid sequence
P01722319A0849|118 118|N
P01722319A0849|159 166|C termini
P01722479A0302|30 32|HCG
P01722479A0302|14 27|concentrations
P01722479A0302|59 69|specificity
P01722479A0302|54 54|%
P01722479A0302|54 54|%
P01722479A0302|37 47|sensitivity
P01723619A0766|130 138|intestine
P01723619A0766|16 16|F
P01723619A0766|16 26|F absorption
P01723619A0766|42 61|plasma F concentration
P01723619A0766|149 154|factor
P01723619A0766|108 114|passage
P01723619A0766|10 13|rate
P01723619A0766|88 95|emptying
P01723619A0766|36 39|rise
P01723619A0766|16 26|F absorption
P01723962A0165|1 1|h
P01723962A0165|13 23|serum lipase
P01723962A0165|27 33|amylase
P01723962A0165|3 10|activity
P01723962A0165|1 1|h
P01723962A0165|88 96|injection
P01723962A0165|99 103|Na-Tc
P01723962A0165|71 77|maximum
P01724982A0237|43 51|HCV EIA kit
P01724982A0237|64 75|North Chicago
P01724982A0237|53 62|Abbott Lab.
P01724982A0237|77 78|IL
P01725547A0354|86 94|blood flow
P01725547A0354|0 8|Diltiazem
P01725547A0354|96 98|CBF
P01725547A0354|31 38|increase
P01725547A0354|51 58|diameter
P01725547A0354|42 42|p
P01725547A0354|63 63|%
P01725547A0354|63 63|%
P01725547A0354|42 42|p
P01725622A0292|57 59|CCI
P01725622A0292|30 46|platelet increment
P01725622A0292|8 18|transfusion
P01725622A0292|51 55|Gpt/l
P01726211A0502|9 15|factors
P01726211A0502|85 90|action
P01726211A0502|45 50|vessel
P01726211A0502|5 15|risk factors
P01726211A0502|33 38|groups
P01726211A0502|9 15|factors
P01726631T0001|15 24|prevention
P01726631T0001|0 11|Epidemiology
P01726631T0001|132 136|usage
P01726631T0001|119 124|agents
P01726631T0001|50 64|Local Health Unit
P01726631T0001|93 102|resistance
P01726631T0001|67 73|Sassari
P01726631T0001|75 81|profile
P01726631T0001|27 44|hospital infections
P01727488A1146|17 21|cDNAs
P01727488A1146|36 46|stimulation
P01727488A1146|82 95|gene expression
P01727494A0000|42 47|nature
P01727494A0000|0 12|Vaccinia virus
P01727494A0000|14 15|VV
P01727494A0000|26 34|immunogen
P01727494A0000|94 101|response
P01727494A0000|107 110|host
P01727494A0000|73 82|activation
P01727494A0000|50 59|VV proteins
P01730412T0000|0 2|Max
P01730412T0000|14 20|domains
P01730412T0000|24 34|interaction
P01730412T0000|39 43|c-Myc
P01730747A0205|26 31|Reilly
P01730747A0205|15 16|G1
P01730747A0205|19 24|S phase
P01730747A0205|33 34|C.
P01731107A0928|0 12|Substitutions
P01731107A0928|60 65|levels
P01731107A0928|44 52|ICR2 motif
P01731107A0928|181 186|genome
P01731107A0928|110 120|maintenance
P01731107A0928|68 82|pRNA replication
P01731107A0928|165 170|strand
P01731107A0928|143 151|structure
P01731107A0928|25 29|bases
P01731933T0000a|0 1|Zn
P01731933T0000a|41 47|protein
P01731933T0000a|33 38|T4 gene
P01731933T0000a|6 30|coordination domain mutants
P01731933T0000b|0 1|Zn
P01731933T0000b|41 47|protein
P01731933T0000b|33 38|T4 gene
P01731933T0000b|6 30|coordination domain mutants
P01731979A1408|3 19|tissue specificity
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01731979A1408|22 35|gene expression
P01732033A0000|59 65|infancy
P01732033A0000|29 38|management
P01732033A0000|69 77|childhood
P01732033A0000|3 17|pathophysiology
P01732033A0000|46 56|brain injury
P01732033A0000|46 56|brain injury
P01732033A0000|123 127|model
P01732736A1076|0 10|Transcripts
P01732736A1076|131 142|gastrulation
P01732736A1076|60 65|levels
P01732736A1076|68 74|oocytes
P01732736A1076|83 89|embryos
P01732736A1076|37 42|Oct-25
P01732736A1076|22 35|POU-domain gene
P01732752A0156|58 72|pre-B-cell lines
P01732752A0156|74 79|LT mRNA
P01732752A0156|33 40|leukemia
P01732752A0156|20 26|Abelson
P01732752A0156|11 16|B cells
P01733105A0127|3 8|genome
P01733105A0127|69 76|sense RNA
P01733105A0127|35 42|segments
P01733105A0127|11 22|Thogoto virus
P01733358A0240|67 80|adenocarcinoma
P01733358A0240|85 87|III
P01733358A0240|48 51|cyst
P01733358A0240|5 10|tumors
P01733358A0240|48 58|cystadenoma
P01733358A0240|107 121|mucin production
P01733358A0240|39 44|groups
P01733358A0240|63 80|cystadenocarcinoma
P01734020A1318|0 13|Immunostaining
P01734020A1318|147 154|PKC alpha
P01734020A1318|102 108|mutants
P01734020A1318|16 20|cells
P01734020A1318|124 129|nuclei
P01734020A1318|41 50|constructs
P01734283A0817|27 38|RAP74 protein
P01734283A0817|134 138|RAP30
P01734283A0817|83 85|DNA
P01734283A0817|101 118|translation product
P01734283A0817|51 59|HeLa cells
P01734570T0000|0 6|Effects
P01734570T0000|122 133|porcine model
P01734570T0000|99 111|translocation
P01734570T0000|84 87|rate
P01734570T0000|68 77|resistance
P01734570T0000|9 39|thromboxane synthetase inhibition
P01735347A0482|127 135|extension
P01735347A0482|115 121|ascites
P01735347A0482|84 95|plasma lipase
P01735347A0482|20 25|insult
P01735347A0482|78 81|rise
P01735347A0482|102 112|development
P01735347A0482|151 158|necrosis
P01735347A0482|51 59|treatment
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|122 134|translocation
P01735447A0271|3 6|size
P01735447A0271|18 25|molecule
P01735447A0271|153 161|reticulum
P01735447A0271|105 116|sec61 mutants
P01735447A0271|64 72|precursor
P01735447A0833|131 139|reticulum
P01735447A0833|47 56|processing
P01735447A0833|8 26|active-site mutation
P01735447A0833|82 90|precursor
P01735447A0833|105 114|kDa pro-PrB
P01735447A0833|93 95|PrB
P01735721A0185|57 87|Bacillus stearothermophilus TyrTS
P01735721A0185|83 87|TyrTS
P01735721A0185|40 40|%
P01735721A0185|40 48|% identity
P01735721A0185|181 184|tyrZ
P01735721A0185|40 48|% identity
P01735721A0185|151 169|B. subtilis TyrTS gene
P01735721A0185|12 28|amino acid sequence
P01735721A0185|41 48|identity
P01736093A0731|74 81|promoter
P01736093A0731|117 119|HSE
P01736093A0731|52 60|sequences
P01736093A0731|97 106|CCAAT boxes
P01736093A0731|136 148|constructions
P01736093A0731|14 24|CAT activity
P01736651A0104|15 21|Infants
P01736651A0104|43 53|Minneapolis
P01736651A0104|9 13|Women
P01736651A0104|26 40|Children clinics
P01736651A0104|55 59|Minn.
P01736844T0000|165 172|function
P01736844T0000|0 11|Testosterone
P01736844T0000|182 189|epilepsy
P01736844T0000|105 127|testosterone measurement
P01736844T0000|17 28|testosterone
P01736844T0000|86 98|androgen index
P01736844T0000|124 126|men
P01736844T0000|17 28|testosterone
P01737741A0000|0 9|BACKGROUND
P01737741A0000|14 26|effectiveness
P01737741A0000|29 54|monoamine oxidase inhibitors
P01737741A0000|82 91|depression
P01737741A0000|131 135|study
P01737741A0000|56 60|MAOIs
P01737789A0800|147 152|intron
P01737789A0800|93 124|down-stream alpha-delta breakpoint
P01737789A0800|64 81|acceptor splice site
P01737789A0800|22 31|breakpoint
P01737789A0800|52 58|repeats
P01738470A0441|86 102|recognition memory
P01738470A0441|0 7|Patients
P01738470A0441|71 75|order
P01738470A0441|20 24|PDDAT
P01738470A0441|48 56|positions
P01738653T0014|0 3|Bone
P01738653T0014|7 11|bones
P01738936A0292|14 28|plasma C-peptide
P01738936A0292|70 77|analysis
P01738936A0292|41 42|pM
P01738936A0292|3 10|patients
P01739439A0257|0 6|Complex
P01739439A0257|17 26|discharges
P01739439A0257|96 108|abnormalities
P01739439A0257|41 47|muscles
P01739439A0257|17 26|discharges
P01739439A0257|138 148|control mice
P01739439A0257|50 56|mdx mice
P01739439A0257|41 47|muscles
P01739439A0257|62 68|complex
P01739956A0638|0 9|Management
P01739956A0638|60 65|type IC
P01739956A0638|31 44|calcium channel
P01739956A0638|53 57|drugs
P01739956A0638|23 26|beta
P01739956A0638|53 57|drugs
P01740121A0136|14 20|problem
P01740121A0136|41 45|Kex2p
P01740121A0136|54 91|baculovirus/insect cell expression system
P01740330A0329|0 1|J.
P01740437A0851|14 24|core protein
P01740437A0851|130 140|fibroglycan
P01740437A0851|30 49|liver HSPG preparation
P01740437A0851|122 127|domain
P01740437A0851|74 81|antibody
P01740448A1735|14 33|transmembrane regions
P01740448A1735|27 32|region
P01740448A1735|72 89|amino acid stretches
P01740448A1735|165 174|attachment
P01740448A1735|177 186|precursors
P01740448A1735|189 197|membranes
P01740682A0703|0 7|Toxicity
P01740682A0703|115 119|grade
P01740682A0703|43 43|%
P01740682A0703|43 43|%
P01740682A0703|43 43|%
P01740682A0703|162 177|thrombocytopenia
P01740682A0703|34 39|emesis
P01740682A0703|49 56|patients
P01740682A0703|49 56|patients
P01740682A0703|87 109|World Health Organization
P01740682A0703|43 43|%
P01740682A0703|43 43|%
P01740682A0703|43 43|%
P01740682A0703|66 72|courses
P01740682A0703|49 56|patients
P01740682A0703|66 72|courses
P01740682A0703|66 72|courses
P01740682A0703|75 84|leukopenia
P01741249A0177|0 3|W.G.
P01742341A0499|89 96|stressor
P01742341A0499|100 109|Beagle dogs
P01742341A0499|4 8|study
P01742341A0499|36 43|reaction
P01742341A0499|66 79|transportation
P01742606A0000|84 91|antibody
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|124 146|kDa spectrin beta-subunit
P01742606A0000|26 29|cDNA
P01742606A0000|50 76|lambda Gt11 expression library
P01742879A0471|0 6|RESULTS
P01742879A0471|73 80|drinking
P01742879A0471|61 70|inhibition
P01742879A0471|8 25|Plasma AVP responses
P01742879A0471|94 101|patients
P01742879A0471|35 45|stimulation
P01742879A0471|116 128|water drinking
P01744039A0511|3 11|fragments
P01744039A0511|18 23|region
P01744039A0511|114 137|conformation polymorphism
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|39 61|polymerase chain reaction
P01744042A1355|55 59|phase
P01744042A1355|3 12|csbA fusion
P01744042A1355|95 102|% glucose
P01744042A1355|109 118|% glutamine
P01744042A1355|74 83|Luria broth
P01744042A1355|62 66|cells
P01744119A0757|150 153|gene
P01744119A0757|44 74|nucleotide substrate requirements
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|101 108|proteins
P01744119A0757|3 13|constraints
P01744119A0757|34 41|sequence
P01744119A0757|101 107|protein
P01744119A0757|111 138|oligoribonucleotide synthesis
P01744119A0757|82 88|effects
P01744119A0757|183 191|templates
P01747972T0000|12 18|therapy
P01747972T0000|40 55|artery dissection
P01748067A0000|56 58|men
P01748067A0000|80 84|women
P01748067A0000|64 66|age
P01748067A0000|64 66|age
P01748067A0000|12 16|trial
P01748067A0000|188 195|fracture
P01748067A0000|71 75|years
P01748067A0000|210 214|femur
P01748067A0000|71 75|years
P01748067A0000|45 52|patients
P01748067A0000|131 141|replacement
P01748067A0000|123 125|hip
P01748067A0000|201 204|neck
P01748067A0000|177 185|arthritis
P01748194A0767|124 138|cord transection
P01748194A0767|81 88|recovery
P01748194A0767|140 140|N
P01748194A0767|34 45|hemisections
P01748194A0767|8 14|lesions
P01748287T0000|16 23|proteins
P01748287T0000|68 74|targets
P01748287T0000|36 45|properties
P01748292A0000|14 18|cDNAs
P01748292A0000|68 89|Lycopersicon esculentum
P01748292A0000|61 66|tomato
P01748292A0000|91 92|cv
P01748292A0000|23 26|gene
P01748292A0000|37 56|G protein alpha subunit
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|175 181|Alvarez
P01748630A0125|59 63|c-Myc
P01748630A0125|201 208|Gonzalez
P01748630A0125|121 126|region
P01748630A0125|196 199|I.C.
P01748630A0125|39 53|phosphorylation
P01748630A0125|165 173|Myc family
P01748630A0125|186 194|Northwood
P01748630A0125|97 101|Ser62
P01748630A0125|153 159|members
P01748630A0125|183 184|E.
P01748630A0125|210 211|F.
P01748630A0125|25 29|cells
P01748630A0125|79 94|activation domain
P01751163A0000|44 56|complications
P01751163A0000|100 105|device
P01751163A0000|3 9|authors
P01751163A0000|126 131|calves
P01751163A0000|68 79|implantation
P01751163A0000|22 30|potential
P01751163A0000|107 118|Sarns/3M-VAD
P01751255A0529|14 15|CO
P01751255A0529|7 12|output
P01751255A0529|10 10|p
P01751255A0529|61 69|MBBF group
P01751970A0209|0 16|Amino acid residues
P01751970A0209|9 16|residues
P01751970A0209|47 54|sequence
P01752441A0000|118 141|TAR RNA stem-loop structure
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|15 24|activation
P01752441A0000|61 68|residues
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|95 112|trinucleotide bulge
P01752441A0000|183 193|transcripts
P01752441A0000|167 172|leader
P01752792A0000|98 104|neurons
P01752792A0000|118 123|cortex
P01752792A0000|69 72|ITDs
P01752792A0000|138 147|albino rats
P01752792A0000|22 29|evidence
P01752792A0000|81 87|stimuli
P01752792A0000|35 40|coding
P01752792A0000|53 67|time differences
P01753317A0879|5 11|results
P01753317A0879|46 48|TTC
P01753317A0879|66 69|FDBA
P01753317A0879|51 61|combination
P01753317A0879|81 93|bone formation
P01753317A0879|116 126|bone defects
P01754381A0000|146 156|Trypanozoon
P01754381A0000|220 227|pol alpha
P01754381A0000|119 128|expression
P01754381A0000|215 218|core
P01754381A0000|134 144|Trypanosoma
P01754381A0000|188 205|DNA polymerase alpha
P01754381A0000|70 81|trypanosomes
P01754381A0000|170 173|gene
P01754381A0000|54 67|DNA polymerases
P01754381A0000|25 40|characterization
P01754381A0000|11 14|step
P01756195A1117|14 14|r
P01756195A1117|41 41|p
P01756195A1117|2 9|addition
P01756195A1117|84 86|age
P01756195A1117|31 38|increase
P01756195A1117|66 79|concentrations
P01756539A0354|103 112|infarction
P01756539A0354|71 79|condition
P01756539A0354|51 59|narrowing
P01756539A0354|9 20|hypertension
P01757341A0591|86 89|area
P01757341A0591|18 19|Vv
P01757341A0591|3 16|volume fraction
P01757341A0591|43 53|capillaries
P01757341A0591|92 96|brain
P01757341A0591|35 36|Na
P01757341A0591|24 33|number/mm2
P01757341A0591|127 145|alkaline phosphatase
P01758750A0000|0 13|Airway pressure
P01758750A0000|81 91|ventilators
P01758750A0000|17 23|air flow
P01758750A0000|53 56|tube
P01758750A0000|72 78|variety
P01758750A0000|61 68|children
P01759052A0786|0 3|Appl
P01759282A0000|117 124|position
P01759282A0000|29 34|energy
P01759282A0000|0 5|Issues
P01759282A0000|85 88|head
P01759282A0000|95 100|impact
P01759282A0000|49 54|object
P01759282A0000|8 19|distribution
P01759282A0000|127 138|biomechanics
P01759282A0000|63 80|contact interaction
P01760166A0963|0 9|CONCLUSION
P01760166A0963|80 89|finger site
P01760166A0963|21 24|SpO2
P01760166A0963|35 44|septum site
P01760166A0963|103 110|patients
P01761736A0158|72 72|P
P01761736A0158|0 8|Diltiazem
P01761736A0158|72 72|P
P01761736A0158|168 177|antipyrine
P01761736A0158|205 216|distribution
P01761736A0158|147 151|hours
P01761736A0158|188 194|changes
P01761736A0158|65 70|mL/min
P01761736A0158|101 120|elimination half-life
P01761736A0158|197 202|volume
P01761736A0158|26 38|body clearance
P01762053A0557|26 33|material
P01762053A0557|53 57|space
P01762053A0557|3 10|granules
P01762053A0557|73 81|particles
P01762914A1218|85 104|translation start site
P01762914A1218|50 57|elements
P01762914A1218|9 19|uPA promoter
P01762914A1218|76 77|kb
P01762917A0615|27 29|Glu
P01762917A0615|80 85|TFIIIA
P01762917A0615|70 75|finger
P01762917A0615|52 67|TGEK tetrapeptide
P01762917A0615|19 23|Gly69
P01762917A0615|33 35|Lys
P01762917A0615|105 114|DNA binding
P01762917A0615|99 102|loss
P01762917A0615|13 15|Ser
P01763065A0913|0 1|P.
P01763106A0070|84 94|test session
P01763106A0070|17 24|behavior
P01763106A0070|36 39|hole
P01763106A0070|49 58|locomotion
P01764899A0399|114 124|cavity level
P01764899A0399|40 56|water fluoridation
P01764899A0399|3 7|model
P01764899A0399|59 64|caries
P01764899A0399|32 37|effect
P01764899A0399|59 74|caries prevalence
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|73 82|expression
P01765095A0680|85 89|mRNAs
P01765095A0680|110 123|regulators CMD1
P01765095A0680|127 134|myogenin
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|19 22|gene
P01765266A0000|90 95|oocyte
P01765266A0000|73 73|O
P01765266A0000|34 56|elongation factor 1-alpha
P01765266A0000|110 116|oocytes
P01765266A0000|125 131|embryos
P01765266A0000|64 73|EF-1 alpha O
P01765269A0308|5 11|introns
P01765269A0308|78 95|consensus sequences
P01765269A0308|111 118|features
P01765269A0308|23 27|class
P01765269A0308|37 51|pre-mRNA introns
P01765375A0290|72 82|transcripts
P01765375A0290|31 38|rat cells
P01765375A0290|3 6|mRNA
P01765375A0290|140 142|kDa
P01765375A0290|51 63|clathrin clone
P01765375A0290|176 180|chain
P01765375A0290|51 58|clathrin
P01765375A0290|152 157|weight
P01765375A0290|101 102|kb
P01765386A0305|69 72|gene
P01765386A0305|20 21|kb
P01765386A0305|69 72|gene
P01765386A0305|20 21|kb
P01765386A0305|6 11|report
P01765386A0305|60 61|bp
P01765386A0305|101 109|junctions
P01765386A0305|60 61|bp
P01765386A0305|24 34|DNA sequence
P01765386A0305|83 86|exon
P01765407A0866|96 104|excretion
P01765407A0866|17 25|mg DMEA/m3
P01765407A0866|5 12|exposure
P01765407A0866|122 139|mmol/mol creatinine
P01765407A0866|40 51|postexposure
P01765407A0866|110 116|mumol/l
P01765407A0866|52 70|plasma concentration
P01766666A0788|0 9|Antibodies
P01766666A0788|102 112|interaction
P01766666A0788|27 33|rNFIL-6
P01766666A0788|41 62|nucleoprotein complexes
P01766666A0788|20 23|rE12
P01766666A0788|83 87|sites
P01766666A0788|127 133|factors
P01766876A0000|155 171|replacement vector
P01766876A0000|56 64|chain gene
P01766876A0000|1 6|method
P01766876A0000|94 104|co-exchange
P01766876A0000|49 50|mu
P01766876A0000|109 121|point mutation
P01766876A0000|78 90|co-conversion
P01766876A0000|137 142|marker
P01766876A0000|38 43|events
P01766999A0000|72 81|volunteers
P01766999A0000|20 49|allergen extract Ambrosia elatior
P01766999A0000|51 52|AE
P01766999A0000|10 17|activity
P01766999A0000|20 27|allergen
P01767060A0000|222 225|head
P01767060A0000|191 196|stages
P01767060A0000|145 152|survival
P01767060A0000|4 8|study
P01767060A0000|71 82|radiotherapy
P01767060A0000|96 104|frequency
P01767060A0000|35 53|c-DDP administration
P01767060A0000|229 232|neck
P01767060A0000|127 135|responses
P01767060A0000|108 115|duration
P01767060A0000|207 216|carcinomas
P01767060A0000|156 163|patients
P01767592A0682|86 122|HAP2/HAP3 consensus recognition sequence
P01767592A0682|177 190|nucleotide-136
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|22 30|sequences
P01767592A0682|78 83|region
P01767592A0682|125 138|nucleotide-154
P01767592A0682|143 174|BAF1 consensus recognition sequence
P01767899A0136|91 108|thromboplastin time
P01767899A0136|61 71|prothrombin
P01767899A0136|34 48|serum fibrinogen
P01767899A0136|161 172|envenomation
P01767899A0136|6 21|thrombocytopenia
P01767899A0136|23 31|depletion
P01767899A0136|138 144|minutes
P01768648A0853|81 87|domains
P01768648A0853|90 93|cRel
P01768648A0853|52 63|dimerization
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|12 21|properties
P01769189A0000|0 10|Plasma lipid
P01769189A0000|139 144|VO2max
P01769189A0000|60 66|runners
P01769189A0000|92 95|body
P01769189A0000|163 166|mean
P01769189A0000|105 105|%
P01769189A0000|151 161|ml kg-1 min-1
P01769189A0000|68 69|RU
P01769189A0000|130 137|km week-1
P01769189A0000|107 122|training distance
P01769189A0000|86 90|years
P01769189A0000|14 32|lipoprotein profiles
P01769189A0000|151 161|ml kg-1 min-1
P01769189A0000|12 12|n
P01769189A0000|105 105|%
P01769189A0000|202 203|UT
P01769189A0000|12 12|n
P01769189A0000|92 95|body
P01769189A0000|139 144|VO2max
P01769189A0000|86 90|years
P01769189A0000|196 200|women
P01769189A0000|170 171|SD
P01769919A0393|8 22|threshold shifts
P01769919A0393|104 106|kHz
P01769919A0393|53 69|brainstem response
P01770651T0001|102 110|thyroxine
P01770651T0001|34 52|equilibrium dialysis
P01770651T0001|22 31|evaluation
P01770651T0001|80 90|measurement
P01770651T0001|93 97|serum
P01770651T0001|55 76|radioimmunoassay system
P01771593A1152|14 15|TA
P01771593A1152|41 43|AGD
P01771593A1152|31 38|decrease
P01771593A1152|74 76|PCD
P01771593A1152|42 43|GD
P01771593A1232|14 19|adults
P01771593A1232|43 51|genitalia
P01771593A1232|64 72|offspring
P01771593A1232|22 26|weeks
P01771959A0442|56 56|p
P01771959A0442|81 88|function
P01771959A0442|5 8|PTCA
P01771959A0442|45 45|%
P01771959A0442|10 25|ejection fraction
P01771959A0442|5 8|PTCA
P01771959A0442|5 8|PTCA
P01771959A0442|5 8|PTCA
P01771959A0442|5 8|PTCA
P01771959A0442|45 45|%
P01771959A0442|126 134|deviation
P01771959A0442|126 134|deviation
P01771959A0442|176 183|segments
P01772201T0001|33 44|subjectivity
P01772201T0001|23 26|work
P01772201T0001|12 18|patient
P01772201T0001|50 55|period
P01772341A0852|173 177|agent
P01772341A0852|45 74|thromboxane synthetase inhibitor
P01772341A0852|123 132|protection
P01772341A0852|5 8|data
P01772341A0852|31 39|treatment
P01772341A0852|79 107|thromboxane receptor antagonist
P01772341A0852|140 158|digoxin intoxication
P01774062A0257|32 44|HLA-DQA1 locus
P01774062A0257|55 61|Y3/Ring
P01774062A0257|40 44|locus
P01774062A0257|104 111|YAC B1D12
P01774062A0257|7 9|YAC
P01774062A0257|5 6|kb
P01774062A0257|11 16|A148A7
P01774063A0161|185 194|chromosome
P01774063A0161|157 161|Actcl
P01774063A0161|86 97|C57BL/6J mice
P01774063A0161|170 176|B2M loci
P01774063A0161|35 41|progeny
P01774063A0161|83 84|F1
P01774063A0161|152 155|Fshb
P01774063A0161|63 81|C57BL/6J x Mus spretus
P01774063A0161|163 165|Ltk
P01774063A0161|13 29|backcross analysis
P01774063A0161|114 131|thrombospondin gene
P01774063A0161|53 59|matings
P01774093T0000|30 32|IgM
P01774093T0000|41 69|Chlamydia trachomatis infection
P01774093T0000|72 80|pregnancy
P01774093T0000|13 19|outcome
P01774822A0289|88 92|cycle
P01774822A0289|23 30|computer
P01774822A0289|40 59|LV time-density curves
P01776306A0572|19 20|VT
P01776306A0572|9 15|patient
P01776715A0489|75 78|loss
P01776715A0489|2 6|delay
P01776715A0489|45 55|measurement
P01776715A0489|147 149|kPa
P01776715A0489|85 97|equilibration
P01776715A0489|45 55|measurement
P01776715A0489|139 142|PCO2
P01776715A0489|81 83|CO2
P01776715A0489|114 123|gas mixture
P01776715A0489|103 108|sample
P01776715A0489|25 38|centrifugation
P01777841A0744|31 41|differences
P01777841A0744|85 93|afferents
P01777841A0744|96 101|adults
P01777841A0744|67 72|muscle
P01777841A0744|56 62|effects
P01777841A0744|11 20|mechanisms
P01777841A0744|105 112|neonates
P01779299A0000|41 49|cockroach
P01779299A0000|101 124|Moniliformis moniliformis
P01779299A0000|85 99|acanthocephalan
P01779299A0000|20 30|alterations
P01779299A0000|51 68|Periplaneta brunnea
P01779433A0694|28 42|Alu family repeat
P01779433A0694|66 73|homology
P01779433A0694|230 238|insertion
P01779433A0694|28 42|Alu family repeat
P01779433A0694|9 15|finding
P01779433A0694|28 42|Alu family repeat
P01779433A0694|96 96|Y
P01779433A0694|129 134|rhesus
P01779433A0694|28 30|Alu
P01779433A0694|48 55|junction
P01779433A0694|275 277|end
P01779433A0694|102 106|alpha
P01779433A0694|123 126|unit
P01779433A0694|201 208|position
P01779433A0694|74 79|block I
P01779433A0694|28 42|Alu family repeat
P01779769A0000|128 137|kDa protein
P01779769A0000|59 63|phage
P01779769A0000|3 10|sequence
P01779769A0000|16 29|repressor locus
P01779769A0000|9 9|c
P01779769A0000|105 116|reading frame
P01779769A0000|65 70|phi C31
P01779769A0000|38 49|Streptomyces
P01780235A0094|41 51|transfusion
P01780235A0094|3 11|EPO levels
P01780235A0094|41 51|transfusion
P01781923A0744|84 91|righting
P01781923A0744|29 30|DB
P01781923A0744|16 26|sensitivity
P01781923A0744|94 95|LS
P01781923A0744|170 180|elimination
P01781923A0744|78 81|loss
P01781923A0744|120 123|rate
P01781923A0744|29 30|DB
P01781923A0744|139 166|barbiturate brain distribution
P01781923A0744|189 193|lines
P01781923A0744|50 62|concentration
P01782424A0278|14 36|threshold concentrations
P01782424A0278|87 90|role
P01782424A0278|3 11|existence
P01782424A0278|93 101|sentinels
P01782424A0278|55 63|phenomena
P01782669A0496|47 54|addition
P01782669A0496|30 41|temperatures
P01782669A0496|57 62|A23187
P01782982A0155|0 9|Felodipine
P01782982A0155|73 78|effect
P01782982A0155|83 91|histamine
P01782982A0155|95 97|AMP
P01782982A0155|105 123|bronchoconstriction
P01782982A0155|24 35|baseline FEV1
P01783088A1136|126 136|fibronectin
P01783088A1136|257 261|WORDS
P01783088A1136|10 17|patients
P01783088A1136|43 51|mast cells
P01783088A1136|33 39|disease
P01783088A1136|235 242|ABSTRACT
P01783088A1136|77 86|hyaluronan
P01783088A1136|109 122|micrograms.l-1
P01783088A1136|109 122|micrograms.l-1
P01783088A1136|33 39|disease
P01783088A1136|75 75|%
P01783088A1136|10 17|patients
P01783375A1066|3 9|mapping
P01783375A1066|30 40|involvement
P01783375A1066|47 50|gene
P01783375A1066|114 137|translocation breakpoints
P01783375A1066|76 84|disorders
P01784589A0000|41 61|5-HT2 receptor activity
P01784589A0000|68 70|rat
P01784589A0000|77 84|behavior
P01784589A0000|35 38|role
P01785749A0695|70 75|weight
P01785749A0695|5 11|changes
P01785749A0695|49 56|children
P01785749A0695|37 41|group
P01786094T0001|7 14|contents
P01786094T0001|23 28|copper
P01787085A0331|39 49|control rats
P01787085A0331|10 20|experiments
P01787085A0331|63 69|colloid
P01788002T0001|29 29|B
P01788002T0001|0 13|Magnetotherapy
P01788002T0001|16 25|hepatitis A
P01788002T0001|32 39|children
P01791363A0208|86 92|testing
P01791363A0208|69 75|sutures
P01791363A0208|5 11|results
P01791363A0208|35 42|patients
P01791754T0000|75 89|secretion signal
P01791754T0000|107 116|haemolysin
P01791754T0000|10 17|analysis
P01791754T0000|27 30|role
P01791754T0000|52 59|features
P01792580A0198|59 72|blood donations
P01792580A0198|31 36|Serbia
P01792580A0198|10 15|donors
P01792580A0198|5 15|blood donors
P01792580A0198|77 86|percentage
P01792580A0198|5 15|blood donors
P01792580A0198|77 86|percentage
P01792580A0198|21 28|Republic
P01792580A0198|51 56|number
P01792914T0000|23 39|childhood leukemia
P01792914T0000|14 20|relapse
P01797459A0103|0 9|Mycoplasma
P01797459A0103|56 62|patient
P01797459A0103|45 49|fluid
P01797467A0000|0 4|RU486
P01797467A0000|16 26|combination
P01797467A0000|8 10|ONO
P01797467A0000|73 81|pregnancy
P01797467A0000|60 70|termination
P01798407A1011|58 67|hypothesis
P01798407A1011|3 10|presence
P01798407A1011|133 138|origin
P01798407A1011|144 159|laughing seizures
P01798407A1011|18 30|abnormalities
P01798407A1011|113 116|lobe
P01798407A1011|75 80|cortex
P01798407A1011|37 44|patients
P01804671A1001|27 31|QS/QC
P01804671A1001|217 224|ml.min-1
P01804671A1001|190 196|gas data
P01804671A1001|201 206|CDCSF6
P01804671A1001|2 5|line
P01804671A1001|18 23|values
P01804671A1001|108 111|lung
P01804671A1001|94 102|air spaces
P01804671A1001|226 231|mmHg-1
P01804671A1001|140 172|ventilation/perfusion distribution
P01804671A1001|36 42|results
P01806314A0322|4 8|cells
P01806314A0322|40 46|markers
P01806314A0322|92 102|muscle actin
P01806314A0322|77 84|antibody
P01808049A0262|0 14|CT abnormalities
P01808049A0262|40 49|hemorrhage
P01808049A0262|88 98|hypodensity
P01808049A0262|66 66|%
P01808049A0262|175 181|atrophy
P01808049A0262|66 66|%
P01808049A0262|40 49|hemorrhage
P01808049A0262|66 66|%
P01808049A0262|88 98|hypodensity
P01808049A0262|66 66|%
P01808049A0262|22 31|term babies
P01808049A0262|66 66|%
P01808049A0262|66 66|%
P01808049A0262|66 66|%
P01808136T0000|27 46|coagulation factor XII
P01808136T0000|3 9|effects
P01808136T0000|12 24|contrast media
P01808186A0984|0 3|Pigs
P01808186A0984|57 58|kg
P01808186A0984|44 47|diet
P01808186A0984|61 63|Exp
P01808602A0000|89 93|serum
P01808602A0000|98 101|acid
P01808602A0000|110 118|excretion
P01808602A0000|98 101|acid
P01808602A0000|68 86|nifedipine treatment
P01808602A0000|9 16|patients
P01808602A0000|53 59|effects
P01808602A0000|38 49|hypertension
P01808829A0510|0 3|TPTA
P01808829A0510|73 83|hemorrhages
P01808829A0510|12 26|brain congestion
P01809854A0106|0 7|Examples
P01809854A0106|40 53|research design
P01809854A0106|65 83|consensus statements
P01809854A0106|20 27|subjects
P01809854A0106|91 103|meta-analysis
P01810108A0000|57 68|inactivation
P